
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

1938
10.1038/s41392-024-01938-6
Review Article
Circulating tumor cells: from new biological insights to clinical practice
Gu Xuyu 1
http://orcid.org/0000-0002-1783-0372
Wei Shiyou 2
Lv Xin xinlvg@126.com

2
1 grid.24516.34 0000000123704535 Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
2 grid.24516.34 0000000123704535 Department of Anesthesiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
2 9 2024
2 9 2024
2024
9 2262 11 2023
31 5 2024
29 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The primary reason for high mortality rates among cancer patients is metastasis, where tumor cells migrate through the bloodstream from the original site to other parts of the body. Recent advancements in technology have significantly enhanced our comprehension of the mechanisms behind the bloodborne spread of circulating tumor cells (CTCs). One critical process, DNA methylation, regulates gene expression and chromosome stability, thus maintaining dynamic equilibrium in the body. Global hypomethylation and locus-specific hypermethylation are examples of changes in DNA methylation patterns that are pivotal to carcinogenesis. This comprehensive review first provides an overview of the various processes that contribute to the formation of CTCs, including epithelial-mesenchymal transition (EMT), immune surveillance, and colonization. We then conduct an in-depth analysis of how modifications in DNA methylation within CTCs impact each of these critical stages during CTC dissemination. Furthermore, we explored potential clinical implications of changes in DNA methylation in CTCs for patients with cancer. By understanding these epigenetic modifications, we can gain insights into the metastatic process and identify new biomarkers for early detection, prognosis, and targeted therapies. This review aims to bridge the gap between basic research and clinical application, highlighting the significance of DNA methylation in the context of cancer metastasis and offering new avenues for improving patient outcomes.

Subject terms

Cancer metabolism
Cancer metabolism
issue-copyright-statement© West China Hospital, Sichuan University 2024
==== Body
pmcIntroduction

The progression of cancer from a localized tumor to a widespread metastatic disease is a complex and multifaceted process, making it cancer patients’ leading cause of death.1 The driving force behind this process is CTCs, which break from the primary tumor site and spread through the bloodstream to colonize other organs.2 The study of CTCs has garnered considerable attention as it opens new avenues for understanding the intricacies of metastasis, offering potential markers for early detection and targets for therapeutic intervention.3

Recent technological advancements in genomics and molecular biology have significantly enhanced our capability to scrutinize the biological mechanisms underpinning CTC dissemination.4 Among the myriad of molecular processes implicated in this journey, DNA methylation emerges as a pivotal regulatory mechanism influencing gene expression and chromosome stability.5 Cellular differentiation, growth, and adaptation to environmental changes all depend on DNA methylation, a reversible epigenetic alteration that adds methyl groups to the DNA molecule.6 For their roles in the development and propagation of cancer, changes in DNA methylation patterns are becoming more and more recognized.7

Hypomethylation across the entire genome, alongside hypermethylation of specific gene loci, has been implicated in the disruption of genomic integrity and the silencing of tumor suppressor genes, respectively.8,9 These epigenetic changes are fundamental to the transformation of normal cells into malignant ones, affecting their ability to proliferate, evade immune detection, and metastasize.10 This comprehensive review delves into the mechanisms of CTC formation, highlighting processes such as EMT, immune system evasion, and the colonization of distant tissues, all of which are critical to the metastatic cascade. Furthermore, this review aims to dissect the role of DNA methylation modifications within CTCs, examining how these alterations influence the aforementioned stages of CTC dissemination. After comprehending the epigenetic landscape of CTCs, researchers can find new targets for therapeutic intervention as well as biomarkers for cancer diagnosis and prognosis. The modulation of DNA methylation in CTCs, in particular, presents a promising path for the development of targeted therapies intended to prevent the spread of cancer.

Biology of CTCs

CTCs enter the peripheral circulation from primary or metastatic lesions either spontaneously or as a result of therapeutic manipulation.11 The notion of CTCs was initially introduced by Ashworth in 1969, and these cells can be categorized into three groups: epithelial, mesenchymal, and hybrid.12–15 While most CTCs can be eliminated by the host immune system, a subset of highly active and metastatic CTCs may evade immune clearance, ultimately resulting in the establishment of microscopic cancer foci, tumor recurrence, and metastasis.16–21 Thus, CTCs are regarded as a plausible origin of fatal metastatic disease in individuals (Fig. 1).Fig. 1 Route and location of CTCs Metastasis. Circulating tumor cells (CTCs) are the fundamental constituents of liquid biopsy, functioning as the cornerstones of this approach. a These neoplastic cells are shed naturally from primary or metastatic tumors and circulate within the bloodstream, b serving as the “seeds” of tumors that can potentially result in fatal metastasis of various sites. The figure was created with BioRender.com

However, there are several obstacles that CTCs must overcome in order to successfully detach from the primary tumor tissue, including: 1) Adhesion: Extracellular matrix (ECM) and surrounding cells in the tissue of the primary tumor are both firmly adhered to by cancer cells, which are typically highly sticky. CTCs must overcome these adhesion forces in order to detach and enter the lymphatic or bloodstream system. 2) Invasion: Cancer cells must also be able to invade the neighboring tissue to reach the lymphatic or blood vessels. This requires the cells to degrade the ECM and surrounding tissues. 3) Shear stress: Once in the bloodstream or lymphatic system, CTCs are subjected to significant shear stress due to the movement of fluid. This can cause mechanical damage to the cells and can also trigger apoptosis (cell death). 4) Immune system surveillance: The immune system is constantly surveilling the bloodstream and lymphatic system for foreign or abnormal cells. CTCs must avoid being detected by the immune system in order to survive and potentially form secondary tumors. Overall, the process of CTC detachment and dissemination is complex and involves many different factors. Understanding these obstacles and how CTCs overcome them is a crucial area of research on the biology of cancer and may lead to new therapies for preventing or treating cancer metastasis.

Molecular markers of CTCs

CTCs have been found in a wide range of cancer types using a comprehensive panel of molecular markers. Table 1 provides a summary of CTC-associated markers utilized in different cancers.22,23 The leading marker for CTCs is epithelial cell adhesion molecule (EpCAM), a “universal” epithelial marker for tumors, since the majority of tumors originate in epithelial tissues.24 Different cancer types25 express EpCAM differently, and EpCAM-based CTC detection systems are widely employed for tumors with significant EpCAM expression, like prostate and breast cancers. Numerous studies have demonstrated that CTCs in prostate and breast cancers are EpCAM-positive, indicating their prognostic value in the disease’s early and metastatic stages.26,27 Other epithelial-derived cancers, including pancreatic,28 colorectal,29 and hepatocellular cancers,30 also exhibit significant detection rates of EpCAM-positive CTCs. Similar to early distant metastases, the presence of these EpCAM-positive CTCs is associated with poorer patient survival.29,31,32 However, there are limitations to using EpCAM as a CTC marker. Tumors that are low-expression or EpCAM-negative, including neurogenic cancers, are unable to be treated with this method. CTCs can undergo EMT, a process during which epithelial markers, including EpCAM, are downregulated. The rate of EpCAM-positive CTC detection is affected by this downregulation. Numerous studies have shown the clinical usefulness of EpCAM-positive CTCs, despite uncertainties about the efficacy of EpCAM-based technology for detecting all CTCs.33 Positive EpCAM CTCs make up a significant subset of all CTCs, indicating that they could serve as a trustworthy biomarker for cancer prognosis and therapy efficacy when necessary. EpCAM-positive CTCs are likely to miss critical biological information associated with EpCAM-negative CTCs, leading to an underestimation of the actual number of CTCs within the population. This phenomenon has been observed in certain types of cancer such as NSCLC (NSCLC), the number of EpCAM-negative CTCs is significantly higher than that of EpCAM-positive CTCs.34 However, the usage of both mesenchymal and epithelial cells, along with marker-independent detection techniques, can enhance the suboptimal isolation of CTCs by EpCAM-based technologies. For example, the use of fluorescent-magnetic nanoparticles with a dual-antibody interface that targets both N-cadherin and EpCAM in breast cancer has accelerated the identification of CTCs and increased the efficiency of CTC isolation.35,36 The identification of both epithelial and non-conventional CTCs, which lacked leukocyte and epithelial markers, enhanced the CTC positivity rate in a single-cell assay for CTC detection in biliary tract cancer.37Table 1 Molecular markers of CTCs

Cancer types	Epithelial markers	Mesenchymal markers	Stemness marker	Specific markers	
Breast cancer	EpCAM/CK	Vimentin	ALDH1	HER2	
CK	Twist	CD44	ER	
E-Cadherin	Fibronectin		AR285	
	N-Cadherin		MRP48	
	SERPINE1/PAI19			
	β-catenin281			
Prostate cancer	EpCAM/CK8,18,19	Vimentin	-	PSMA	
	Twist		PSA	
			EGFR	
			ARV7	
			PIM1	
			AR v567es	
Kidney cancer	EpCAM	-	-	CD147296	
Bladder cancer	EpCAM/CK8,18,19	-	-	-	
Colorectal cancer	EpCAM/CK8,18,19	Vimentin		PI3K α	
	Twist		CEA	
	SNAI1		PRL3	
	AKT2			
	LOXL3			
	Plastin3			
Non-small-cell lung cancer	CK7/8/18/19	Vimentin	ABCG2	Folate receptor	
EpCAM/CK8,18,19	Twist	CD44	Telomerase activity	
	N-Cadherin	ALDH1		
	AXL			
Small-cell lung cancer	EpCAM/CK8,18,19	Vimentin	ABCG2	DLL3	
Pancreatic cancer	EpCAM/CK8,18,19	Vimentin	ABCG2	-	
	Twist	CD44		
	KLF8			
Hepatocellular carcinoma	EpCAM/CK8,18,19	Vimentin	ABCG2	GPC3	
EpCAM,CK19346	Twist		ASGPR	
EpCAM348	-		-	
Gastric cancer	EpCAM/CK	Vimentin	ABCG2	XAF	
CK19/CK20	N-Cadherin	CD44	MT1-MMP	
			Survivin	
			HER	
Esophageal cancer	EpCAM/CK8,18,19	-	-	-	
Cervical cancer	EpCAM/CK8,18,19	-	-	-	
Melanoma	-		-	MART	
			HMW-MAA	
			CD146	
			MAGE A	
			GalNAc-T	
			MAGE A1-6	
			hTERT	
			MLANA	
			B4GALNT1	
			PAX3	
			DCT	

Molecular changes accompany the EMT in cancer cells. Among these are the downregulation of epithelial indicators like ZO-1, claudins, and occludins and the upregulation of mesenchymal markers like Vimentin, N-cadherin, fibroblast-specific protein 1, and fibronectin.38 EMT is regulated by EMT-related transcription factors, mainly from the TWIST, ZEB, and SNAIL families.39 All these EMT-related molecules have the potential to be utilized in targeting methods for EMT-associated CTCs. Many EMT-related molecules, however, are nuclear or cytoplasmic proteins, limiting their application in current membrane-based CTC detection techniques. The usage of proteins like E-cadherin, Vimentin, and TWIST has been common in the past because of their detectability in traditional CTC detection methods, including as flow cytometry sorting, immunostaining, and fluorescence in situ hybridization (FISH) staining.40 Nevertheless, the advent of single-cell CTC sequencing technologies41 holds the promise of more comprehensively revealing the EMT status of CTCs, encompassing all EMT-related molecular alterations at the RNA level.

Numerous studies have proposed that either differentiated progenitor cells or somatic stem cells may be the source of cancer stem cells (CSCs) with tumor initiating capacities. Evidence suggests that this specific subpopulation of cancer cells may be responsible for relapse and metastasis.42 If the majority of cancer cells are unable to form new tumors and only the rarest CSCs may travel to cause metastatic disease, therefore the main goal of CTC research is to identify and eliminate this circulating-CSC population. After identifying and isolating CSCs within CTCs, it would be possible to combat residual cancer more effectively. Two hypotheses can be taken into consideration to clarify the origin of circulating CSCs. First, cancerous somatic stem cells EMT and exit the main tumor into the circulation. These cells are known as mesenchymal CSCs. Second, these cells can be the result of fully differentiated cancer cells that have undergone EMT pathways to acquire migratory properties.43 Regardless of the pathway, the end result is the dispersal of CSCs, which move in the direction of niches via intermediary cells that display a combination of mesenchymal, epithelial, and stemness characteristics. This could explain the diversity of surface markers and/or transcription factors observed in tumor-initiating cells within CTCs. The heterogeneity of CTCs, originating from either EMT in CSCs or differentiated cancer cells, underscores the challenge of selecting significant identification markers. This complexity is further compounded by the specific organ of tumor origin. During EMT, cancer cells acquire stemness characteristics, transforming into mesenchymal stem cancer cells. The MET, which is a reverse process, transforms them into epithelial stem cancer cells. ALDH1 expression, initially observed in 1–2% of normal breast epithelial cells, was first documented in breast cancer tissue by Ginestier et al.44 Barriere et al. found in a clinical study for early breast cancer diagnosis that blood samples from patients with non-metastatic breast cancer had a stemness CTC population. Out of 130 patients, 17 had ALDH1 markers and 49 were CTC-positive.45 CD44, a cell surface glycoprotein implicated in metastasis and cell migration,46 characterizes a subpopulation of breast CSCs capable of intravasating into the bloodstream, identified by the CD44+/CD24low/–/Lin–markers.47 In colorectal cancer, CSCs expressing CD44v6 are associated with metastatic potential.48 Additionally, CSCs have decreased levels of certain glycosphingolipids that are important for cell growth and motility, such as Fuc-(n) Lc4Cer and Gb3Cer, while elevated levels of GD2, GD3, GM2, and GD1a are seen. These gangliosides have the potential to function as markers of CTC stemness. Specifically, GD2 is associated with the CD44high CD24low phenotype linked to CSCs, and GD3 similarly indicates stemness features, although GD1a remains a putative marker.49,50 Recent research has also linked the CSCs phenotype to high ABCG2 transporter expression levels. This transporter is responsible for removing a variety of xenobiotics, including chemotherapy drugs. This chemoresistance implies that ABCG2 expression and stemness are closely associated. It has been found that CSCs from lung, pancreatic, and retinoblastoma tumors exhibit high levels of ABCG2.51,52 Additional biomarkers have been found to be markers for CTCs in a variety of cancers, each with unique therapeutic implications. These include human epidermal growth factor receptor-2 (HER-2)53,54; estrogen receptor55–57; prostate-specific membrane antigen58,59; folate receptor60,61; and survivin.62 Table 1 provides specifics on these CTC markers. The majority of these markers match the unique molecular markers of the primary tumor. However, the expression of specific markers in CTCs often differs from that of the primary tumor. For example, there is about a 15%63 discrepancy in HER-2 gene amplification between primary breast tumors and CTCs, indicating that genetic instability is most likely the cause of clonal selection or acquisition. CTC detection technologies are dependent on a number of melanoma cell adhesion molecules, which are highly specific molecular markers for melanoma and include HMW-MAA,62,64 MART-1,65,66 CD146,67,68 and MAGE A.66,67,69–71 Melanoma is a kind of skin cancer that starts in melanocytes. The diverse range of CTC markers underscores the heterogeneity of CTCs across various cancer types. Even within a single patient, CTCs display spatio-temporal heterogeneity, possibly attributable to spatially distinct microenvironments within the bloodstream and temporal variations in response to therapy. As such, characterizing the whole population of CTCs using the few molecular markers that are currently accessible is difficult. Furthermore, CTC markers vary over the course of cancer treatment and at different stages of the disease.

The biological progress of CTCs development

Epithelial cells typically undergo anoikis, a form of programmed cell death, upon detachment from their surrounding environment. This characteristic makes metastatic seeding generally inefficient.72–74 This raises an important question: what characteristics allow CTCs to metastasize successfully? Enhanced survival and tumor-seeding ability appear to be restricted to a small subset of cells initiating tumors or metastases with stem-like properties.75 EMT has been proposed as an essential factor for metastasis since it increases both invasive potential and contact-independent survival (i.e., resistance to anoikis).75–77 Preclinical studies have shown that EMT transcription factors, like TWIST and SNAIL, enhance motility and invasiveness in vitro while suppressing cell-cell adhesion.78,79 Silencing SNAIL and TWIST, however, can reduce metastasis in vivo but does not totally prevent it, raising doubts about the absolute requirement of EMT-related transcriptional regulators in the metastatic process.80,81 Interestingly, it has been found that EMT can inhibit the effective seeding of metastatic tumors by deleting E-cadherin or modifying TWIST expression in several EMT lineage tracing models.80,82 The observed plasticity of the epithelium-to-mesenchymal transition raises the possibility that this change is fluid and transitional rather than binary and irreversible, acting more as a catalyst for metastasis than as a direct cause.83,84 Consequently, CTCs have been seen to exhibit an intermediate degree of EMT, which is linked to their adaptability, stem cell-like qualities, poor response to therapy, and progression of the disease.76,84,85 There have been multiple hybrid states found at the invasive boundary of patient tumor tissues from common carcinoma types and xenografts.84,86,87 Their functional role in invasion, invasion, and metastatic colonization requires further studies.

There may be concurrent existence of metastasis pathways that are both plasticity-dependent and plasticity-independent.88 The discovery of collectively moving, highly metastatic clusters of cell contact-dependent CTCs, which were first reported several decades ago, offers a significant refutation of the idea that EMT is necessary for metastasis.89,90 Metastatic colonies are polyclonal,91–94 and subclones interact synergistically,95,96 suggesting that heterogeneous CTC clusters97,98 as well as solitary CTCs are involved in cancer propagation. Despite making up a small portion of all CTC events in peripheral circulation, multiple studies have demonstrated that CTC clusters have up to a 100-fold higher potential for metastasis than individual CTCs.82,97–99 Intratumor hypoxia is shown to upregulate genes producing cell adhesion proteins in patient samples and mice models, which promotes collective CTC cluster shedding.98 Homotypic clustering has been shown to improve a number of cellular characteristics, such as the overexpression of stem-like traits100,101 via the hypomethylation of binding sites for transcription factors OCT4, SOX2, and NANOG102 and the methylation of metastasis suppressor genes.5 Clustering can also be augmented by circulating galectin 3 or cancer-associated MUC1,100 homotypic ICAM interactions,103 or CD44 interacting with PAK2.98 This clustering can also enhance survival and self-renewal capacity through CDK6 or increased size or number of desmosomes and hemidesmosomes.97,104 CD44 was among the first markers discovered to detect breast cancer cells with elevated tumor-initiating capacity in solid tumors.47 Later, it was demonstrated that CD44, along with MET, epithelial EpCAM, and CD47, could identify subpopulations of breast cancer that were highly metastatic.76 Importantly, CD44 expression should not be employed as a CTC marker alone because it is widely expressed in the hematopoietic cell compartment.105 Previously thought to be specific to stem-like cells, CK14 expression is more common in CTC clusters than in individual CTCs and is required for distant metastasis.106 EpCAM–, HER2+, EGFR+, heparanase (HPSE)+, and NOTCH1+ are stem-like phenotypic signatures in CTCs that have been shown to provide competence for brain and lung metastasis.104

Heterotypic clusters, which include platelets, myeloid cells, and cancer-associated fibroblasts (CAFs), as well as homotypic clusters formed by CTCs, can potentially form between CTCs or other cell types.107–111 The rapid interaction of CTCs with platelets in circulation112 enhances plasticity and metastasis-initiating capacity107 through mechanisms like RhoA–MYPT1–PP1-mediated YAP1 signaling113 and increased vascular permeability via platelet-derived ATP–P2Y2 interaction.114 The glycoprotein A additionally, protecting against T cell-mediated clearance and NK cell-mediated clearance, respectively, are repetitions predominant (GARP)–TGFβ axis115 and platelet-derived major histocompatibility complex class I.116 Barbara Maria Szczerba et al. demonstrated that neutrophils also participate in forming heterotypic CTC clusters.117 Neutrophils are drawn to CTCs by chemotaxis that is dependent on CXCL5 and CXCL7111 and connects with them via adhesion mediated by vascular cell adhesion molecule 1 (VCAM1), which enhances their potential for proliferation and metastasis.111 Through the formation of neutrophil extracellular traps or the secretion of matrix metalloproteinases and IL-1β, neutrophils facilitate adhesion and extravasation.108 In addition, neutrophils protect CTCs from immune surveillance118,119; macrophages and myeloid-derived suppressor cells in CTC clusters also provide this protection.118,120 It has been demonstrated that heterotypic adherens junctions, mediated by N-cadherin in stromal CAFs and E-cadherin in invasive cancer cells, promote collective invasion. Here, CAFs serve as invasive and migrating leader cells,110,119 facilitating metastasis by allowing tumors to “bring their own soil”.121 Mathematical models indicate that the form of clusters influences CTC behavior during circulation in addition to the biological consequences of clustering. Compact clusters usually flow closer to the endothelium wall compared to linear clusters.122 However, clusters move in a “single chain” structure as they pass through narrow capillaries.109,123–125 The metastatic potential of CTCs is significantly impacted by the phenotypic plasticity and clustering differences, which highlights potential strategies for inhibiting the metastatic process.

Furthermore, the dynamics of CTC propagation are becoming recognized as an equally important component for the dissemination of tumor cells.111,126 Chronotherapy has been used to study and evaluate the clinical application of the circadian rhythm’s function in tumor onset127,128 and growth dynamics.129,130 This therapeutic approach seeks to optimize therapy timing in order to increase the effectiveness of antitumor drugs.131,132 However, it has only recently been established how circadian rhythm impacts CTC release and the dissemination of metastatic disease.111,126 The way that CTCs are currently detected frequently assumes that peripheral blood counts remain stable throughout the day, which may lead to inconsistent results and make it more difficult to use CTCs as a liquid biopsy analyte in clinical settings. Fluorescence in vivo flow cytometry studies in orthotopic mice models of human prostate cancer have suggested circadian rhythmicity.133 The temporal dynamics of CTC intravasation, demonstrating significant circadian rhythm-based variations both in breast cancer patients and in mouse models. CTC counts are highest during sleep because to these variations, which are caused by rhythmic changes in hormone levels, such as melatonin.128

The role and mechanism of CTC in drug resistance

The manifestation of an EMT phenotype in CTCs has been associated with therapeutic resistance and tumor relapse. For example, in patients with metastatic colorectal cancer, overexpression of CSV and plastin 3 in EMT-positive CTCs has been associated with drug resistance.134 CTC survival is improved by the acquisition of stem cell characteristics during EMT, which promotes enhanced migratory and invasive abilities as well as resistance to therapy. Tumor relapse following targeted therapy can be driven by CTCs with stem cell features,135 such as in colorectal cancer,136 where drug-resistant CTCs may act as metastasis-initiating cells, driving tumors to become more aggressive as a result of anticancer drugs’ selection pressure. Targeted therapy-induced tumor relapse in melanoma patients has been linked to phenotypic switching of CTCs to a less differentiated state.137 Therapies resistance in breast, prostate, pancreatic, and NSCLC have also been linked to phenotypic switching.138 Therapeutic resistance mechanisms seen in primary tumor cells include target mutation or inactivation, improved genomic DNA repair, faster drug efflux, upregulation of markers associated with quiescence, downregulation of markers associated with proliferative activity, and inhibition of the formation of oxygen radicals,139 are also evident in CTCs. Tumor cells can separate from the original tumor and circulate in the blood as clusters of tiny cells, challenging the idea that CTCs with EMT and/or stem cell phenotypes are the sole type that initiates metastasis (i.e., groups of >2 CTCs and up to large micro-emboli).97 Metastatic potential and drug resistance may be influenced by CTC clusters. The absence of proliferation in CTC clusters, as indicated by Ki67 staining, has been linked to their resistance to cytotoxic therapies.140 Significantly reduced overall survival following systemic therapy is observed in PDAC patients who harbor a high number of CTC clusters (more than 30 clusters per 2 mL of blood).141 Expanding CTCs from patients into cell lines or xenografts may reveal insights into their therapeutic resistance and present an opportunity for targeted therapy.142 However, high CTC numbers and several months of establishment make CTC-derived cell lines or xenografts impractical for clinical use. Furthermore, prolonged passage of CTCs in culture is likely to induce irreversible adaptation and clonal expansion.143

Stem cell and EMT markers exhibit frequent overexpression in CTCs of metastatic breast cancer.144 Recently, within breast tumors, a subpopulation displaying a stem cell-like phenotype characterized by CD44 positivity and CD24 negativity has been delineated.47 This subpopulation potentially disseminates into the bloodstream, evading therapeutic measures,145 and demonstrates an expression profile associated with metastatic recurrence.146 The modulation of HER2 signaling has been reported to augment cancer stem cell reservoir, potentially necessary for its maintenance; a significant association between HER2-like tumors and stem cells has been observed.147 A breast cancer stem cell-like phenotype, exhibiting higher resistance to treatment and reduced proliferation in circulation, is suggested by preliminary evidence.148 ALDH1, a marker indicative of both normal and neoplastic breast stem cells,144 has been found to be overexpressed in 70% of CTCs, correlating with therapy resistance. A substantial proportion of CTCs display detectable levels of at least one EMT marker such as TWIST, AKT2, and PI3Kalpha, in addition to ALDH1, thereby delineating a highly tumorigenic subset of EMT-associated breast CSCs.44 This subset of CTCs has clinical value since it predicts drug resistance and a poor result for patients with metastatic cancer.44 Notably, ALDH1 and EMT markers were discernible even prior to CTC detection in circulation, as evidenced by their positivity in RT-PCR for transcripts such as HER2, MUC1, and EpCAM.44 Consistently, stem cell-like phenotypes, particularly CD44+CD24−/low and ALDH1highCD24−/low, have been found in 35.2% and 17.7% of CTCs, respectively.63 Among ALDH1-highly positive CTCs, the subset expressing CD44+CD24−/low exhibits heightened tumorigenic potential.149 Though ALDH1-positive cells constitute just 5% of cells in tumors expressing ALDH1, ALDH1 positivity is associated with a high histological grade and poor clinical outcomes.149

According to the cancer stem cell model, putative cancer stem cells44 are necessary for tumor growth and drug resistance, and their existence should be associated with a worsened prognosis,149 albeit data on this matter are still inconsistent.44,150,151 Because of their capacity to self-renew and resistance to chemotherapeutic drugs, eradicating these cells during therapy poses challenges. Notably, patients’ chances of responding to chemotherapy are poorer when their CTCs are ALDH1-positive.44 It has recently been shown that CTCs express one or more multidrug resistance-related proteins (MRPs) in 86% of metastatic breast cancer patients, with patients exhibiting positive MRP-positive CTCs having considerably shorter progression-free intervals.57,144,152,153 Further investigations are warranted to elucidate the association between the presence of CD44+CD24− or ALDH1highCD24−/low CTCs and clinical trajectory as well as disease progression.

CTC isolation and identification

For CTCs to be used as a liquid biopsy analyte in clinical settings, it is essential to adopt impartial, affordable, quick, and effective capture technologies that can reliably isolate adequate numbers of CTCs. In order to facilitate the development of data necessary for precise patient stratification and therapeutic decision-making, these capture approaches must also be compatible with functional assays and cutting-edge sequencing technologies. For probing the biology and vulnerabilities of metastatic cancer at the molecular and functional levels, CTCs provide a wide variety of scope when they are isolated in a viable state. CTCs have a unique role as a liquid biopsy analyte because they can represent aggressive subclones with greater metastatic potential. There is conjecture that their molecular and phenotypic analysis may provide more pertinent insight than traditional tissue biopsies (which involve the random subclone isolation)154,155 or other circulating analytes like circulating tumor DNA (which mainly identify dying subclones). However, further exploration is warranted. The ease of access provided by minimally invasive blood draws may allow for regular, long-term assessments of the effectiveness of treatment interventions, which may also make early cancer detection or recurrence possible.156 As a result, CTCs become an optimal biomarker repository for personalized therapy and real-time clinical applications. However, it is still challenging to obtain CTCs because of their paucity, and effective CTC enrichment is required for reliable downstream analysis and applications.

In the previous ten years, numerous technical progress has been made to improve CTC analysis and detection157,158 by utilizing distinct characteristics and phenotypes of CTCs. These developments can be broadly categorized into antigen-dependent and antigen-independent techniques. The most widely used strategies currently in use help to promote positive selection by using antigens that are expressed on CTCs and minimally expressed on other circulating cells. This strategy is frequently combined with CD45-based negative selection to reduce the number of hematopoietic cells and enhance discrimination. It is notable that the CellSearch system (Menarini Silicon Biosystems, Italy) and AdnaTest CTC Select (QIAGEN, Germany), which have been approved by the US Food and Drug Administration (FDA), utilize immunomagnetic selection based on EpCAM expression.159,160 To increase sensitivity and specificity, respectively, more markers are used, such as pan-CK and CD45. For CTC capture, antibody-coated magnetic beads are used in the Magnetic-Activated Cell Separation (MACS) method (Miltenyi Biotec, Germany).85 Additionally, the Geometrically Enhanced Differential Immunocapture method combines microfluidics with different antibodies according to the kind of tumor (tumor includes, for instance, HER2 in breast cancer and PSMA in prostate cancer) and positive for cytokeratin for counting.161

Physical characteristics including size, charge, density, or elasticity are used by antigen-agnostic detection systems to enrich CTCs. Detection of CTCs based on physical properties is facilitated by several methods, including density gradient centrifugation, filter-based devices, capture surfaces, and microfluidic systems. Notable examples of microfluidic systems are ISET (Rarecells Diagnostics, France), Smart Biosurface Slides, CTC-iChip (TellBio, USA), and the FDA-approved Parsortix (ANGLE, UK).162,163 To improve sensitivity and specificity even more, multimodality techniques are being developed. For example, Isoflux (Fluxion Biosciences, USA) combines immunomagnetic beads,164 with flow control, and the Cyttel system (CYTTEL Biosciences, China) is an image-based detection tool that identifies CTCs by combining immunohistochemistry, fluorescence in situ hybridization, and centrifugation in that order. With the use of the microfluidic platforms Parsortix and CTC-iChip, marker-based positive and negative selection (such as EGFR, HER2, CD45, and EpCAM) can be combined with imaging and micromanipulation to identify pure CTC subsets.5,111,162,165

Novel in vivo CTC detection tools have emerged to address the challenge of low CTC levels in peripheral blood samples. CTCs can be directly extracted from the bloodstream using methods such as intravascular CTC-catching guidewires coated with EpCAM-directed antibodies, as exemplified by the CellCollector device from GILUPI in Germany.166 When combined with antigen-dependent selection, cytopheresis facilitates the enrichment of cell fractions from vast blood volumes and offers promise for the isolation of CTCs.167 The adoption of this approach into routine clinical practice may pose challenges due to its lengthy and invasive nature, alongside potential vascular health issues in heavily treated cancer patients. Studies comparing different methods of accessing the vasculature shows that patients with early-stage NSCLC have higher CTC counts in tumor-draining vessels than in peripheral locations.156,168 For early-stage cancer patients undergoing surgery, this concept provides an attractive opportunity for liquid biopsy. Despite its significance, it remains impractical to use these findings to routine CTC evaluation or to patients with advanced illness who do not undergo surgery.

Advances in capture methods have enabled thorough molecular and functional studies of CTCs at both bulk and single-cell levels, epigenomic, exploring genomic, proteomic, transcriptomic, and functional properties. This has extended research on these cells beyond mere counting to comprehensive analysis. Since these advances have been extensively reviewed, we will focus primarily on aspects related to cell multi-omics and the functional evaluation of CTCs.2,157,169,170 For instance, assessing drug responses alongside single-cell examination of individual CTCs and CTC clusters can uncover biological dependencies and potential targets for therapy.5 CTC proteins and secreted factors are being characterized using microfluidic platforms that employ single-cell resolution mass spectrometry and bead-based immunoassays.171–173 A key barrier to ex vivo CTC cultures’ clinical applicability is their low success rates, despite the fact that experimental proof-of-principle studies174,175 have demonstrated their efficacy. Although the feasibility and therapeutic relevance of CTC capture and downstream analysis have been shown, most of the above approaches are not currently used as routine. Existing CTC technologies face limitations that necessitate resolution for robust integration into clinical settings. These issues encompass the necessity for a more profound comprehension of epitope expression and plasticity, along with challenges associated with cell loss caused by variations in size and deformability, low purity of CTCs, device blockage, the need for substantial blood volumes, time limitations, and difficulties with automation. Additional challenges include the need to improve functional assays, such as enhancing culture methods and developing CTC-derived xenografts, and ensuring robust validation of molecular analyses. This involves addressing issues like stochastic variations, limited sequencing coverage, biases in amplification, high error rates, and variability in bioinformatics approaches.2 If these challenges are overcome, CTCs may become prominent sources of comprehensive biomarkers that are minimally invasive and personalized.

Metastasis of CTCs

Stephen Paget first proposed the “seed theory” or the soil and seed hypothesis of metastasis in 1889.176 According to the hypothesis, cancer cells (seeds) have a selective affinity for certain organs (soil) and that the capacity of cancer cells to establish colonies in distant locations is determined not only by the characteristics of the cells themselves but also by the specific microenvironment of the secondary site. According to the seed theory, cancer cells must go through a sequence of steps in order to successfully metastasize to a distant site. encompass the cancer cells’ ability to invade the nearby tissue, penetrate the bloodstream or lymphatic system, survive while circulating, extravasate into the secondary site, and establish a new colony of cancer cells.

Initiation of metastasis

According to the “seed theory”, metastasis typically entails two distinct steps. The first step entails a tumor cell’s detachment from its original site and subsequent circulation through the bloodstream or lymphatic system to a distant location. The second step involves the successful colonization of the tumor cell in the distant site, which requires the cancer cell to be able to proliferate and establish a secondary tumor.177 CTCs are crucial for the process of tumor metastasis, and it is believed that a specific subgroup of CTCs found in patient blood is what initiates the metastatic cascade.76 During the early stages of cancer, cellular properties like adhesion and stroma formation act as physical obstacles that impede distant metastasis. To overcome these barriers, carcinoma cells must boost their motility within the stroma and gain access to the bloodstream through either active or passive entry mediated by either the EMT or non-EMT pathways. CTCs that are viable in the bloodstream have the potential to arrest at various locations, including the secondary metastatic sites, or new distant locations.178–181 Upon arrest, these CTCs have the potential to undergo MET, which can facilitate extravasation and allow the cells to either enter a dormant state or colonize and engraft at the site (Fig. 2). CTCs with stem-like properties, demonstrating increased resistance to anoikis and invasive potential, are identified as crucial for successful metastatic dissemination due to their phenotypic heterogeneity.182 Notably, CTC clusters, characterized by polyclonality and enhanced metastatic potential, exhibit superior survival in circulation compared to individual CTCs.183 These clusters are formed through homotypic interactions among tumor cells or heterotypic interactions involving other cell types such as platelets or myeloid cells.184 The formation of these clusters not only boosts the proliferation and survival of CTCs in the bloodstream but also enhances their metastatic efficiency by aiding in immune evasion and seeding competency at distant sites (Fig. 3). Key factors like intratumor hypoxia and platelet interactions are implicated in promoting CTC cluster formation and the initiation of metastasis.185Fig. 2 Schematic representation of EMT-associated mechanisms supporting CTC survival and early metastasis. a CTCs are liberated into the bloodstream by means of epithelial-mesenchymal transition (EMT)-related mechanisms, including individual cell or collective migration, intravasation, as well as passive processes such as the detachment of isolated tumor cells or clumps through damaged blood vessels. Certain individual or clustered CTCs have the ability to survive in the bloodstream and form metastases in secondary organs. This is due to their possession of characteristics that are elevated in EMT-induced cells, and that facilitate their survival in the bloodstream and establishment of metastases. Specifically, b the Fas/FasL signaling pathway plays a crucial role in tumorigenesis, where impairment in cancer cells can lead to resistance to apoptosis and contribute to tumor progression and CTCs generation, c EMT progression is regulated by signaling pathways such as integrin and TGF-β that can cooperate to induce downstream responses to promote CTCs survival and anti-apoptosis properties. The figure was created with BioRender.com

Fig. 3 Mechanisms of CTCs cluster generation and the potential CTC subpopulations survival in the blood circulation. CTCs that undergo EMT express Tissue Factor (TF), which significantly contributes to platelet activation. These coagulation-dependent mechanisms initiate the formation of a fibrin/platelet-rich cocoon around tumor cells, believed to offer protection from shear stress, anoikis, and immune attack. The formation of the aforementioned cocoon is crucial for CTC seeding and early establishment. Additionally, neutrophils have been observed to physically interact with tumor cells and platelets, thereby promoting tumor cell survival and proliferation. Furthermore, neutrophils aid in the adhesion of CTCs to the vascular wall. Neutrophils, through their capacity to capture tumor cells in Neutrophil Extracellular Traps (NETs)—structures that also facilitate coagulation events - aid in the formation of a protective and anchoring scaffold that supports CTC survival. This process facilitates the arrest of CTCs in capillaries and early phases of metastatic establishment. The coagulation- and neutrophil-dependent shielding mechanisms described above safeguard CTCs from immune destruction. Furthermore, CTCs, especially those that undergo EMT, possess an increased ability to evade immune surveillance. One mechanism that contributes to this is the expression of immune checkpoint proteins such as PD-L1, which likely enhances their resistance to cytotoxic immune cells. After a possible period of dormancy, CTCs can eventually resume growth and initiate secondary tumors. The figure was created with BioRender.com

EMT of CTCs

Through a process called EMT, tumor cells can acquire on mesenchymal characteristics like enhanced motility and invasiveness.186–188 The dynamic and intricate process of EMT in cancer cells involves changes in gene expression and the activation of various signaling pathways. During the early stages of EMT, cancer cells undergo a transformation in which they lose their epithelial traits, such as intercellular adhesion and polarity, and gain mesenchymal characteristics to acquire an invasive phenotype.189,190 Alongside this, a number of genes show changed expression, including those related to ECM remodeling, cytoskeletal organization, and cell adhesion.191–193 As the EMT process progresses, cancer cells may undergo additional changes, such as the activation of stemness, which can lead to tumor heterogeneity and treatment resistance. EMT can also facilitate the formation of metastases, as mesenchymal-like cancer cells are better able to invade neighboring tissues and enter the bloodstream or lymphatic system.194,195 The progression of EMT in cancer cells is influenced by various factors such as signaling pathways (TGF-β, WNT, and NOTCH, etc.) including the TME, such as hypoxia and inflammation.38,196 Furthermore, EMT is regulated by a number of transcription factors, such as Twist, Slug, and Snail, which have the ability to either activate or inhibit the expression of genes connected to EMT.197–199 In general, EMT in cancer cells is a dynamic and complex process that is orchestrated by multiple signaling pathways and transcription factors. Understanding the mechanisms that drive EMT in cancer cells may provide new ideas for the management of cancer.

Initiation of EMT

Several signaling pathways, such as TGF-β, WNT, and NOTCH signaling, initiate the process of EMT. These pathways trigger transcription factors, such as Twist, Snail, Slug, and zinc finger E-box binding homeobox 1 (ZEB1), that promote mesenchymal genes and suppress epithelial genes.200–202 By reducing cell-cell interaction, EMT-related transcription factors including Snail and TWIST promote motility and invasiveness in vitro. Nevertheless, knockdown of these factors could only partially limit metastasis in vivo, which challenges the necessity of them for the metastatic process.80,81 Interestingly, loss of E-cadherin or TWIST modulation was found to prevent the successful metastatic seeding of in several EMT lineage tracing models.82 Many studies have investigated several genes associated with EMT in CTCs. Among the commonly studied EMT target genes, Vimentin is often included.203–205 Vimentin, primarily expressed in mesenchymal cells as a type III intermediate filament, is a well-known indicator of EMT and is frequently studied in relation to CTCs. Moreover, it has been associated with tumor metastasis, including promoting CTC survival and tumor cell migration.206,207 EMT has been observed to affect the expression of a variety of epithelial adhesion molecules, thereby modifying intercellular interactions. A typical example is the modulation of adhesion molecules, which involves suppression of E-cadherin and up-regulation of N-cadherin. This change in expression has been linked to the EMT process,208,209 and both E-cadherin and N-cadherin, molecules that modulate cell-cell interactions and whose expression is altered in EMTs, are often evaluated in CTCs. The adhesion molecule EpCAM, previously utilized in CTC studies for enrichment purposes, is another EMT target gene that is frequently investigated in CTC research.210,211

Disassembly of cell–cell junctions

EMT begins with the disruption of tight junctions, adherens junctions, and desmosomes, which hold epithelial cells together.111,212,213 In order for tumor cells to separate from the main tumor and infiltrate nearby tissues, this step entails the breakdown of the intercellular adhesion molecules that hold epithelial cells together. One key player in the disassembly of cell-cell junctions during EMT is Snail.214 Snail suppresses the E-cadherin expression, which is a key component of adherens junctions that hold epithelial cells together. By recruiting co-repressors such histone deacetylases (HDACs) and chromatin remodeling factors, snail is able to repress this gene by attaching to E-box elements in the E-cadherin promoter region.63,215 This results in the E-cadherin silencing and the subsequent loss of cell-cell adhesion. Other transcription factors such as ZEB1 and Slug also exerts crucial functions in the disassembly of cell-cell junctions during EMT. Slug represses E-cadherin expression by binding with its promoter and recruiting HDACs and other co-repressors. ZEB1 upregulates mesenchymal genes including Vimentin and fibronectin while suppressing the expression of E-cadherin, further supporting the mesenchymal phenotype of cancer cells.216,217 A role for signaling pathways in the disassembly of cell-cell junctions during EMT has also been studied in previous research. For instance, it is known that the TGF-β pathway induces EMT in different forms of cancer by increasing the expression of associated transcription factors that inhibit E-cadherin.218,219 The Notch and Wnt pathways have also correlated with EMT and cell-cell junction disassembly in different cancer types.114,220,221 In conclusion, the disassembly of cell-cell junctions is a complex process that entails the dysregulation of multiple signaling pathways and transcriptional networks. The development of novel therapies for the control and prevention of metastatic cancer may result from improving our understanding of the molecular mechanisms underlying this process.

Remodeling of the ECM

During EMT, cancer cells undergo changes that allow them to break down the ECM and invade surrounding tissues.191 Several studies have investigated the molecular mechanisms underlying this process in various cancer types. One of the key players in ECM remodeling during EMT is the matrix metalloproteinases (MMPs). MMPs are a class of zinc-dependent endopeptidases that can degrade collagens, laminins, and proteoglycans, among various ECM components.222–224 MMPs are upregulated during EMT in numerous cancer types, and their expression is manipulated by a number of signaling pathways and transcription factors, including Twist and Snail.225,226 Other proteases have also been implicated in ECM remodeling during EMT, including urokinase-type plasminogen activator (uPA) and its receptor.227,228 uPA is an enzyme belonging to the class of serine proteases that can activate plasminogen, leading to the degradation of ECM components.229 uPA expression is upregulated during EMT in various cancer types, and its expression is governed by various transcription factors such as Snail and ZEB1.230,231 The remodeling of the ECM during EMT also involves changes in the expression and activity of integrins, a group of transmembrane receptors that regulate cell-ECM interactions. A variety of signaling pathways and transcription factors, such as TGF-β and Snail, orchestrate the upregulation of integrin expression during EMT in various cancer types.232 Integrins can promote the invasiveness of cancer cells by activating downstream pathways such as phosphatidylinositol 3-kinase (PI3K) and focal adhesion kinase.233,234 Studies have also shown the involvement of non-coding RNAs (nc), including long nc RNAs (lncRNAs) and microRNAs (miRNAs), in ECM remodeling during EMT. For example, miR-29b has been shown to inhibit the expression of MMP2 and MMP9, leading to the suppressed ECM degradation and inhibited EMT in lung cancer cells. Similarly, the lncRNA MALAT1 has been demonstrated to trigger ECM remodeling and EMT in bladder cancer cells by manipulating the expression of MMP2 and uPA.235–237

Non-EMT with CTCs

Recent studies utilizing transgenic mouse models has indicated that invasion and metastasis may happen without the involvement of EMT. These findings support the concept that the initiation of metastasis may not necessarily require EMT.80,81 The deletion of EMT-related transcription in transgenic mouse models suggests that EMT inhibition does not affect the development of systemic metastasis.81 Moreover, it has been reported by Godinho et al. that cancer cell invasion can also be triggered by centrosome amplification. This occurs through the disruption of cell-cell adhesion and an increase in actin polymerization dependent on Arp2/3.238 Moreover, passive infiltration, which is caused by external forces such as mechanical stress and tumor growth, can lead to the genesis of “accidental” CTCs in the bloodstream.239,240 The disseminated cancer cells that arise from invasion not mediated by EMT can reside either as individual cells or clusters and maintain their epithelial phenotype.80,239

CTC clusters pose a higher risk for cancer metastasis compared to individual CTCs, and they also have unique properties that make them resistant to chemotherapy and immune surveillance. Though the mechanism of CTC cluster formation remains elusive, several studies have shed light on the process. A study by Aceto et al. investigated the role of E-cadherin, a cell adhesion molecule, in CTC cluster formation. They found that E-cadherin was downregulated in single CTCs, but it was upregulated in CTC clusters. Furthermore, they showed that blocking E-cadherin expression prevented CTC cluster formation, suggesting that E-cadherin plays a crucial role in CTC cluster formation.241,242 Gasic et al. was one of the first to suggest that platelets might be involved in CTC cluster formation.84 They found that platelets accumulated around CTCs in the bloodstream, and they speculated that platelets might facilitate CTC cluster formation. More recent studies have confirmed this hypothesis. For instance, a study by Haemmerl found that platelets promoted CTC cluster formation by activating the TGF-β signaling pathway, which upregulates EMT genes and downregulates cell adhesion molecules.243,244 The role of integrin in CTC cluster formation. They found that CTCs overexpressed several integrins, including integrin α5β1, which promoted CTC cluster formation by facilitating cell-cell adhesion.245,246 The role of chemokines, a group of signaling proteins that recruit immune cells to the location of inflammation or infection, in CTC cluster formation. CTCs secreted several chemokines, including CXCL1 and CXCL2, which promoted CTC cluster formation by attracting neutrophils, a type of immune cell, to the site of CTCs.247,248 The role of hypoxia, a condition of low oxygen levels, in CTC cluster formation. Hypoxia upregulated the expression of a transcription factor called HIF-1α, which promoted CTC cluster formation by upregulating EMT genes and downregulating cell adhesion molecules. The role of physical forces, such as shear stress and hydrodynamic forces, in CTC cluster formation. CTCs were more likely to form clusters in areas of low shear stress and high hydrodynamic forces, such as in the corners of blood vessels.249–251 In summary, CTC cluster formation is a multifactorial and complex process that entails multiple biological and physical factors. Despite our incomplete comprehension of the mechanism of CTC cluster formation, technological advancements have facilitated a more precise and comprehensive examination of CTCs and CTC clusters, offering new potential for understanding and treating metastatic cancer.

Aniokis

When epithelial cells detach from their surrounding tissue, they usually undergo programmed cell death known as anoikis, which limits the efficacy of metastatic seeding.72–74 However, a small proportion of tumor- or metastasis-initiating cells with stem-like characteristics have been found to have an enhanced ability to survive and seed tumors.47,75,85 EMT is considered as a prerequisite for metastatic dissemination, as it enhances contact-independent survival and invasive potential.78,79 This indicates that EMT may function as a modulator rather than a promoter of metastasis. Meanwhile, a moderate level of EMT has been observed in CTCs, which links to stem-like properties, plasticity, reduced response to treatment and disease development.76,85 On the invasive edge of xenografts and patient tumor tissues of common carcinoma types, intermediate EMT stages have been seen.84,86,87 However, further investigation is needed to determine their functions in invasion, and metastatic dissemination.

The investigation of EMT within the context of CTCs is a field that is rapidly evolving, with numerous essential factors being explored. Commonly examined within CTCs are EMT-associated genes such as Vimentin, adhesion molecules, and core transcription factors. The analysis of signaling pathways triggered by membrane receptors and Receptor Tyrosine Kinases (RTKs) is a common practice in CTC studies, as these pathways, such as EGFR, TGF-β, Notch, c-Met, and Wnt, are crucial in the regulation of EMT. The investigation of Axl, an RTK associated with EMT, is gaining momentum in CTC studies, given that clinical trials are currently evaluating commercial inhibitors for Axl. It is noteworthy that EMT is associated with cancer-stem cells, and the majority of EMT-related markers examined in CTCs affect CTC survival and the ability to metastasize. Numerous studies have provided evidence of the heterogeneity of EMT-associated molecules present in the CTC population and have identified hybrid epithelial/mesenchymal (E/M) phenotypes in lung cancer. Table 2 highlights these findings.Table 2 Summary of the clinical prognosis of CTC markers

EMT and Stemness Markers (+Other Associated)	Correlation between EMT Markers and Clinical Parameters	References	
EpCAM, CK8, CK18, CK19, Vimentin, Twist, OCT4	Associated with distant metastasis and correlated with high total CTC counts	72–74	
EpCAM, Vimentin	Poor response to chemotherapy and correlation with a decreased PFS	47,47,75,75,85,85	
EpCAM, CK8, CK18, CK19, Vimentin, EGFR, KRAS	Reduced OS	78,79	
EpCAM, CK8, CK18, CK19, Twist, Vimentin	Associated with metastasis	72–74	
EpCAM, EGFR, CK7	Negative correlation with clinical stage	74	
CK8, CK18, CK19, EpCAM, Vimentin, N-Cadherin, PD-L1	Associated with poorer survival	85	
CK8, CK18, CK19, AXL, EGFR	Poor prognosis	86	
PD-L1, EpCAM, CK8, CK18, CK19, Vimentin, Twist, PD-L1 EGFR, KRAS, BRAF, ROS1 mutation, ALK rearrangement	Poor prognosis	86	
Vimentin, CK, AXL	Poor prognosis	85	
EpCAM, Vimentin, CK	Poor prognosis	85	

Intravasation of CTCs

Intravasation, which involves the entry of cancer cells into the bloodstream, can occur through either active or passive mechanisms. The exact mechanism utilized by the tumor cells depends on various factors, including the tumor types, the micro-environment, and the integrity of the blood vessels.252 Active intravasation occurs when tumor cells or clusters actively migrate into the bloodstream through EMT. Passive intravasation, on the other hand, happens when single cells or groups of cells separate from the main promise and enter the bloodstream as a result of broken tumor blood vessels brought on by tumor growth or treatment.181 After entering the bloodstream, CTCs are subjected to various obstacles that can threaten their survival, including shear stress caused by blood flow, anoikis, all of which can potentially lead to their elimination.253 Tumor cells can gain access to the bloodstream through either a blood vessel or a lymphatic vessel, which can be influenced by several factors such as accessibility, physical constraints, and the existence of active mechanisms that lure cells to specific types of vessels.254,255 Additionally, tumor cells can utilize lymphatic vessels as a pathway to enter the bloodstream since these vessels ultimately empty into the major thoracic duct.254,256 Although lymphatic vessels can aid in the entry of certain cancer cells into the blood circulatory system, current evidence is limited, and cancer cells may encounter dead ends in lymphatic deposits. This observation highlights the degree of concurrent dissemination from the primary tumor.75,257,258 Alternatively, cancer cells are likely to spread primarily through the bloodstream for distant metastasis. In this process, lymphatic fluid passes through a sequence of lymph nodes, which frequently serve as the primary sites of metastasis.252,259

Colonization of CTCs

The colonization of tumor cells is the final step of the metastasis process and involves the establishment of tumor cells in a distant organ.232,260,261 The colonization process is complex and involves several steps that are regulated by multiple signaling pathways and molecular networks. This process requires the re-activation of epithelial factors and the suppression of mesenchymal ones, a process known as MET. Several studies have investigated the molecular mechanisms underlying this process in various cancer types. One of the key players in the colonization of tumor cells is p63, which is a member of the p53 group of tumor suppressors. P63 is upregulated during MET in a variety of cancer types and is essential for the maintenance of epithelial stem cells.262 P63 promotes the reactivation of epithelial genes like E-cadherin and cytokeratins, while suppressing mesenchymal genes like Vimentin and fibronectin.263 Twist and Snail have also been implicated in the regulation of MET and the colonization of tumor cells. Twist is upregulated during EMT and downregulated during MET.264 Twist improves the mesenchymal phenotype of tumor cells by suppressing E-cadherin expression and increasing N-cadherin and fibronectin expression.265 Snail, on the other hand, promotes EMT and invasion by inhibiting E-cadherin expression, but its role in MET and colonization is less clear. Several signaling pathways also participated in the regulation of MET and tumor cell the colonization.266,267 The TGF-β pathway, for example, can induce EMT in various cancer types but can also promote MET and colonization by activating the expression of p63 and other epithelial genes.268 Other signaling pathways, such as Notch, Hedgehog, and Wnt, have also been implicated in the regulation of MET and colonization in various cancer types.269,270 During metastasis, CTCs and the target organ microenvironment engage in a critical dialog that determines the fate of metastatic colonization. This interaction encompasses various components such as ECM proteins, immune cells, and soluble factors, which collectively influence the survival, dormancy, and growth of CTCs. Key processes include the EMT, which CTCs undergo to establish new tumors, and the evasion of immune surveillance. The microenvironment’s role extends to either supporting CTC colonization through the provision of growth factors or hindering it by presenting physical barriers and immune challenges.271,272

The CTCs under immune system surveillance

The mechanism by which CTCs overcome immune system surveillance is not completely understood, but there are several possible ways in which they may evade detection by the immune system. One explanation is that CTCs suppress or mask the expression of surface antigens that immune cells often recognize as abnormal or foreign. This can make the CTCs less visible to the immune system and allow them to escape detection. Another possibility is that CTCs produce factors that suppress or inhibit the immune response, such as cytokines or chemokines that recruit immune cells to the tumor microenvironment but then suppress their function. For example, studies have shown that CTCs can produce the cytokine TGF-β, which can suppress the activity of T cells and other immune cells (Fig. 4). Finally, CTCs may be able to evade immune surveillance by mimicking normal cells or using other mechanisms to avoid detection. For example, some CTCs may express proteins or molecules that are normally present in healthy cells, leading to a challenge for the immune system in differentiating them from healthy cells.273,274Fig. 4 Immune-escape mechanisms of CTCs in the peripheral blood. The diagram depicts the various mechanisms employed by CTCs to circumvent the immune system and the interactions that take place between CTCs and immune cells in the peripheral blood. The interaction between circulating tumor cells (CTCs) and natural killer (NK) cells is a prominent area of investigation, given that CTCs secrete LDH5 and shed the MICA/MICB ligand via ADAM10, which inhibits recognition and elimination of CTCs through NK cell-mediated lysis. The diagram portrays three mechanisms employed by CTCs to evade recognition by NK cells and T cells through MHC I molecules. These strategies include masking MHC I recognition by TCR via cytokeratins (CK8, CD18, and CK19) bound to the cell surface, gaining a “pseudo-normal” phenotype through membrane transfer from platelets to CTCs, and reducing or eliminating MHC I expression altogether. The interaction between CTCs and natural killer (NK) cells is a key area of focus, as the release of LDH5 and shedding of MICA/MICB ligands by ADAM10 from CTCs prevents their recognition and elimination via NK cell-mediated lysis. Additionally, LDH5 enhances NKG2D ligand expression on circulating monocytes, which in turn reduces NKG2D expression on NK cells. Furthermore, the diagram illustrates other strategies employed by CTCs to evade the immune system, such as the upregulation of the inhibitory immune checkpoint molecule PD-L1, expression of the “don’t eat me” signaling receptor CD47 and altered expression of apoptotic proteins FAS and/or FASL. The figure was created with BioRender.com

Immune evasion through antigen loss

CTCs can downregulate or lose expression of antigens normally recognized by the immune system, making them less visible to immune cells. MHC class I molecules, for example, are required for T cell recognition, and their expression is downregulated by certain CTCs. For example, in 2012, researchers found that the expression of EpCAM, a common antigen used for CTC detection, was downregulated in CTCs from breast cancer patients who had received chemotherapy.275,276 Similarly, a study reported that CTCs from breast patients who received anti-HER-2 therapy reduced their expression of HER-2, another common antigen.277–279

CTCs secreted immunosuppressive factors

CTCs have the ability to secrete immunosuppressive factors including TGF-β and IL-10, which can inhibit immune cell activation and function and create an immunosuppressive milieu that shields CTCs from immune attack. A previous work demonstrated that CTCs from breast cancer patients secrete high levels of TGF-β, which can and promote tumor growth and metastasis because of immune cell inactivation.280–282 Similarly, another study showed that CTCs from melanoma patients release IL-1, which has the ability inhibit T cell activation and proliferation, a crucial part of the immune system’s defense against cancer.103,283,284 Besides, Zhao et al. reported that CTCs from lung cancer patients secrete CCL2, which can attract immune-suppressive cells to the tumor microenvironment, thereby suppressing the immune response. Then, a clinical trial demonstrated that CTCs from prostate cancer patients secrete GAL-3, which can induce the apoptosis of tumor-killing immune cells, thereby blocking the immune response against cancer.285–287 In order to promote angiogenesis and suppress the immune response, CTCs from breast cancer patient have also been reported to secrete VEGF.288–290 Also, CTCs from colorectal cancer patients secreted PGE2 and led to immune suppression and tumor progression as well.291,292 Moreover, CTCs from melanoma patients secrete IL-10, which can inhibit the proliferation and promote tumor growth and metastasis by activating T cells.293,294 A study showed that CTCs from lung cancer patients expressed high levels of programmed cell death ligand 1(PD-L1), which inhibited the activity of immune cells and promoted immune evasion.295–298

Immunological checkpoint (IC) proteins

CTCs have the ability to express IC proteins, such as PD-L1, which bind to the receptors on immune cells to prevent the immune cells from activating and functioning. This can prevent immune cells from attacking CTCs and allow them to escape immune surveillance. CTCs from patients with advanced colorectal, breast, or prostate cancer exhibit IC proteins such PD-L1 and CTLA-4, which can promote immune evasion and support in tumor growth, according to Krebs MG.297–299 Maheswaran et al. demonstrated that CTCs from lung cancer patients express PD-L1 and other IC proteins, and that PD-L1 expression is linked to poor prognosis.300,301 Gkountela et al. reported that CTCs from breast cancer patients express PD-L1, which is linked to resistance to chemotherapy.302 Zhang W et al. showed that CTCs from gastric cancer patients express PD-L1 and TIM-3, which is associated with advanced stage and poor prognosis.303 Sanmamed et al. demonstrated that CTCs from melanoma patients express PD-L1 and other IC proteins, and that PD-L1 expression leads to treatment resistance and poor outcome.304 Similar results have been observed in patients with breast cancer.305 Another study revealed that CTCs from lung cancer patients who received IC inhibitor therapy have downregulated PD-L1 expression.306–308 The dual inhibition strategy of blocking PD-L1 and CD47 on CTCs has been found to significantly enhance the effectiveness of IC therapy. By enabling the immune system to more efficiently target and eliminate CTCs, this approach holds promise for reducing the risk of tumor recurrence and metastasis. Preclinical models have demonstrated that this combination therapy is more effective, indicating its potential for successful clinical application in cancer treatment.309

Production of extracellular vesicles

By promoting the detachment of CTCs from the original site, extracellular vesicles (EVs) play a vital role in the metastatic process. EVs enhance the shedding of CTCs and protect them in circulation, thereby influencing their metastatic direction. The detachment of CTCs from the main site is facilitated by EVs, which also contribute to EMT and ECM remodeling, promote angiogenesis, and improve vascular permeability. In addition, EVs protect CTCs by activating platelets, inducing immunosuppression, and determining the organotropism of metastasis, thus influencing the colonization of CTCs in distant organs.310 EVs released by CTCs can interact with immune cells and modulate their function, creating an environment that favors CTC survival and growth. Armstrong AJ showed that CTCs from prostate cancer patients produce extracellular vesicles that can suppress the immune response by suppressing the T cell and NK cell activity.311–313 Keklikoglou demonstrated that CTCs from breast cancer patients produce extracellular vesicles that can promote immune evasion by inducing the differentiation of monocytes into immunosuppressive macrophages.314–316 Whiteside TL et al. discussed the role of extracellular vesicles produced by CTCs and other tumor cells in promoting immune suppression and tumor progression.317 Peinado H et al. showed that CTCs from breast cancer patients produce extracellular vesicles that can promote metastasis by modifying the microenvironment at distant sites and suppressing the immune response.318 Liu C et al. demonstrated that extracellular vesicles produced by CTCs from lung cancer patients can induce immunosuppression by blocking the activity of NK and T cells.319 Melo SA et al. showed that CTCs from pancreatic cancer patients produce extracellular vesicles that can promote immune evasion by inducing the differentiation of monocytes into immunosuppressive macrophages.320 Lu J et al. demonstrated that extracellular vesicles produced by CTCs from lung cancer patients can induce immunosuppression.321,322 Hoshino et al. showed that CTCs from melanoma patients produce extracellular vesicles that can promote immune evasion by inhibiting the activity of tumor-killing immune cells, and that targeting these vesicles can enhance the effectiveness of immunotherapy.323

Formation of immune-resistant micro-metastases

CTCs can establish small metastatic lesions that are immune-resistant. These lesions can create a reservoir of CTCs that can escape immune surveillance and facilitate further metastatic spread. ICAM1 is essential for the development of CTC clusters and their trans-endothelial migration in lung metastases of BRCA. It has been found to facilitate metastasis more effectively in clusters as opposed to single cells, thereby contributing to a decrease in overall survival rates. In lung metastases of patient-derived xenografts of TNBC, the expression of ICAM1 is noticeably elevated. The inhibition of ICAM1 has been shown to impede the lung colonization of TNBC cells by disrupting the formation of tumor cell clusters, suggesting that ICAM1 could serve as a promising therapeutic target for inhibiting metastasis initiation in TNBC.100 Janssen LME showed that CTCs can form immune-resistant micro-metastases by secreting extracellular vesicles that modulate the immune response and create a favorable microenvironment for metastatic growth.324 Krebs et al. demonstrated that CTCs can form micro-metastases that are resistant to chemotherapy and immune surveillance in breast cancer patients.325 Focusing on the formation of osimertinib-resistant micro-metastases following treatment, a study described an orthotopic model of lung cancer. This model provides a platform for analyzing resistance mechanisms and evaluating new therapeutic strategies against metastases of NSCLC.326 Kallergi et al. showed that CTCs can form micro-metastases that are resistant to chemotherapy and immune surveillance in breast cancer patients, and that targeting the immune system can improve treatment outcomes.326 Aceto N et al. showed that CTCs can form micro-metastases that are resistant to chemotherapy and immune surveillance in breast cancer patients, and that targeting the immune system can improve treatment outcomes.327 Bidard FC et al. demonstrated that CTCs can form micro-metastases that are resistant to chemotherapy and immune surveillance in breast cancer patients, and that targeting the immune system can improve treatment outcomes.328

Platelets coordinate with CTCs

It has been indicated that the lifespan of certain CTCs is brief, as a majority of them are undetectable within 24 h after primary tumor excision.329 Research reported that the interaction of CTCs with other blood components, particularly platelets, significantly affects their survival and potential for metastasis.329 CTCs shortly after entering the bloodstream, are known to create a thrombus rich in platelets around them, serving as a protective shield against shear stress and immune response. Furthermore, this thrombus promotes the attachment of CTCs to the endothelial lining of blood vessels, enabling extravasation.121,309,330 Upon entering the bloodstream, CTCs can form a shield of platelets through the action of platelet tissue factor. The formation of a thrombus rich in platelets can offer protection to CTCs against shear stress and immune system attacks, while also aiding in the attachment of tumor cells to the blood vessel wall and extravasation. Moreover, studies have shown that activated platelets can transfer the MHC to CTCs, enabling them to evade immune surveillance by mimicking host cells.117,331 In addition, platelets have been shown to reduce the recognition and elimination of tumor cells by NK cells. Platelets can release soluble factors that impair the cytotoxicity of NK cells and promote the expansion of regulatory T cells, which further interfere with the immune responses. Platelets can also inhibit the recognition and destruction of tumor cells by immune cells, as they express molecules that interact with receptors on immune cells and prevent their activation. One such molecule is CD47, which can bind to SIRPα on macrophages and inhibit their engulfment of tumor cells. These mechanisms collectively enhance the survival and dissemination of CTCs.117,243

Moreover, the transfer of MHC molecules by platelets is a mechanism by which CTCs can evade immune surveillance.117,332 Platelets have the ability to impede the identification and destruction of neoplastic cells by NK cells.18,322,333 The invasiveness and metastasis of CTCs can be enhanced by platelets, which release TGFβ and promote the EMT in these cells. This phenomenon has been demonstrated in previous research.107,334 CTCs have been found to interact with different types of leukocytes such as, monocytes, and macrophages, which can enhance the survival of CTCs and facilitate their interaction with endothelial cells, leading to extravasation.21,107

Role of epigenetic modifications in deciphering the properties of CTCs

Recent research has highlighted that significant epigenetic alterations in normal cells can lead to the acquisition of a malignant phenotype.335 Epigenetics involves the investigation of inheritable alterations in gene expression that occur without modifications to the DNA sequence itself.336 A number of epigenetic modifications, including histone acetylation and methylation patterns, microRNA-mediated gene regulation, hypomethylation of oncogenes, hypermethylation of tumor suppressor genes, and others, greatly contribute to the progression of cancer.337 Understanding the intratumor heterogeneity and gaining insight into tumor-specific epigenetic markers linked to metastasis may be facilitated by mapping the epigenetic landscape of CTCs. This approach may also identify subpopulations of CTCs capable of metastatic dissemination. The main areas of epigenetic research that apply to this scenario are gene regulation and DNA methylation.

DNA methylation

DNA methylation is the addition of methyl groups to DNA’s cytosine residues, and it is essential for regulating gene expression. DNA methylation patterns that deviate from the normal or expected patterns have been linked to various health conditions, including cancer. Several studies have shown that CTCs have distinct DNA methylation profiles compared to primary tumors, which could be useful in detecting early-stage cancer, predicting cancer prognosis, and developing targeted therapies.338,339

CTCs exhibit unique DNA methylation patterns that differ from primary tumor.339 For instance, in breast cancer patients, CTCs had increased DNA methylation levels compared to primary tumors.121 They identified several differentially methylated genes that were specific to CTCs, including the FBLN1, FBN2, and IGFBP6 genes. A prognostic factor for cancer may be the DNA methylation status of CTCs, as these genes have been linked to the progression and metastasis of cancer. Similarly, in prostate cancer, CTCs had unique DNA methylation patterns compared to primary tumors.340 They identified several differentially methylated genes, including the FOXA2, HOXA9, and PTEN genes. These genes are involved in cancer progression, invasiveness, and metastasis. Additionally, they discovered a correlation between the DNA methylation status of CTCs and patient survival, suggesting that this biomarker may have applications in the prediction of cancer prognosis. Moreover, DNA methylation patterns of CTCs can also differ based on the origin of the tumor. For instance, a study by Xu et al. compared DNA methylation profiles of CTCs separated from lung cancer and pancreatic cancer patients.341 They found that CTCs from lung cancer patients exhibited higher DNA methylation levels compared to CTCs from PAAD patients. Furthermore, they identified differentially methylated genes specific to each cancer type, such as the RASSF1A gene in lung cancer CTCs and the TGFBI gene in pancreatic cancer CTCs. This evidence support that the DNA methylation pattern of CTCs could be used to distinguish between different cancer types and aid in personalized cancer treatment.342

In addition, DNA methylation patterns of CTCs can also be influenced by treatment. DNA methylation patterns of CTCs changed after chemotherapy in breast cancer patients.343 They identified several genes, including the CDH1 and ZEB1 genes, which had differentially methylated CpG sites before and after chemotherapy. These results imply that monitoring alterations in the DNA methylation patterns of CTCs could be utilized to evaluate the effectiveness of cancer treatments.

Further research is required to unravel the gene methylation landscape of CTCs and how these methylation changes contribute to CTC-mediated metastasis. Such studies can reveal the tumor-specific epigenetic characteristics related to metastasis and the heterogeneity of tumor populations.344,345 Gkountela et al. analyzed the DNA methylation patterns of CTCs from BRCA patients and tumor xenograft models in NSG mice and discovered numerous differentially methylated regions (DMRs) in CTCs.5,346 CTCs showed lower DNA methylation levels of genes such as JUN, MIXL1, SHOX2, and MEF2C, which are often enriched in various types of cancer. CTC clustering was associated with low methylation levels of TFBSs that regulate and proliferation- and stemness-related genes, such as OCT4, MANOG, SOX2, and SIN3A.17,97,347 This was accompanied by hypermethylation and H3K27me3 repression of target gene promoters and bodies of PRC2 targets, including SUZ12 and EED, collectively increasing the hematogenous metastatic potential of CTC clusters.348,349 In a study comparing the DNA methylation of CTCs from cancer patients and normal blood controls, abnormal methylation changes were found in multiple genes, and were associated with resistance to sunitinib. This ample evidence suggests that abnormal gene methylation in CTCs may play a crucial role in their clustering and promote distant metastatic ability (Table 3).Table 3 Summarizes the aberrant methylation of different genes in CTCs across cancers

Cancer type	Model of CTC studied	Genes studied	Functional class of the genes	Nature of methylation change	Effect of aberrant methylation on cancer cell	Reference	
Breast cancer	Patient-derived CTCs	SOX17

CST6

	tumor suppressor	hypermethylated	promotes invasion	5	
BRMS1	tumor suppressor	hypermethylated	promotes invasion	5	
ESR1	metastasis suppressor	hypermethylated	promotes invasion, stemness, and mesentchymal phenotype	5	
ITIH5			promotes tumor growth and resistance to immunotherapy	346	
RASSF1A	tumor suppressor	hypermethylated	increased invasiveness, stemness, and proliferative potential	97	
NANOG	tumor suppressor	hypermethylated	increased invasiveness, stemness, and proliferative potential	5	
SOX2	tumor suppresor	hypermethylated	promotes cluster formation in CTCs	97	
SIN3A	represses oncogenic activity	hypomethylated	promotescluster formation in CTCs	5	
RASSF1A	transcription factor that helps maintain self-renewal and pluripotency		promotes cluster formation in CTCs	346	
hVIM	represses oncogenic activity	hypomethylated	increases metastatic potential of CTCs	347	
Melanoma	Patient-derived CTCs	SFRP2	tumor suppressor	hypermethylated	increases invasion		
Colorectal Cancer	Patient-derived CTCs	RASSF1A	tumor suppressor	hypermethylated	increases metastatic potential		
MLL3	tumor suppressor	hypermethylated	promotes proliferation		
CDH1	EMT suppressor	hypermethylated	activates EMT and increases invasiveness		

Aberrant DNA methylation leading to mutation and inactivation of oncogenes or tumor suppressor genes

TSGs play a critical role in orchestrating cellular processes and maintaining genomic stability. Their mutations can cause excessive cell proliferation, which can contribute to the development of tumors. They are also in responsible for causing apoptosis, repairing DNA damage, and regulating cell division. One example of a TSG is hMLH1, which is involved in DNA mismatch repair.350 Studies have shown that hMLH1 gene mutations and Microsatellite Instability are positively correlated with hMLH1 promoter hypermethylation. The Knudson hypothesis proposes that mutations in both alleles are necessary to inactivate TSGs, and epigenetic modifications, such as the silencing of one allele through promoter hypermethylation, can satisfy this requirement.351

Some patients showed evidence of epigenetic silencing of the MGMT gene by promoter hypermethylation, which was connected to a higher frequency of activating mutations in KRAS, a proto-oncogene frequently mutated in colorectal cancer. It has been indicated that hypermethylation of the MGMT promoter may contribute to the development of colorectal cancer by promoting KRAS mutations through the inactivation of a DNA repair gene. A study of 244 patients with colorectal cancer analyzed the effects of epigenetic alterations on proto-oncogenes by examining the MGMT gene. The study found that the promoter hypermethylation-mediated MGMT inactivation was linked with a rise in guanine-to-adenine mutations in K-Ras oncogenes. The MGMT gene expression helps to prevent such transitions in the Ras genes.352 The aforementioned discoveries underscore the essential function of epigenetic modifications in stimulating proto-oncogenes and consequently, advancing the growth and advancement of cancer. A study revealed that lung cancer CTCs demonstrate a distinctive DNA methylation pattern in comparison to primary tumors and normal tissues. This signature is characterized by a substantial reduction in CTC DNA methylation overall, indicating a process of gradual demethylation that progresses from primary tumors to normal tissues and ultimately to CTCs. This underscores the dynamic epigenetic alterations linked to cancer metastasis and spread. Notably, this demethylation phenomenon is observed throughout various genomic regions, encompassing promoters, gene bodies, introns, and intergenic regions. There is a noticeable decrease in methylation at CpG-poor promoters in CTCs when contrasted with primary tumors.338 We have summarized the different mechanisms of DNA methylation modifications in CTCs to promote metastasis in Fig. 5.Fig. 5 Different DNA methylation modifications operating in CTCs to promote metastasis. The process by which methylation promotes detachment and invasiveness of CTCs is intricate and involves both hypermethylation and hypomethylation of various genes. a Specifically, hypermethylation of tumor suppressor genes (TSGs) and metastasis-associated genes (MSGs) triggers the detachment of CTCs and contributes to their enhanced proliferative capacity. CTC clusters exhibit distinct DNA methylation profiles compared to single CTCs, featuring hypomethylation of binding sites for transcription factors like OCT4, NANOG, SOX2, and SIN3A, b which are stemness-related transcription factors play crucial roles in the pluripotency network of induced pluripotent stem cells (iPSCs). The figure was created with BioRender.com

Hypomethylation regulation of CTC clusters and increases metastatic potential

The sustained proliferation and self-renewal capacities of embryonic stem cells require the maintenance of stemness and proliferation properties.353 It has been indicated that stemness-related genes may be entailed in the dissemination of cancer cells. However, the precise mechanisms underlying the ability of CTCs to disseminate and form metastases are not yet fully elucidated, and their survival in the bloodstream is critical for this process. A research study on breast cancer patients aimed to examine the metastasis of CTCs by investigating their ability to form clusters. In the study, single CTCs and CTC clusters from patients with progressing breast cancer were isolated using Parsortix microfluidic technology. Subsequently, whole-genome bisulfite sequencing was conducted on single-cell resolution matched CTCs, which were selected from eight out of a total of 43 analyzed samples (19%). The sequencing outcomes revealed that clusters had hypomethylation of stemness-related genes, specifically SOX2, NANOG, and SIN3A, compared to sing CTCs. This observation facilitated the identification of potential therapeutic targets that might diminish the metastatic potential of the CTC clusters. Specifically, the researchers identified the alteration of methylation patterns in the promoter of the related genes by a Na+/K+ ATPase inhibitor led to the separation of the clusters and the reduced tumor metastasis in mice.5

A study identified DMRs between CTCs and primary lung cancer samples, revealing a significant number of hypomethylated DMRs in CTCs. This trend towards decreased DNA methylation at aberrantly methylated loci in CTCs suggests a potential mechanism underlying their unique characteristics. A potential function in regulating crucial physiological processes such cell proliferation, differentiation, and apoptosis was discovered in the hypomethylated regions of CTCs, which were found to be highly enriched for transcription factor binding sites (TFBSs). Consequently, the evidence supports the idea that hypomethylation in CTCs may play a crucial role in the formation of CTC clusters and enhance their metastatic potential by influencing gene expression related to EMT and other pathways critical for cancer progression.338 The significance of this study lies in its use of genome-wide sequencing-based methylation profiling for CTCs, making it the first of its kind. This emphasizes the importance of generating comprehensive methylation patterns for CTCs in the context of broader biological research. The incorporation of advanced technology in this research signifies a significant advancement in the current understanding of metastasis and the recognition of novel drug targets.

Hypermethylation regulation the invasiveness of CTCs

The process of detachment of CTCs from their primary tumors and their subsequent migration to distant organs is a pivotal event in the progression of metastasis. To facilitate this process, the cells require the ability to detach and enhance their plasticity, allowing them to penetrate through capillaries and settle in different organs. The mechanism that plays a crucial role in this process is known as EMT, which endows the cells with increased invasiveness and motility.354 Utilizing peripheral blood samples from 52 patients with metastatic colorectal cancer, the researchers extracted CTCs and examined the methylation patterns of two crucial EMT genes, Vimentin and SFRP2, to investigate the function of EMT in CTC invasiveness. The findings of the study indicated that the selected genes were heavily methylated in the isolated CTCs as compared with the healthy tissue samples. The study demonstrated that the Vimentin gene was suppressed by DNA methylation, causing a disruption in the formation of the cytoskeleton, and consequently promoting increased plasticity and invasiveness of the cells. In contrast, the study revealed that the suppression of the SFRP2 gene by methylation activated the Wnt signaling pathway, which led to increased invasiveness of the CTCs.355 In another study, researchers evaluated the methylation status of E-cadherin, an EMT suppressor gene that is responsible for preserving the epithelial phenotype. The methylation pattern was assessed in CTCs obtained from six individuals diagnosed with metastatic prostate cancer. The findings indicated that E-cadherin was highly methylated in the CTCs from the cancer patients. Furthermore, the study presented an association between E-cadherin hypermethylation and an increased invasiveness of CTCs.356 The role of EMT in CTCs is crucial for their adaptability and survival in the bloodstream during the early stages of metastatic colonization, as highlighted in a recent review. Therefore, a comprehensive analysis of EMT in CTCs is essential for informing personalized medicine strategies that target specific aspects of this biological process.178 The research conducted by Zavridou et al. offers compelling evidence for the effectiveness of the size-based method in addressing the heterogeneity of CTCs.357

DNA methylation and CTCs immune escape

The dysregulation of DNMTs and TET enzymes can profoundly influence gene expression and contribute to transcriptional silencing or activation in various pathologies, such as cancer.358 Studies have provided evidence indicating that the dysregulation of TET enzymes and DNMTs can have significant impacts on gene expression, leading to transcriptional activation or silencing in several pathological states, including cancer. Studies have shown that breast cancer and colorectal cancer patients exhibit increased expression of TET enzymes and decreased expression of DNMTs in both their tumor tissues and circulation, which correlates with DNA hypomethylation and upregulation of IC molecules or their ligands359,360 (Fig. 6).Fig. 6 DNA methylation regulation in CTCs related Immunity. DNA methylation play key roles in adaptive immune response, including dendritic cell development and T cell priming and activation. a Recent studies revealed the contributions of chromatin remodeling responding to cytotoxic attack in tumor cells and exhaustion phenotype in tumor infiltrating CD8+ T cells. b CTLA-4 DNA hypermethylation significantly correlated with a poor response to treatment, highlighting the potential of CTLA-4 methylation as a predictive biomarker for therapy outcomes. c In tumor cells, DNA modifications affects production of tumor antigens, silencing of anti-tumor cytokines, and induction of the PD-L1 checkpoint. d In NK cells, the methylation status of killer Ig-like receptors (KIR) CpG islands is crucial for maintaining clonal KIR expression and modulating NK cell recognition and lysis of abnormal cells. The figure was created with BioRender.com

Furthermore, it has been demonstrated that restoring normal DNA methylation patterns can enhance the therapeutic efficacy of various cancer treatments. Specifically, the use of epigenetic modifiers that target DNA methylation in combination with chemotherapy, radiotherapy, and immunotherapy has shown increased treatment effect on preclinical models and early clinical trials of several cancers, including breast, prostate, and colon cancer.361–363 Based on the outcomes of diverse preclinical models and preliminary clinical trials, it appears that epigenetic modulators aimed at DNA methylation may have the ability to function as adjunctive therapy to conventional cancer treatments. Nevertheless, further large-scale clinical trials are required to verify these findings and establish the optimal combination of treatments for different cancer types. To sum up, there is a correlation between abnormal DNA methylation patterns in cancer cells and immune evasion, tumorigenesis, and resistance to cancer treatments. Therefore, DNA methylation patterns may be a crucial target in cancer therapy, and reinstating regular DNA methylation patterns could be a promising strategy to enhance the therapeutic efficacy and overcome resistance mechanisms.

The evidence provided by these studies suggests that the control of ICs and IC ligand expression in cancer patients, particularly in breast and colorectal cancers, is critically influenced by DNA methylation. According to the study, significant upregulation of ICs, including PD-L1 and TIGIT, as well as other ICs/IC ligands in both circulation and tumor tissues, can be attributed to DNA hypomethylation. The significance of DNA methylation in predicting the effectiveness of immunotherapeutic treatments is highlighted by the correlation between overall hypomethylation and inadequate clinical responses. Based on these findings, therapeutic manipulation of DNA methylation has the potential to serve as an effective strategy for enhancing the outcomes of immunotherapies. However, further investigation is demanded to fully understand the mechanism by which DNA methylation impacts the expression of ICs and to develop efficient therapeutic approaches that target these epigenetic alterations.364

DNA methylation alterations have been linked to the expression of several immunomodulatory genes in breast and colorectal cancer tissues. A study demonstrated that the hypomethylation of CpG islands led to the upregulation of PD-1, CTLA-4, and TIM-3 in breast cancer.359 Moreover, the study observed complete hypomethylation of LAG-3 gene promoter regions in both breast tumor tissues and their corresponding normal tissue. This suggests that DNA methylation is not entailed in the elevation of these genes in breast cancer.359 According to another study, DNA hypomethylation is responsible for the overexpression of CTLA-4 and TIGIT in human colorectal cancer tissues.360 By contrast, in colorectal tumor tissues, the PD-1, PD-L1, galectin-9, and TIM-3 overexpression was not found to be associated with DNA methylation, according to the study.360 Marwitz et al. reported that the PD-1 and CTLA-4 upregulation in tumor tissues of patients with lung cancer is attributed to DNA hypomethylation.365 However, the study did not find any relationship between the elevated PD-L1 expression and DNA methylation in the tumor tissues.365 Conversely, DNA hypomethylation was discovered to be the underlying cause of the upregulation of PD-L1 expression in HNSCC tumor tissues.366 In a study by Goltz et al., the promoter methylation of PD-L1 was predictive of favorable prognosis in several cancer types, including colorectal cancer, HNSCC, and acute myeloid leukemia.367,368 DNA hypomethylation was identified as the cause of the increased expression of CTLA-4, PD-1, PD-L1, and PD-L2 in patients with lower-grade gliomas, according to a study by Rover et al. Overall, these findings support that DNA hypomethylation is entailed in the upregulation of IC molecules and ligands in different types of cancers, although the specific genes that are regulated by DNA methylation may vary across different cancer types.

DNA methylation of CTCs cluster formation

Recent research has suggested that there may be a relationship between CTC cluster formation and DNA methylation. One study found that DNA methylation changes in CTCs may contribute to the CTC cluster formation, and that these changes may be associated with increased metastatic potential. Specifically, the researchers found that methylation changes in genes associated with cell adhesion and motility were more frequent in CTC clusters than in single CTCs. Jang et al. investigates the DNA methylation status of CTCs in gastric cancer patients and its correlation with CTC cluster formation.369 The authors find that DNA methylation alterations in CTCs are associated with increased cluster formation and suggest that targeting these alterations may be a potential therapeutic approach.370–372 Gkountela et al. demonstrates that CTC clustering induces DNA methylation changes that promote metastatic seeding. The authors claim that targeting these epigenetic changes may be a potential therapeutic strategy for preventing metastasis.373,374 Zhang et al. demonstrate that DNA methylation changes in CTCs are involved in their ability to form brain metastases in breast cancer patients. The authors suggest that targeting these epigenetic alterations may represent a potential strategy for preventing brain metastases.376 Huang et al. investigates the correlation between DNA methylation in CTCs and their ability to resist EGFR inhibitors in lung adenocarcinoma patients.253 The findings of the authors indicate that targeting DNA methylation abnormalities in CTCs may enhance treatment response, as these variations are linked to higher resistance to EGFR inhibitors.375,376 Overall, while the relationship between CTC cluster formation and DNA methylation is still not fully understood, the current evidence suggests that changes in DNA methylation may be involved in the progression of metastatic cancer.

Histone modification

Histones are essential components of the dynamic architecture of chromatin. The octameric core of these proteins is formed by the assembly of two copies of each histone variation, including H3, H4, H2A, and H2B. This structure serves as a pool around which a DNA sequence consisting of 146 base pairs coils elaborately.377 The globular structures of histones are enriched in basic amino acids like arginine and lysine in their tails, which serve as excellent locations for a wide range of covalent posttranslational modifications (PTMs). The chromatin landscape is altered by these chemical modifications, which also generate docking sites for proteins that control chromatin functionality.378 These modifications also modify the interaction between histones and DNA.379 Extensive studies has shown phosphorylation, methylation, and acetylation as the central histone modifications. All of these PTMs, however, add to the complexity of the regulation of gene expression by expanding the histone code. These additional PTMs include crotonylation, lactylation, citrullination, ubiquitination, and adenosine diphosphate (ADP)-ribosylation.380 Enzymes known as “writers”, “readers”, and “erasers”, whose dysregulation is usually linked to cancer, meticulously control this dynamic epigenetic gene landscape.381 Decoding the histone modification patterns presents a challenge since, even in identical cellular contexts, same configurations can produce divergent biological responses.378 Abnormalities in this molecular communication have the potential to cause oncogenic transformation,382 alter gene regulatory networks, and upset cellular equilibrium. Understanding this molecular dialog is critical for both understanding and fighting the molecular bases of CTC metastasis. It is also fundamental to elucidating cellular physiology.

Dysregulation in the landscape of histone modifications on TSG and oncogenes

By regulating transcriptional activity, histone alterations play a critical role in the initiation and proliferation of tumors. This often results in the upregulation of oncogenes and the downregulation of tumor suppressor genes. The erratic patterns of H3K27me3, which have a substantial influence on genomic stability, are a notable example of this dysregulation385.383 The enhancer of EZH2 gene, which encodes the methyltransferase responsible for the specific histone modification H3K27me3, can be influenced by recurring mutations that may alter the levels of this modification.384 The transcriptional landscape undergoes a significant reconfiguration during tumorigenesis. After being found to be tumor suppressors in a variety of cancers,385 CBP/p300 has lately come to light as essential regulators of transcriptional activation mediated by enhancers and super-enhancers, especially with regard to important oncogenes.386,387 In ALL, binding sites for the MYB transcription factor are created upstream of the TAL1 oncogene by heterozygous somatic mutations. This MYB interaction attracts CBP, resulting in the formation of a super-enhancer that promotes cell transformation and leukemogenic expression by driving the overexpression of TAL1.388 Similar to this, p300 has been associated with a substantial reprogramming of super-enhancers in HCC, which results in the upregulation of critical oncogenes such MYC, MYCN, and CCND1, which promotes cancer cell proliferation both in vitro and in vivo.389

Due to their important role in tumorigenesis, chromatin remodeling complexes (CRCs), especially the SWI/SNF family, are crucial in the DNA damage response (DDR). More than 20% of cancers have mutations in the SWI/SNF complex genes, highlighting the significance of these genes in the genesis of cancer.390 Gene mutations can be caused by environmental factors such as UV light and gamma radiation that damage DNA. Prompt damage detection, repair signaling, repair factor mobilization, and cellular fate direction towards apoptosis or senescence are done by the DDR machinery. The historical background of DDR deficits in carcinogenesis is well established, having begun with the finding of chromosomal abnormalities in genes and continuing through the revelation that inadequate telomere maintenance catalyzes genomic instability and the detection of important tumor-suppressive functions of DDR components.391–393 The SWI/SNF complexes affect DNA repair pathways by increasing nucleosome mobility through ATPase activity, which facilitates DDR. There are several roles that SWI/SNF subunits play in DDR. Some directly recruit DDR proteins, whereas others alter the chromatin architecture at DNA damage sites.394–396 The PBAF and cBAF complexes are associated with DNA repair processes such as homologous recombination (HR) and non-homologous end joining.337,397 To be more precise, DNA lesions are attracted by SMARCA4 and the cBAF-exclusive ARID1A, which help in double-strand break resolution and repair.398 Poly-ADP ribose polymerase 1 (PARP1) and SMARCA4 have been shown to collaborate at damage sites, promoting chromatin remodeling to lower nucleosome density and assisting in the repair process.396 SMARCA4 and ARID1A deficiencies are linked to mitotic abnormalities and erratic chromosomal segregation, suggesting that these proteins also play roles in DNA decatenation and telomere cohesion.399 DDR also involves PBRM1, a component of PBAF. It is involved in centromeric cohesion maintenance, which is essential for genomic integrity, and transcriptional suppression at double-strand breaks to speed DNA lesion repair.400 CHD1L plays a key role in the regulation of checkpoint control following DNA damage. It facilitates the movement of nucleosomes, which is promoted by PARP1, and also regulates checkpoint activities.401 A lack of CHD1L impairs the accessibility of chromatin and the recruitment of repair factors, resulting in increased sensitivity to PARP.402 The multifaceted involvement of cancer highlights their pivotal role in maintaining genomic integrity and preventing cancer. Understanding these complex interactions and mechanisms not only elucidates cellular physiology but also provides insights into potential therapeutic targets for cancer treatment.

Topologically Associating Domains (TADs) borders breaking down in the oncogenic landscape represent a fundamental abnormality. These disruptions are often caused by structural variations or damaged CCCTC-binding factor (CTCF) interaction due to changes in DNA methylation.403 The proto-oncogene TAL1 is activated by microdeletions that obliterate TAD boundaries in T-ALL.403 Broken genomic insulation in gliomas and gastrointestinal stromal tumors interferes with CTCF anchoring at loop structures. Like with PDGFRA and FGF4, this results in oncogene activation and ectopic enhancer-promoter crosstalk.404,405 An explanation for the observed correlation between increased CCNE1 expression in gastric cancer primary tumors and CCNE1 rearrangement in response to changed TAD borders and interactions has been found.406 Because the promoter-enhancer looping dynamics are dysregulated, this rearrangement promotes oncogenicity. An example of such a dynamic is the interaction between the MYC gene and the lncRNA PVT1 promoter. The PVT1 promoter blocks the promoter-enhancer looping of MYC, which in healthy cells decreases MYC expression competitively. On the other hand, malignant transformation often silences the PVT1 promoter by structural or epigenetic changes, re-establishing MYC’s enhancer-gene interaction and quickening tumorigenesis.407 The loss of a single CTCF allele, which has been linked to oncogenic drivers in cancers including breast and endometrial, has supported CTCF’s role as a tumor suppressor through numerous genetic aberrations.408–410 Prostate, ovarian, and breast cancers411 frequently have hemizygous deletions of CTCF, while kidney and endometrial cancers with an allelic loss of CTCF are linked to lower patient survival.412,413 Since hypermethylation of CpG islands is associated with a decrease in CTCF binding, this tumor-suppressing mechanism may entail the regulation of DNA methylation patterns. On top of that, PD-L1 upregulation is associated with CTCF deficiency, which allows cancer cells to evade immune monitoring.414

Histone H3 and H4 acetylation patterns have become characteristic indicators of cancer cells, and dysregulation in the histone modification landscape is becoming more and more associated with metastasis. Histone acetylation states in cancer are impacted by metabolic reprogramming, which modifies the absolute amounts of acetyl-CoA and the ratio of acetyl-CoA to coenzyme A. Because of its role in acetyl-CoA gene rating through the ligation of acetate and CoA, ACSS2 can cause HIF-2 to become acetylated, which inhibits EMT under hypoxic conditions in HCC.415 Overexpression of ACSS2, which promotes acetylation of H3K27 in the ATG5 promoter region, is used to achieve reduced breast cancer cell proliferation, migration, and invasion. This, in turn, ensures the maintenance of autophagic flow.416 ACOT12, also referred as cytoplasmic acetyl-CoA hydrolase, is a predominant liver enzyme that selectively hydrolyzes the thioester bond of acetyl-CoA, gene rating acetate and CoA.417 Reduced levels of ACOT12 in HCC lead to increased levels of acetyl-CoA, which in turn promotes the acetylation of H3K9 and H3K56. This acetylation process facilitates the EMT mediated by TWIST2.418,419

Acetyl groups are transferred from acetyl-CoA to lysine residues by histone acetyltransferases (HATs). This process helps neutralize the positive charge on histones, thereby loosening the interaction between histones and DNA. As a result, genes become more accessible to transcription factors, facilitating gene expression.420 GCN5, the initial identified HAT, controls a diverse array of biological processes including cellular proliferation, gene expression, and metabolism. It has also been demonstrated to play a role in the growth and metastasis of cancer cells.421 GCN5 is recruited to the Runx2 promoter to sustain H3K27ac levels, which leads to the upregulation of Runx2 and promotes lung metastasis in osteosarcoma.422 The biological function of HDACs in cancer is well-established. HDACs have the ability to both promote and inhibit tumor metastasis. Specific types, mainly through facilitating the downregulation of E-cadherin, have been linked to the proliferation and potential for metastasis of a variety of cancers. These include HDAC1, HDAC2, HDAC4, HDAC5, and HDAC6.423,424 Simultaneously, HDAC8 has been identified as a new TGF-β pathway regulator. It works by transcriptionally suppressing SIRT7 via specific chromatin remodeling. Lung cancer metastasis is accelerated by this HDAC8 activity, which functions as a cofactor to the SMAD3/4 complex and triggers the activation of TGF-β signaling.425 Histone H3K27 can be maintained in a deacetylated state by recruiting HDAC1 to the promoter of the DUSP2 gene. This results in DUSP2 being silenced and elevated MMP2 levels, promoting metastasis of nasopharyngeal metastesis.426 In colorectal cancer, HDAC11 suppresses metastasis by downregulating MMP3 expression. This occurs through the reduction of histone H3K9 acetylation at the MMP promoter.427 On the progression and metastasis of breast cancer, HDAC11 may have divergent effects. The survival and proliferation of tumors within the lymph nodes can be enhanced by increased HDAC11 expression, whereas a migratory phenotype is promoted by reduced HDAC11 expression, which significantly increases migration from the lymph nodes to distant organs.428

Dysregulation in the landscape of histone modifications in CTCs immune escape

CTCs employ various strategies to evade immune surveillance by cytotoxic T cells. These mechanisms include suppressing T-cell activation, altering the expression of MHC-I at both transcriptional and posttranscriptional levels, reducing the levels of TAAs, and overexpressing IC molecules such as PD-L1 and GAL-9.429 Downregulation of MHC-I molecules hinders CD8 + T-cell activation against TAAs presented by CTCs. The WNT/β-catenin signaling pathway regulates STT3, which glycosylates and stabilizes PD-L1, leading to increased PD-L1 levels on CTCs and facilitating evasion from cytotoxic T-cell immune surveillance.430

In hypoxic conditions within the TME, PD-L1 and VEGF expression is elevated in CTCs. VEGF promotes the expression of TIM-3, the T-cell inhibitory receptor. Interaction between overexpressed PD-L1 and Gal-9 on CTCs with their corresponding receptors (e.g., PD-1 and TIM-3) on T cells suppresses T-cell proliferation, reduces cytokine production, induces T-cell exhaustion, and ultimately enables CTC evasion from cytotoxic T-cell activity.429,431 Mature dendritic cells (DCs) are pivotal in initiating T-cell-mediated immune responses by presenting TAAs and expressing costimulatory molecules.432 However, CTCs employ diverse mechanisms to inhibit DC-mediated antitumor responses, including the release of TGF-β. Specifically, CTCs hinder the recruitment of CD103+ DCs to tumors,433 impair their maturation, promote differentiation into immunosuppressive regulatory DCs,434 and induce the development of PD-1+ DCs that deactivate CD8 + T cells.435 Through its negative regulation of DCs, macrophages, and T cells expressing their receptors, CD200, an increased immune checkpoint in CLL, BRCA, NSCLC, and COAD, develops immunological tolerance.436 The interaction between TAMs and CTCs promotes CTC survival and the establishment of an immunosuppressive TME.437 Numerous cells, including fibroblasts, endothelial cells, and immune cells, make up the CTC niche within the TME. These cells are enriched with factors like periostin (OSF-2, an osteoblast-specific factor), TGF-β, and colony-stimulating factor 1.438 These factors drive the polarization of macrophages towards an immunosuppressive M2 or TAM phenotype.439 TAM-secreted molecules like WNT, TGF-β, and VEGF promote cancer stemness, create an immunosuppressive TME, facilitate EMT, and support cancer metastasis.440 Additionally, TAMs enhance PD-L1 expression on CTCs and PD-1 on T cells, thus dampening T-cell-mediated cytotoxicity.441

MDSCs play a pivotal role in the TME by secreting cytokines and chemokines that foster an immunosuppressive niche, thereby impairing the efficacy of immunotherapy.442 Granulocyte-macrophage colony-stimulating factors are released by CTCs via the mTOR signaling pathway, promoting MDSC infiltration into tumors.443 Within the TME, MDSCs release IL-6 and nitric oxide, which epigenetically upregulate CTCs markers such as EpCAM, while also facilitating the activation of Tregs through TGF-β release.444,445 By interacting with the immunosuppressive TME, Tregs, an immunosuppressive T-cell fraction, promote CTC immune evasion, suppressing the effects of cancer immunotherapy. CTC-derived TGF-β facilitates Treg infiltration into tumors, correlating with poorer survival rates.446 Additionally, CTCs upregulate CCL1 expression through epigenetic mechanisms that decrease H3K27me3 levels at the CCL1 promoter, enhancing Treg recruitment to the TME.447 Moreover, CTCs evade T-cell-induced apoptosis by inducing the differentiation of uncommitted CD4 + T cells into Tregs.448 Specifically, Tregs in the hypoxic TME release VEGF, promoting CTCs stemness, angiogenesis, and EMT.449,450 Natural killer (NK) cells express receptors like NKG2D, FASL, and TRAIL, which selectively target and eliminate MHC-I-negative CTCs.451 NK cell-mediated cytotoxicity has been observed in MHC-I-negative colon and ovarian CTCs expressing NKG2DL and ligands for activating receptors NKp30 and NKp44.452 However, CTCs from some ovarian and renal carcinoma patients upregulate MHC-I molecules, reducing susceptibility to NK cell-mediated lysis.444,445 Interestingly, latent competent cancer cells expressing SOX2/SOX9 induce dormant CTCs (or latency-competent cancer cells) that downregulate NKG2DL through a unique mechanism involving WNT inhibitor DKK1, thereby evading NK cell-mediated immunity.446 Epigenetic modifications, such as H3K27 acetylation, are enforced by CBP and p300 in the regulatory regions of genes crucial to Treg cell and MDSC survival and function. Through upregulating these genes, CBP/p300 promotes the growth of tumors by inhibiting lymphocyte activation, proliferation, and immunity mediated by cytotoxic T-cells.453 Additionally, it has become clear that the sirtuin family of NAD+-dependent deacetylases, which includes mitochondrial SIRT3, SIRT4, and SIRT5, is essential for regulating epigenetic changes like as acetylation, demalonylation, and desuccinylation.454 It has been demonstrated that SIRT4 loss enhances breast cancer stem cells’ capacity for self-renewal, which is essential for nutritional catabolism.455 Increased cancer cell proliferation has been associated with desuccinylation and consequently decreased activity of succinate dehydrogenase (SDH), which has been linked to high levels of SIRT5 activity. In contrast, SDH hyper-succinylation and reactivation result from silencing SIRT5, which inhibits the growth of cancer cells.456 Interferon serves as a potent cytokine with antitumor properties, inhibiting the expansion of CTCs and suppressing their tumor-initiating capabilities.448 IFN-stimulated genes also play a role in overcoming chemoresistance in CTCs.448 However, CTCs can develop resistance mechanisms against IFN’s antitumor effects, thereby promoting their survival and inducing the expression of CTC markers while evading immune surveillance through IFN signaling pathways.447,449 The dual role of IFNs in cancer therapy may vary depending on the duration and concentration of IFN exposure.450,451 Suboptimal type-I IFN signaling triggered by immunogenic cell death (ICD) does not consistently result in effective anticancer immunity. Instead, it can paradoxically promote tumor progression by increasing the population CTCs equipped with enhanced immune evasion capabilities.452 Under specific conditions, elevated levels of IFN-γ have been demonstrated to trigger apoptosis in NSCLC through activation of the JAK1/STAT1/caspase pathway. Conversely, low concentrations of IFN-γ can enhance the properties of CTCs through the ICAM1/PI3K/AKT/NOTCH1 pathway, potentially contributing to tumor progression.457 Overall, the interplay between various immune cells and CTCs fosters an immunosuppressive TME that facilitates immune evasion, thereby leading to adaptive resistance against cancer immunotherapy.

Clinical research progress targeting CTCs and therapeutic advances

Current methodologies for eradicating metastasis mirror those utilized for primary tumors: focusing on proliferation and tumorigenesis rather than directly addressing the metastatic cascade.458,459 Surgical intervention or systemic treatments for primary tumors may not always eradicate the source of metastasis if dissemination have already happened.460–463 The majority of anticancer agents undergo initial evaluation in metastatic contexts before being repurposed for adjuvant therapy to deter metastatic spread, albeit with only moderate success.464 The scarcity of agents specifically targeting metastasis is being confronted by numerous preclinical investigations and considerations for future clinical trial frameworks.1,459 Theoretically, therapies aimed at CTCs at different points in the metastatic process could halt the progression of metastatic cancers as CTCs are the cause of metastatic cancers and may come from different subpopulations within tumors.

CTCs in clinical trials

As a preventive approach against metastasis in preclinical models, addressing hypoxia-induced cluster release with vascular normalization-inducing drugs (e.g., ephrin B2 Fc chimaera protein, modulating VEGFR signaling) has been proposed.465 The PLK1 inhibitor BI 2536 also impedes CTC intravasation,165 suggesting its clinical utility in mitigating metastatic dissemination.466 Targeting integrins, cadherins, cell-surface glycoproteins,467 invadopodia (e.g., through N-WASP inhibition),468,469 or employing antibodies against CD36, P-selectin, αIIbβ3, and α6β1 integrins could prevent intravasation and extravasation. HPSE, which facilitates ICAM1-mediated cell adherence in CTC clusters, is the target of one newly developed drugs class.470 Additionally, urokinase and Na+/K+-ATPase inhibitors like digoxin exhibit promise in dissociating CTC clusters, leading to metastasis suppression in animal models.5 Digoxin is now under studied in a phase I trial to determine its potential to disrupt CTC clusters in patients with advanced or metastatic breast cancer (NCT03928210). Through cell-cell dissociation, heterotypic clustering may also be disrupted. Blocking key platelet receptors on CTCs, like glycoprotein Ib–IX–V and glycoprotein VI, reduces the potential for metastasis by interfering with platelet–cancer cell interactions.108 Similarly, targeting VCAM1 on CTC–neutrophil clusters retards proliferation and metastatic efficiency.111,471–473 Alternatively, utilizing CTCs’ VCAM1-mediated affinity for neutrophils for immune-based targeting could imitate the lethal activity of NK cells by energizing neutrophils with nanoscale liposomes that carry TRAIL and E-selectin.474 Metabolic vulnerabilities could be exploited by either increasing oxidative stress or inhibiting pyruvate metabolism.475–477 Immune checkpoint inhibitors have the ability to identify CTCs for T cell destruction,478 and when combined with immune checkpoint inhibitors, dual targeting of HER2 or EpCAM results in improved cancer cell killing as compared to monotherapy.479,480 Additionally, by employing mechanically disrupted CTCs as nanolysates, CTCs can be used as a source to produce cancer vaccines. Harnessing the homing capacity of CTCs to TME could be therapeutically advantageous by identifying homing signals and delivering therapeutic payloads.126,481 Systemically administered CTCs engineered to express the prodrug-converting enzyme cytosine deaminase-uracil phosphoribosyl transferase can convert non-toxic 5′-fluorocytosine into the cytotoxic compound 5′-fluoruridine monophosphate. This conversion causes the CTCs to attach to the neoplastic tissues, where they kill the surrounding cancer cells. Lastly, given the rhythmic nature of CTC release into the bloodstream,126,481 making the most of the current therapeutic opportunities by timing chronotherapy-based designs to coincide with CTC production peaks could optimize efficacy. Although these methods show promise in future research on CTCs, there is a lack of specific tools for dealing with metastatic cells, and the metastatic process is complicated, so testing their effectiveness in clinical settings will necessitate innovative and bold trial designs.

The results of clinical trials have demonstrated that CTCs are found in peripheral blood in all major carcinoma types, and their significance for prognosis in colorectal, breast, prostate, and small- and non-small-cell lung malignancies has been validated.482,483 When a patient is first diagnosed with metastatic breast cancer, higher CTC counts before starting treatment are predictive indicators of shorter disease-free and total survival times.484–486 For patients with colorectal487 and prostate488,489 cancer, a negative relationship between pretreatment CTC counts and clinical prognosis has also been reported. Significantly, numerous studies have illustrated that fluctuations in CTC counts following treatment administration offer more robust prognostic insights compared to baseline CTC levels. The persistence of CTCs post-therapy correlates with a poorer prognosis.490–492 In patients receiving therapy, evaluation of CTC cluster abundance significantly improves the prognostic value in addition to single-CTC counts.493 However, since most of the studies used antigen-dependent CTC methods, enumeration carries the risk of producing false-negative results in this situation.

CTC counts can be detected 7–9 weeks before the disease’s clinical manifestation. This suggests that CTC analysis in patients may help predict the likelihood of minimal residual disease and relapse in later stages,163 of the illness163,494 and serve as a tool for early cancer diagnosis. In NSCLC, CTCs taken following surgery showed a strong mutational concordance with metastatic tumors found 10 months later (91%).156 Although CTCs are useful for risk assessment, there has been limited success in using CTCs for therapeutic patient stratification. This includes monitoring treatment response over time and identifying the onset of therapy resistance in many clinical trials.491,495,496 The METABREAST STIC disease trial highlighted scenarios where CTC count could provide useful advice for therapeutic decisions, even though the interventional SWOG-S0500 trial did not show an advantage of CTC count-guided intervention compared to physician’s choice upon disease development.495 The benefit of therapy selection based on CTC molecular features has been explored in a number of interventional studies.497,498 In two proof-of-principle studies, trastuzumab–emtansine or lapatinib (HER2-targeted treatments) were used to target HER2-positive CTCs in HER2-negative metastatic breast cancer.498,499 Although one trial (DETECT III) still awaits completion, the studies have only found a little benefit thus far.499 Results from patients receiving endocrine therapy for metastatic prostate cancer are predicted by the expression of AR-V7 in CTCs (PROPHECY trial).500,501 A phase II trial was then started to explore how the microtubule inhibitor cabazitaxel affected patients with AR-V7-positive CTCs and metastatic castration-resistant prostate cancer. However, the European Society for Medical Oncology guidelines do not support AR-V7 testing in this context due to the recent negative outcome of that trial, as it offers no advantage over current decision algorithms.502–504

In conclusion, CTCs are now included in both the seventh edition of the AJCC Cancer Staging Manual and the fifth version of the WHO Classification of Tumours: Breast Tumours. The designation “cM0 (i+)“ indicates the absence of overt metastasis but the presence of tumor cells in the blood, bone marrow, or lymph nodes. Important cancer societies have yet to incorporate CTCs into their clinical practice recommendations, including the European Society for Medical Oncology and the American Society for Clinical Oncology. Arguably, CTCs’ actual potential lies in their ability to represent highly metastatic tumor subclones and in their abundance as modern biomarkers for molecular and functional studies. CTCs, as living cells, can be cultured outside of the body and analyzed for drugs response, which could offer significant insight to inform treatment choices in a timely manner.175,505,506

Despite these advancements, significant enhancements to such workflows are necessary for their transition to clinical application. Innovative, prospective, randomized interventional trials are required to determine whether the use of CTCs as diagnostic aids offers clear benefits over standard-of-care (SOC) methods for specific cancer types. Future validation efforts should give priority to the predicted strengths of CTCs, including their ability to detect little residual illness, express clinically actionable targets for therapy selection, and provide longitudinal follow-up.

Diagnostic and prognostic value of methylation patterns of CTCs

The investigation of DNA methylation patterns in CTCs spans multiple cancer types, offering insights into their potential as biomarkers for diagnosis, prognosis, and therapeutic targeting.97,126 Madhavan et al. highlighted the importance of methylation patterns in circulating cell-free DNA as markers of tumor progression and response to treatment in their investigation of CTC DNA’s potential as a prognostic diagnostic in metastatic breast cancer.507 Cabel et al. investigated the role of CTCs and circulating tumor DNA in prostate cancer, focusing on DNA methylation markers as potential tools for assessing disease progression and therapeutic response.508 Widschwendter et al. demonstrated that the methylation status of circulating tumor DNA can be used as a non-invasive diagnostic marker for ovarian cancer, enabling early detection and therapeutic response monitoring.509 Powrózek et al. examined SHOX2 gene methylation in CTCs of NSCLC patients and discovered that SHOX2 methylation could function as a non-invasive biomarker for NSCLC prognosis and diagnosis. This suggests the possible utility of methylation analysis in CTCs for clinical purposes.510 The potential of circulating tumor DNA to identify EGFR mutations in lung cancer patients was examined by Hulbert et al.511 In identifying individuals who may benefit from treatment with tyrosine kinase inhibitors, the study demonstrated the utility of circulating tumor DNA as a feasible alternative to invasive tissue biopsies. Furthermore, the research shed light on the expansion of genetic and epigenetic profiling using circulating tumor material, such as exploring DNA methylation patterns. This highlights the growing importance of utilizing non-invasive biomarkers for precision medicine applications in oncology.511 Mazor et al. demonstrated how the methylation patterns of circulating tumor DNA in lung cancer patients can serve as indicators of tumor burden and heterogeneity.512 Their study underlines the potential of DNA methylation profiling of circulating tumor DNA, encompassing CTC-derived DNA, in providing crucial prognostic and diagnostic insights.512 Aberrant DNA methylation profiles have been detected in CTCs from cancer patients, and these patterns have shown promise as diagnostic or prognostic biomarker. For instance, Wong et al.’s study, which examined the DNA methylation patterns of CTCs from lung cancer patients, found a correlation between patient survival and the methylation levels of specific genes.513,514 Specifically, high methylation of HOXA9 and LMX1A genes was associated with poor overall survival, while high methylation levels of the IGFBP3 gene were associated with better overall survival.515,516 Another study by Wu et al. investigated the DNA methylation patterns of CTCs from patients with lung adenocarcinoma and identified differentially methylated genes that were associated with metastasis.5,111,126 They identified that the methylation levels of GABRB2, CLDN3, and SFRP1 were conspicuously different between CTCs from patients with and without metastasis.517 In addition to their potential as diagnostic or prognostic biomarkers, DNA methylation patterns in CTCs may also have therapeutic implications. For instance, a study by Chen et al. suggested that treatment with a DNA-demethylating agent called decitabine reduced the metastasis of CTCs from lung cancer patients by reversing the aberrant DNA methylation patterns in these cells.332,518 The DNA methylation profile of CTCs has demonstrated a significant potential for lung cancer diagnosis, prognosis, and treatment (Table 4).495,519–525Table 4 Application of DNA methylation of CTCs in lung cancer

Application	Genes	DNA methylation level	References	
Early detection	PCDHGB7	Hypermethylation	519	
Prognosis	RASSF1A and APC	methylation	520	
Predicting treatment response	MGMT	methylation	521	
Resistance to targeted therapy	PTEN	Hypermethylation	522	
Tumor heterogeneity	\	methylation	523	
Tracking disease progression	HOXA9	methylation	524	
Minimal residual disease detection	RASSF1A and APC	methylation	525	
Personalized treatment	\	methylation	495	

DNA methylation detection in CTCs

The principal methodology utilized in liquid biopsy is the identification of DNA methylation within the circulatory system. Circulating tumor DNA has better sensitivity and specificity for cancer screening than traditional tumor markers, especially in the early stages of the disease. The sensitivity of Vimentin gene methylation in serum for the diagnosis of CRC was found by Atsushi Shirahata et al. to be significantly higher (57.1% vs. 14.3%) for diagnosing CRC in situ (Stage 0) than for the tumor marker CEA (32.6% vs. 33.1%).432 Similar to this, the FDA has approved SEPT9, a circulating tumor DNA test, as an effective early non-invasive screening method for colorectal cancer.526,527 SEPT9, also referred to as MSF, was originally discovered by Osaka et al.530 They observed that MSF acts as a proto-oncogene, promoting leukemia upon fusion with the MLL gene.528 Further research has shown that SEPT9 generates 18 transcriptional products, each contributing uniquely to the development and progression of cancer.529 Specifically, the SEPT9 gene, particularly the SEPT9_v2 variant, functions as a tumor suppressor in colorectal cancer.530 Hypermethylation of the SEPT9_v2 promoter region, leading to decreased SEPT9 gene expression, is a defining characteristic of colorectal cancer (CRC) and is closely associated with the progression from adenoma to atypical hyperplasia to CRC. In their 2021 study, Guoxiang Cai et al. developed a classifier named “ColonAiQ”, which incorporates six circulating tumor DNA markers (SEPT9, SEPT9 region 2, BCAT1, IKZF1, BCAN, VAV3).531 Their findings showed that “ColonAiQ” was able to achieve a greater detection rate in both early and advanced CRC than fecal immunochemical tests, CEA, and SEPT9.531 Additionally, the “ColonAiQ” classifier predicted early postoperative recurrence and poor prognosis of CRC, with patients exhibiting higher ColonAiQ risk scores more likely to experience early postoperative recurrence.531 Using whole-genome bisulfite sequencing technology, Liu et al. conducted a prospective clinical trial to examine tissue and circulating tumor DNA methylation in breast cancer.423 They found methylation patterns that differed between cancer patients and those with benign tumors, and they developed a diagnostic model. The detection of breast cancer was significantly improved by this combined diagnostic models. One benefit of the study is that it uses whole-genome bisulfite sequencing to identify differential methylation sites in detail. This method measures the average degree of DNA methylation at each CpG site in the target genome. However, this method does not precisely pinpoint methylation sites. A variety of methods have been used in investigations to identify site-specific DNA methylation, including digital PCR, pyrosequencing, bisulfite sequencing, and methylation-specific PCR.532–534 The study’s examination of methylation differences in tissues and circulating tumor DNA from cancer and benign lesion patients enables the exclusion of non-cancer-related methylation sites in circulating tumor DNA. Differential diagnosis on patients with benign masses improves the detection of tumor-specific sites in contrast to many other studies that employ healthy controls. Additionally, combining imaging examinations (e.g., ultrasound, mammography) with circulating tumor DNA testing improves breast cancer detection sensitivity and specificity, reducing unnecessary invasive procedures. This prospective clinical trial focused on early-stage cancer lesions, offering insights distinct from studies utilizing advanced cancer tissues, which might not be as effective for early cancer screening. Nevertheless, the study had limitations, such as unmatched patient age, smoking, and other influencing factors between case and control groups, potentially introducing heterogeneity and affecting site detection efficacy.535,536 Moreover, the study’s small sample size (10 tissue pairs) diminished locus selection efficiency, likely influenced by the high cost of whole-genome sequencing. Therefore, developing cost-effective sequencing technologies is crucial for early cancer screening. Colonoscopy, ultrasonography, mammography, and low-dose chest CT have become widely used and have greatly improved early screening for lung cancer, breast cancer, and colorectal cancer, as well as early diagnosis rates and patient prognoses.537–539 However, effective screening tools for pancreatic cancer (PC) remain lacking. Nine studies on blood-based DNA methylation biomarkers for early PC diagnosis, all published in the last decade, have been retrieved.533,540–544 Notably, three studies identified ADAMTS1 methylation as a liquid biopsy marker for PC, achieving high diagnostic efficacy (sensitivity >80%, specificity >85%).540,545,546 Keiko Shinjo et al. also demonstrated the diagnostic capability of a five-DNA molecule panel, including ADAMTS2, for PC, with sensitivity and specificity of 68 and 86%, respectively, when combined with KRAS mutation.542 The ADAMTS family, comprising 19 members, plays crucial roles in arthritis, cardiovascular diseases, and cancer,547 particularly in regulating ECM structure and function. Given the abundant stroma in PC, certain ADAMTS family subtypes may serve as effective biomarkers for PC diagnosis, warranting further investigation.548 The circulating tumor DNA methylation model is also pivotal in prognosis. Mastoraki et al. discovered that non-small cell lung cancer patients with methylation in the KMT2C promoter region of circulating tumor DNA experienced poorer overall survival (OS) and disease-free survival (P = 0.017 and P < 0.001, respectively).549 Promising results have been found in numerous studies examining the role of circulating tumor DNA in predicting the prognosis of different cancers, including colorectal, prostate, and ovarian cancer.549–555 Establishing a prognostic model based on blood-based DNA methylation facilitates early identification of high-risk groups, enabling timely and effective intervention, while non-high-risk individuals may undergo milder treatment or follow-up, thus minimizing unnecessary invasive treatments and conserving medical resources. Despite the utility of circulating tumor DNA methylation in reflecting patient prognosis across various cancers, challenges remain in developing prognostic methylation markers. The lack of consensus on detection methods and the difficulty in identifying universally accepted prognostic methylation sites contribute to these challenges. In order to determine prognosis and choose adjuvant treatment, DNA gene mutation data derived from tumor tissue or blood is widely used. The clinical application of assessing the methylation status of the MGMT gene promoter in gliomas, which indicates tumor response to temozolomide chemotherapy and patient prognosis, has been successful.556,557 Unfortunately, this application is based on tumor tissue-derived MGMT gene promoter methylation status, with no mature clinical studies on circulating tumor DNA.

Therapeutic targeting of methylation in CTCs

To evaluate the effectiveness of treatment and track any tumor recurrence, tumor markers and cross-sectional exams are widely used in the postoperative follow-up of cancer patients. After surgery, a decrease in serum tumor markers indicates effective treatment, whereas an increase indicates a possibility of metastasis or recurrence.558,559 Tumor marker detection has been shown to predict tumor recurrence up to six months ahead of cross-sectional imaging560; however, higher tumor markers are correlated with tumor burden and may not be visible in the early stages of relapse.561 Other factors can also elevate tumor marker levels; for example, CA19-9, a reliable marker for monitoring postoperative PAAD recurrence, can be elevated due to pancreatic inflammation, obstructive jaundice, and persistent diabetes.558 Approximately 8–10% of the population are Lewis-negative, and over 70% of Lewis-negative PAAD patients exhibit low CA19-9 expression, rendering this marker ineffective for prognosis in these patients who typically have worse outcomes.562 Because it is noninvasive, highly reproducible, and sensitive, the detection of circulating tumor DNA methylation has become a crucial method for dynamically monitoring tumor response after treatment.563 In order to highlight the importance of circulating tumor DNA in cancer surveillance, Michail Ignatiadis et al. introduced the term “circulating tumor DNA relapse”.564 Nakayama et al. found that P16INK4a methylation is a sensitive marker of colorectal cancer recurrence, highlighting the crucial role circulating tumor DNA plays in the postoperative follow-up of CRC patients.565 In their study of 21 CRC patients, 13 exhibited elevated P16INK4a methylation pre-surgery, with all patients showing decreased methylation levels within 2 weeks post-surgery, except for two with residual metastases or subsequent relapse. In these two patients, there was noticeably higher P16INK4a methylation at relapse; this was not the case in the individuals without tumor recurrence.565 Jin et al. found that cfDNA follow-up could detect colon cancer recurrence early, with circulating tumor DNA reappearing in 70% of patients (14 cases) before recurrence, approximately eight months earlier than imaging suggested.566 Therefore, early tumor relapse detection is made possible by dynamic monitoring of circulating tumor DNA methylation, which aids in clinical decision-making. The tumor information provided by circulating tumor DNA aids in guiding subsequent targeted therapy selection. Tumor heterogeneity partially explains the poor response to antitumor therapy, with new clonal subtypes forming during tumor progression, a significant factor in therapeutic inefficacy.567 Circulating tumor DNA detection provides great reproducibility when compared to standard tissue biopsy, which decreases the effects of tumor tissue heterogeneity and allows for timely treatment plan adjustments and dynamic monitoring of therapy response. However, compared to traditional tissue exams, circulating tumor DNA extraction and sequencing involves greater technical demands and expenses.

Current research primarily focuses on mutation information within circulating tumor DNA. Detailed gene mutation analysis can elucidate the cancer molecular landscape, potentially leading to more suitable treatment options. However, studies on using circulating tumor DNA methylation for therapeutic target selection are scarce. This disparity might result from the theory that tumor responses rather than tumor causes are the reason for variations in the circulating tumor DNA methylation state in cancer patients. More research is needed in this area. DNA methylation in tissues is critical for tumor suppressor gene inactivation and tumorigenesis. Cancers including pancreatic, breast, and bladder cancer have demonstrated benefit from targeted therapy of DNA methylation, notably when DNA methyltransferase inhibitors are used.568–570

Therapeutic targeting of histone modification enzyme in CTCs

Beyond broad-spectrum modifiers, drugs designed to target particular mutations within enzymes that modify the epigenome are becoming part of the landscape of epigenetic therapies. One such drug is tazemetostat, a selective inhibitor that specifically targets the EZH2 mutation. EZH2, the PRC2 complex’s catalytic component, regulates transcriptional repression via H3K27 trimethylation. Overexpression of EZH2 is associated with poor prognosis and increased malignancy in various cancers,571 prompting its exploration as a therapeutic target. Based on phase 2 trial results that demonstrated a 69% objective response rate (ORR) in patients with EZH2 mutations, compared to 35% in those with wild-type EZH2, Tazemetostat was approved by the FDA.572 Dual inhibitors that target both EZH1 and EZH2 have been found to be more effective than selective EZH2 inhibition in reducing cellular H3K27me3 levels and increasing anticancer effects in mouse models of hematologic malignancies.573 In a phase 2 trial, the dual inhibitor valemetostat demonstrated promise in treating adult T-cell leukemia/lymphoma, with a 48% ORR.574 Currently, a phase 1 trial for metastatic urothelial cancer is exploring the possible synergistic effects of valemetostat with ipilimumab. In a similar vein, DOT1L, the sole H3K79 methyltransferase, has been studied as a possible therapeutic target in tumors containing MLL gene rearrangements, particularly in cases of acute leukemia.575 Even though the outcomes of early clinical trials of DOT1L inhibitors were inconsistent, pinometostat may make juvenile AML cells more sensitive to the multikinase inhibitor sorafenib, opening the door to novel therapeutic options.576 These developments are poised to reshape the therapeutic landscape for pediatric AML and highlight the evolving precision in targeting specific epigenetic mutations for cancer therapy.

The advancement of cancer has been linked to abnormal LSD1 amplification and activity.577 LSD1’s role in transcriptional repression involves removing methylation from H3K4me1/2, a marker of gene activation.578 Preclinical evidence of differentiation and growth attenuation has prompted the evaluation of LSD1 inhibitors, including pulrodemstat (CC-90011), iadademstat, seclidemstat, and GSK2879552, in a number of clinical trials. Results from early phase studies, notably those employing pulrodemstat for solid tumors and non-Hodgkin lymphoma, show significant anti-neoplastic effects, particularly in neuroendocrine tumors.579 Several non-histone proteins, including as DNMT1, are impacted by LSD1 in addition to histones.580 LSD1-mediated demethylation of DNMT1 is critical for its stabilization and the maintenance of global DNA methylation patterns.581 LSD1 inhibitors have the potential to be used in combination therapy for hematological malignancies. A clinical trial, with the ClinicalTrials.gov code NCT04734990, is presently exploring the use of seclidemstat in combination with azacytidine for the treatment of chronic myelomonocytic leukemia. Preclinical studies have also demonstrated that by raising tumor immunogenicity and T-cell infiltration, LSD1 inhibition can improve the effectiveness of immune checkpoint blockade. Clinical trials exploring combination therapies have been started to optimize the effects of immunotherapy, particularly in tumor forms with previously limited responses, including lung cancer.582,583 These developments underscore the expanding potential of LSD1 inhibitors in both standalone and combination treatments across a spectrum of cancers.

HDACs have zinc-enriched active sites, which HDAC inhibitors (HDACi) bind to in order to impede their function and maintain a hyperacetylated state of chromatin that promotes a transcriptionally active configuration.584 In order to treat cutaneous T-cell lymphoma, the FDA approved vorinostat, one of the first-generation HDACi, in 2006. This approval was based on clinical trials demonstrating ORRs of ~30%.585 Similar to DNMT inhibitors, HDACi have shown synergistic effects in preclinical studies when combined with other anticancer agents, leading to the strategic design of combination clinical trials. HDAC inhibitors not only enhance the expression of PD-L1, potentially priming tumors for immunotherapy, but also reduce populations of Tregs, which can bolster immune responses against tumors.586 Vorinostat’s capacity to make hormone-resistant ER-positive breast tumors more susceptible to apoptosis has been validated in preclinical studies, indicating that it may be used in combination with antiestrogen drugs to improve therapeutic results in hormone therapy.587 In 2014, Belinostat, a second-generation HDAC inhibitor, obtained expedited FDA approval for the treatment of peripheral T-cell lymphoma based on the results of a single-arm trial with 120 patients.588 To address toxicity concerns related to earlier generations of HDACi, selectivity against specific members of the HDAC family has been improved through advancements in HDAC inhibition. A benzamide derivative called entinostat has shown promise as a strong and specific inhibitor of class I and IV HDACs. Low-dose azacitidine plus entinostat has been explored in clinical studies for patients with advanced breast cancer and recurrent metastatic NSCLC, particularly in those who have had extensive prior treatment.589,590 These studies reflect ongoing efforts to optimize the efficacy and safety profiles of HDAC inhibitors in cancer therapy.

Proteins called bromodomain and extraterminal (BET) domains are important chromatin dynamics regulators and have become promising targets in cancer research. The BRD2, BRD3, BRD4, and BRDT proteins belong to the BET protein family and use their bromodomains to identify acetylated lysine residues on histones. This recognition initiates chromatin remodeling and gene expression by recruiting additional transcriptional effectors.591 A key factor in identifying the oncogenic functions of BET proteins has been the emergence of small-molecule BET inhibitors like JQ1. These inhibitors disrupt the binding of BET proteins to acetylated histones, thereby modulating the expression of key oncogenes implicated in cancer progression.592,593 Despite their initial promise in preclinical models, the clinical translation of BET inhibitors has been limited by pharmacokinetic challenges, including short half-lives and poor oral bioavailability. Tyrosine kinase inhibitors like lapatinib can be resistant to BET inhibitors like JQ1 and I-BET151 in TNBC. In order to prolong the therapeutic response, they achieve this by suppressing the production of certain kinases which drive resistance mechanisms.594,595 Furthermore, homologous recombination, a crucial DNA damage repair pathway, is disrupted by BET inhibitors by the transcription of proteins involved. This disruption has significant implications for cancer therapy, particularly in combination approaches. When PARP inhibitors and BET inhibitors are used together, tumors that are proficient in homologous recombination may become more sensitive to the PARP inhibitors and may eventually acquire resistance to them.596,597 Clinical investigations have been prompted by the synergistic benefits between PARP and BET inhibition observed in preclinical studies, particularly in breast and ovarian cancers. In order to provide novel avenues for targeted cancer therapy, these studies aim to validate these results in patient populations.598,599 This strategic combination approach highlights the potential of BET inhibitors to enhance the efficacy of existing therapies and to address resistance mechanisms in cancer treatment.

Conclusion and perspective

Cancers remain the highest number of cancer-related deaths globally. CTCs are tumor cells that have separated from the primary tumor and entered the lymphatic or circulatory system. This allows the tumor cells to spread throughout the body and result in the formation of new tumors. According to studies, patients with lung cancer can have CTCs in their blood, and the number of CTCs in a patient’s blood is correlated with the disease’s progression and chances of metastasis. CTCs have been found in the blood of lung cancer patients even before a tumor has been identified by conventional methods, providing evidence that they may be a valuable tool for the early identification and monitoring of lung cancer.

DNA methylation is the addition of methyl groups to the cytosine residues of DNA, and it is necessary for regulation the expression of certain genes. Numerous cancer types, including lung cancer, have been related to abnormal DNA methylation patterns at the onset and progression of the disease. It has been discovered that DNA methylation has a role in both immune surveillance and metastasis in the setting of CTCs.600 The immune system’s method of identifying and getting rid of cancer cells is called immune surveillance. However, by DNA methylation, CTCs can suppress the expression of immune-related genes, enabling them to elude the immune system and persist in the bloodstream. For example, some CTCs have been found to have DNA hypermethylation of genes that are involved in antigen processing and presentation, which may help them escape recognition and elimination by the immune system. Furthermore, DNA methylation has also been involved in the metastasis of CTCs. The EMT process, for example, is essential for cancer cell invasion and metastasis, and it has been linked to DNA hypermethylation of E-cadherin, a gene involved in cell adhesion and migration. Additionally, it has been found that the metastatic potential of CTCs273,601 is influenced by hypomethylation of genes related to DNA repair and cell cycle regulation.273,601

There are several limitations that must be addressed before CTC analysis can be widely employed in the clinic, despite the fact that it has showed promise in the diagnosis and treatment of lung cancer. One of the major limitations is the low sensitivity of CTC detection methods. The number of CTCs in the bloodstream is usually very low, and current methods for CTC detection and isolation may miss a significant proportion of these cells. This may limit the clinical value of CTC analysis and lead to false negative results. The diversity of CTCs presents another difficulty. In contrast to the primary tumor or other CTCs, CTCs are a diverse population of cells that may exhibit various phenotypic and genetic characteristics. This heterogeneity can make it difficult to identify and isolate CTCs that are representative of the entire tumor and to develop targeted therapies.602,603 Furthermore, CTCs are often found in a dormant state, meaning they are not actively dividing or producing detectable levels of tumor markers. This can make it challenging to monitor the response of the tumor to therapy using CTC analysis alone. Finally, there are technical challenges correlated with CTC analysis, such as the need for specialized equipment and expertise, which may limit the availability and accessibility of this technology to all patients. Addressing these limitations may require the development of new technologies and methods for the detection and analysis of CTCs as well as an improved comprehension of CTC biology and role in lung cancer.604,605

This review has encapsulated the obstacles surrounding the genesis of CTCs in the context of cancers, as well as the effect of epigenetics modifications on CTCs pertaining to EMT, immune surveillance, cluster formation, and colonization. The epigenetic modifications resulting from DNA methylation in CTCs may serve as a key to unlock the underlying mechanisms of metastasis in lung cancer, and holds significant promise in the areas of lung cancer diagnosis, prognosis, and treatment.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 82372155), Project of Key Supported Disciplines by Shanghai Municipal Health Commission (grant number: 2023ZDFC0204), Program of Shanghai Academic Research Leader (No. 21XD1402800), and Development Fund for the Department of Anesthesiology, Shanghai Pulmonary Hospital.

Author contributions

Xin Lv, Xuyu Gu, and Shiyou Wei proposed the study conception. Xuyu Gu and Shiyou Wei searched the references. Xuyu Gu assisted with the chart making. Xuyu Gu and Shiyou Wei drafted the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

These authors contributed equally: Xuyu Gu, Shiyou Wei
==== Refs
References

1. Ganesh K Massagué J Targeting metastatic cancer Nat. Med. 2021 27 34 44 10.1038/s41591-020-01195-4 33442008
Ganesh, K. & Massagué, J. Targeting metastatic cancer. Nat. Med. 27, 34–44 (2021).33442008 10.1038/s41591-020-01195-4
2. Castro-Giner F Aceto N Tracking cancer progression: from circulating tumor cells to metastasis Genome Med. 2020 12 31 10.1186/s13073-020-00728-3 32192534
Castro-Giner, F. & Aceto, N. Tracking cancer progression: from circulating tumor cells to metastasis. Genome Med. 12, 31 (2020).32192534 10.1186/s13073-020-00728-3
3. Lawrence R Watters M Davies CR Pantel K Lu YJ Circulating tumour cells for early detection of clinically relevant cancer Nat. Rev. Clin. Oncol. 2023 20 487 500 10.1038/s41571-023-00781-y 37268719
Lawrence, R., Watters, M., Davies, C. R., Pantel, K. & Lu, Y. J. Circulating tumour cells for early detection of clinically relevant cancer. Nat. Rev. Clin. Oncol. 20, 487–500 (2023).37268719 10.1038/s41571-023-00781-y
4. Lin D Circulating tumor cells: biology and clinical significance Signal Transduct. Target Ther. 2021 6 404 10.1038/s41392-021-00817-8 34803167
Lin, D. et al. Circulating tumor cells: biology and clinical significance. Signal Transduct. Target Ther. 6, 404 (2021).34803167 10.1038/s41392-021-00817-8
5. Gkountela S Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding Cell 2019 176 98 112.e114 10.1016/j.cell.2018.11.046 30633912
Gkountela, S. et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 176, 98–112.e114 (2019).30633912 10.1016/j.cell.2018.11.046
6. Mattei AL Bailly N Meissner A DNA methylation: a historical perspective Trends Genet. 2022 38 676 707 10.1016/j.tig.2022.03.010 35504755
Mattei, A. L., Bailly, N. & Meissner, A. DNA methylation: a historical perspective. Trends Genet. 38, 676–707 (2022).35504755 10.1016/j.tig.2022.03.010
7. Papanicolau-Sengos A Aldape K DNA methylation profiling: an emerging paradigm for cancer diagnosis Annu. Rev. Pathol. 2022 17 295 321 10.1146/annurev-pathol-042220-022304 34736341
Papanicolau-Sengos, A. & Aldape, K. DNA methylation profiling: an emerging paradigm for cancer diagnosis. Annu. Rev. Pathol. 17, 295–321 (2022).34736341 10.1146/annurev-pathol-042220-022304
8. Guo H DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs Cell 2023 186 2765 2782.e2728 10.1016/j.cell.2023.05.028 37327786
Guo, H. et al. DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell 186, 2765–2782.e2728 (2023).37327786 10.1016/j.cell.2023.05.028
9. Li Y Liang J Hou P Hypermethylation in gastric cancer Clin. Chim. Acta 2015 448 124 132 10.1016/j.cca.2015.07.001 26148722
Li, Y., Liang, J. & Hou, P. Hypermethylation in gastric cancer. Clin. Chim. Acta 448, 124–132 (2015).26148722 10.1016/j.cca.2015.07.001
10. Ehrlich M Hypomethylation and hypermethylation of DNA in Wilms tumors Oncogene 2002 21 6694 6702 10.1038/sj.onc.1205890 12242669
Ehrlich, M. et al. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 21, 6694–6702 (2002).12242669 10.1038/sj.onc.1205890
11. Praharaj PP Bhutia SK Nagrath S Bitting RL Deep G Circulating tumor cell-derived organoids: current challenges and promises in medical research and precision medicine Biochim. Biophys. Acta Rev. Cancer 2018 1869 117 127 10.1016/j.bbcan.2017.12.005 29360544
Praharaj, P. P., Bhutia, S. K., Nagrath, S., Bitting, R. L. & Deep, G. Circulating tumor cell-derived organoids: current challenges and promises in medical research and precision medicine. Biochim. Biophys. Acta Rev. Cancer 1869, 117–127 (2018).29360544 10.1016/j.bbcan.2017.12.005
12. Gwark S Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients Sci. Rep. 2020 10 17466 10.1038/s41598-020-74577-w 33060768
Gwark, S. et al. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. Sci. Rep. 10, 17466 (2020).33060768 10.1038/s41598-020-74577-w
13. Tellez-Gabriel, M., Knutsen, E. & Perander, M. Current status of circulating tumor cells, circulating tumor DNA, and exosomes in breast cancer liquid biopsies. Int. J. Mol. Sci. 21, 9457 (2020).
14. Vismara M Reduzzi C Daidone MG Cappelletti V Circulating tumor cells (CTCs) heterogeneity in metastatic breast cancer: different approaches for different needs Adv. Exp. Med. Biol. 2020 1220 81 91 10.1007/978-3-030-35805-1_6 32304081
Vismara, M., Reduzzi, C., Daidone, M. G. & Cappelletti, V. Circulating tumor cells (CTCs) heterogeneity in metastatic breast cancer: different approaches for different needs. Adv. Exp. Med. Biol. 1220, 81–91 (2020).32304081 10.1007/978-3-030-35805-1_6
15. Piñeiro R Martínez-Pena I López-López R Relevance of CTC clusters in breast cancer metastasis Adv. Exp. Med. Biol. 2020 1220 93 115 10.1007/978-3-030-35805-1_7 32304082
Piñeiro, R., Martínez-Pena, I. & López-López, R. Relevance of CTC clusters in breast cancer metastasis. Adv. Exp. Med. Biol. 1220, 93–115 (2020).32304082 10.1007/978-3-030-35805-1_7
16. Cui T DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1 Cell Death Dis. 2018 9 561 10.1038/s41419-018-0585-y 29752431
Cui, T. et al. DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1. Cell Death Dis. 9, 561 (2018).29752431 10.1038/s41419-018-0585-y
17. Singh M Yelle N Venugopal C Singh SK EMT: Mechanisms and therapeutic implications Pharm. Ther. 2018 182 80 94 10.1016/j.pharmthera.2017.08.009
Singh, M., Yelle, N., Venugopal, C. & Singh, S. K. EMT: Mechanisms and therapeutic implications. Pharm. Ther. 182, 80–94 (2018).10.1016/j.pharmthera.2017.08.009
18. Zhang Q Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications Theranostics 2020 10 12060 12071 10.7150/thno.48918 33204329
Zhang, Q. et al. Circulating tumor cells in hepatocellular carcinoma: single-cell based analysis, preclinical models, and clinical applications. Theranostics 10, 12060–12071 (2020).33204329 10.7150/thno.48918
19. Deng Z Wu S Wang Y Shi D Circulating tumor cell isolation for cancer diagnosis and prognosis EBioMedicine 2022 83 104237 10.1016/j.ebiom.2022.104237 36041264
Deng, Z., Wu, S., Wang, Y. & Shi, D. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine 83, 104237 (2022).36041264 10.1016/j.ebiom.2022.104237
20. Tayoun, T. et al. CTC-derived models: a window into the seeding capacity of circulating tumor cells (CTCs). Cells 8, 1145(2019).
21. Ward MP Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? Mol. Cancer 2021 20 59 10.1186/s12943-021-01347-1 33789677
Ward, M. P. et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? Mol. Cancer 20, 59 (2021).33789677 10.1186/s12943-021-01347-1
22. Lianidou ES Markou A Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges Clin. Chem. 2011 57 1242 1255 10.1373/clinchem.2011.165068 21784769
Lianidou, E. S. & Markou, A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin. Chem. 57, 1242–1255 (2011).21784769 10.1373/clinchem.2011.165068
23. Thanh Huong, P. et al. Emerging role of circulating tumor cells in gastric cancer. Cancers 12, 695 (2020).
24. Gires O Pan M Schinke H Canis M Baeuerle PA Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? Cancer Metastasis Rev. 2020 39 969 987 10.1007/s10555-020-09898-3 32507912
Gires, O., Pan, M., Schinke, H., Canis, M. & Baeuerle, P. A. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? Cancer Metastasis Rev. 39, 969–987 (2020).32507912 10.1007/s10555-020-09898-3
25. Popovic D Vucic D Dikic I Ubiquitination in disease pathogenesis and treatment Nat. Med. 2014 20 1242 1253 10.1038/nm.3739 25375928
Popovic, D., Vucic, D. & Dikic, I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 20, 1242–1253 (2014).25375928 10.1038/nm.3739
26. Criscitiello C Sotiriou C Ignatiadis M Circulating tumor cells and emerging blood biomarkers in breast cancer Curr. Opin. Oncol. 2010 22 552 558 10.1097/CCO.0b013e32833de186 20706122
Criscitiello, C., Sotiriou, C. & Ignatiadis, M. Circulating tumor cells and emerging blood biomarkers in breast cancer. Curr. Opin. Oncol. 22, 552–558 (2010).20706122 10.1097/CCO.0b013e32833de186
27. Gorin MA Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer Nat. Rev. Urol. 2017 14 90 97 10.1038/nrurol.2016.224 27872478
Gorin, M. A. et al. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Nat. Rev. Urol. 14, 90–97 (2017).27872478 10.1038/nrurol.2016.224
28. Varillas JI Microfluidic isolation of circulating tumor cells and cancer stem-like cells from patients with pancreatic ductal adenocarcinoma Theranostics 2019 9 1417 1425 10.7150/thno.28745 30867841
Varillas, J. I. et al. Microfluidic isolation of circulating tumor cells and cancer stem-like cells from patients with pancreatic ductal adenocarcinoma. Theranostics 9, 1417–1425 (2019).30867841 10.7150/thno.28745
29. Marcuello M Circulating biomarkers for early detection and clinical management of colorectal cancer Mol. Asp. Med. 2019 69 107 122 10.1016/j.mam.2019.06.002
Marcuello, M. et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol. Asp. Med. 69, 107–122 (2019).10.1016/j.mam.2019.06.002
30. Xia W In vivo coinstantaneous identification of hepatocellular carcinoma circulating tumor cells by dual-targeting magnetic-fluorescent nanobeads Nano Lett. 2021 21 634 641 10.1021/acs.nanolett.0c04180 33264027
Xia, W. et al. In vivo coinstantaneous identification of hepatocellular carcinoma circulating tumor cells by dual-targeting magnetic-fluorescent nanobeads. Nano Lett. 21, 634–641 (2021).33264027 10.1021/acs.nanolett.0c04180
31. Gall TMH Belete S Khanderia E Frampton AE Jiao LR Circulating tumor cells and cell-free DNA in pancreatic ductal adenocarcinoma Am. J. Pathol. 2019 189 71 81 10.1016/j.ajpath.2018.03.020 30558725
Gall, T. M. H., Belete, S., Khanderia, E., Frampton, A. E. & Jiao, L. R. Circulating tumor cells and cell-free DNA in pancreatic ductal adenocarcinoma. Am. J. Pathol. 189, 71–81 (2019).30558725 10.1016/j.ajpath.2018.03.020
32. Ye Q Ling S Zheng S Xu X Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA Mol. Cancer 2019 18 114 10.1186/s12943-019-1043-x 31269959
Ye, Q., Ling, S., Zheng, S. & Xu, X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol. Cancer 18, 114 (2019).31269959 10.1186/s12943-019-1043-x
33. Eslami, S. Z., Cortés-Hernández, L. E. & Alix-Panabières, C. Epithelial cell adhesion molecule: an anchor to isolate clinically relevant circulating tumor cells. Cells 9,1836 (2020).
34. Wang J Label-free isolation and mRNA detection of circulating tumor cells from patients with metastatic lung cancer for disease diagnosis and monitoring therapeutic efficacy Anal. Chem. 2015 87 11893 11900 10.1021/acs.analchem.5b03484 26531886
Wang, J. et al. Label-free isolation and mRNA detection of circulating tumor cells from patients with metastatic lung cancer for disease diagnosis and monitoring therapeutic efficacy. Anal. Chem. 87, 11893–11900 (2015).26531886 10.1021/acs.analchem.5b03484
35. Wang Z High-efficiency isolation and rapid identification of heterogeneous circulating tumor cells (CTCs) using dual-antibody-modified fluorescent-magnetic nanoparticles ACS Appl. Mater. Interfaces 2019 11 39586 39593 10.1021/acsami.9b14051 31577122
Wang, Z. et al. High-efficiency isolation and rapid identification of heterogeneous circulating tumor cells (CTCs) using dual-antibody-modified fluorescent-magnetic nanoparticles. ACS Appl. Mater. Interfaces 11, 39586–39593 (2019).31577122 10.1021/acsami.9b14051
36. Wang Z Antifouling hydrogel-coated magnetic nanoparticles for selective isolation and recovery of circulating tumor cells J. Mater. Chem. B 2021 9 677 682 10.1039/D0TB02380A 33333542
Wang, Z. et al. Antifouling hydrogel-coated magnetic nanoparticles for selective isolation and recovery of circulating tumor cells. J. Mater. Chem. B 9, 677–682 (2021).33333542 10.1039/D0TB02380A
37. Reduzzi C A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer Int. J. Cancer 2020 146 3495 3503 10.1002/ijc.32822 31814120
Reduzzi, C. et al. A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. Int. J. Cancer 146, 3495–3503 (2020).31814120 10.1002/ijc.32822
38. Lee SY Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation Mol. Cancer 2017 16 10 10.1186/s12943-016-0577-4 28137309
Lee, S. Y. et al. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Mol. Cancer 16, 10 (2017).28137309 10.1186/s12943-016-0577-4
39. Mittal V Epithelial mesenchymal transition in tumor metastasis Annu. Rev. Pathol. 2018 13 395 412 10.1146/annurev-pathol-020117-043854 29414248
Mittal, V. Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol. 13, 395–412 (2018).29414248 10.1146/annurev-pathol-020117-043854
40. Okabe, T. et al. Mesenchymal characteristics and predictive biomarkers on circulating tumor cells for therapeutic strategy. Cancers 12, 3588 (2020).
41. Xu J Liao K Yang X Wu C Wu W Using single-cell sequencing technology to detect circulating tumor cells in solid tumors Mol. Cancer 2021 20 104 10.1186/s12943-021-01392-w 34412644
Xu, J., Liao, K., Yang, X., Wu, C. & Wu, W. Using single-cell sequencing technology to detect circulating tumor cells in solid tumors. Mol. Cancer 20, 104 (2021).34412644 10.1186/s12943-021-01392-w
42. Sun S Qiu XS Cancer stem cells and tumor metastasis J. Cancer Res. Ther. 2013 9 S150 S152 10.4103/0973-1482.122510 24516051
Sun, S. & Qiu, X. S. Cancer stem cells and tumor metastasis. J. Cancer Res. Ther. 9, S150–S152 (2013).24516051 10.4103/0973-1482.122510
43. Liu S Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts Stem Cell Rep. 2014 2 78 91 10.1016/j.stemcr.2013.11.009
Liu, S. et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2, 78–91 (2014).10.1016/j.stemcr.2013.11.009
44. Ginestier C ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 2007 1 555 567 10.1016/j.stem.2007.08.014 18371393
Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007).18371393 10.1016/j.stem.2007.08.014
45. Barriere G Riouallon A Renaudie J Tartary M Rigaud M Mesenchymal characterization: alternative to simple CTC detection in two clinical trials Anticancer Res. 2012 32 3363 3369 22843916
Barriere, G., Riouallon, A., Renaudie, J., Tartary, M. & Rigaud, M. Mesenchymal characterization: alternative to simple CTC detection in two clinical trials. Anticancer Res. 32, 3363–3369 (2012).22843916
46. Balic M Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype Clin. Cancer Res. 2006 12 5615 5621 10.1158/1078-0432.CCR-06-0169 17020963
Balic, M. et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615–5621 (2006).17020963 10.1158/1078-0432.CCR-06-0169
47. Al-Hajj M Wicha MS Benito-Hernandez A Morrison SJ Clarke MF Prospective identification of tumorigenic breast cancer cells Proc. Natl Acad. Sci. USA 2003 100 3983 3988 10.1073/pnas.0530291100 12629218
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).12629218 10.1073/pnas.0530291100
48. Todaro M CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis Cell Stem Cell 2014 14 342 356 10.1016/j.stem.2014.01.009 24607406
Todaro, M. et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342–356 (2014).24607406 10.1016/j.stem.2014.01.009
49. Battula VL Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis J. Clin. Investig. 2012 122 2066 2078 10.1172/JCI59735 22585577
Battula, V. L. et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J. Clin. Investig. 122, 2066–2078 (2012).22585577 10.1172/JCI59735
50. Liang YJ Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells Proc. Natl Acad. Sci. USA 2013 110 4968 4973 10.1073/pnas.1302825110 23479608
Liang, Y. J. et al. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc. Natl Acad. Sci. USA 110, 4968–4973 (2013).23479608 10.1073/pnas.1302825110
51. Ho MM Ng AV Lam S Hung JY Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells Cancer Res. 2007 67 4827 4833 10.1158/0008-5472.CAN-06-3557 17510412
Ho, M. M., Ng, A. V., Lam, S. & Hung, J. Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827–4833 (2007).17510412 10.1158/0008-5472.CAN-06-3557
52. Seigel GM Campbell LM Narayan M Gonzalez-Fernandez F Cancer stem cell characteristics in retinoblastoma Mol. Vis. 2005 11 729 737 16179903
Seigel, G. M., Campbell, L. M., Narayan, M. & Gonzalez-Fernandez, F. Cancer stem cell characteristics in retinoblastoma. Mol. Vis. 11, 729–737 (2005).16179903
53. Mishima Y Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric cancer patients Target Oncol. 2017 12 341 351 10.1007/s11523-017-0493-6 28508152
Mishima, Y. et al. Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric cancer patients. Target Oncol. 12, 341–351 (2017).28508152 10.1007/s11523-017-0493-6
54. Wülfing P HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients Clin. Cancer Res. 2006 12 1715 1720 10.1158/1078-0432.CCR-05-2087 16551854
Wülfing, P. et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 12, 1715–1720 (2006).16551854 10.1158/1078-0432.CCR-05-2087
55. Beije N Prognostic impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor Neoplasia 2016 18 647 653 10.1016/j.neo.2016.08.007 27764697
Beije, N. et al. Prognostic impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor. Neoplasia 18, 647–653 (2016).27764697 10.1016/j.neo.2016.08.007
56. Forsare, C. et al. Evolution of estrogen receptor status from primary tumors to metastasis and serially collected circulating tumor cells. Int. J. Mol. Sci. 21, 2885 (2020).
57. Gradilone A Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization Ann. Oncol. 2011 22 86 92 10.1093/annonc/mdq323 20603432
Gradilone, A. et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann. Oncol. 22, 86–92 (2011).20603432 10.1093/annonc/mdq323
58. Todenhöfer T Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients Anticancer Res. 2012 32 3507 3513 22843938
Todenhöfer, T. et al. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res. 32, 3507–3513 (2012).22843938
59. Yin C Molecular profiling of pooled circulating tumor cells from prostate cancer patients using a dual-antibody-functionalized microfluidic device Anal. Chem. 2018 90 3744 3751 10.1021/acs.analchem.7b03536 29464943
Yin, C. et al. Molecular profiling of pooled circulating tumor cells from prostate cancer patients using a dual-antibody-functionalized microfluidic device. Anal. Chem. 90, 3744–3751 (2018).29464943 10.1021/acs.analchem.7b03536
60. Chen L Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer Sci. Rep. 2018 8 1188 10.1038/s41598-018-19391-1 29352248
Chen, L. et al. Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer. Sci. Rep. 8, 1188 (2018).29352248 10.1038/s41598-018-19391-1
61. Wei S Effect of vein-first vs artery-first surgical technique on circulating tumor cells and survival in patients with non-small cell lung cancer: a randomized clinical trial and registry-based propensity score matching analysis JAMA Surg. 2019 154 e190972 10.1001/jamasurg.2019.0972 31042283
Wei, S. et al. Effect of vein-first vs artery-first surgical technique on circulating tumor cells and survival in patients with non-small cell lung cancer: a randomized clinical trial and registry-based propensity score matching analysis. JAMA Surg. 154, e190972 (2019).31042283 10.1001/jamasurg.2019.0972
62. Cao W Using detection of survivin-expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer J. Surg. Oncol. 2011 103 110 115 10.1002/jso.21777 21259243
Cao, W. et al. Using detection of survivin-expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer. J. Surg. Oncol. 103, 110–115 (2011).21259243 10.1002/jso.21777
63. Steinemann G Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer Mol. Oncol. 2019 13 2679 2696 10.1002/1878-0261.12582 31583820
Steinemann, G. et al. Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer. Mol. Oncol. 13, 2679–2696 (2019).31583820 10.1002/1878-0261.12582
64. Krishnamurthy S Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer Cancer Med. 2013 2 226 233 10.1002/cam4.70 23634290
Krishnamurthy, S. et al. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med. 2, 226–233 (2013).23634290 10.1002/cam4.70
65. Bidard FC Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma Int. J. Cancer 2014 134 1207 1213 10.1002/ijc.28436 23934701
Bidard, F. C. et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int. J. Cancer 134, 1207–1213 (2014).23934701 10.1002/ijc.28436
66. Lucci A Circulating tumor cells and early relapse in node-positive melanoma Clin. Cancer Res. 2020 26 1886 1895 10.1158/1078-0432.CCR-19-2670 32015020
Lucci, A. et al. Circulating tumor cells and early relapse in node-positive melanoma. Clin. Cancer Res. 26, 1886–1895 (2020).32015020 10.1158/1078-0432.CCR-19-2670
67. Hoshimoto S Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma Ann. Surg. 2012 255 357 362 10.1097/SLA.0b013e3182380f56 22202581
Hoshimoto, S. et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann. Surg. 255, 357–362 (2012).22202581 10.1097/SLA.0b013e3182380f56
68. Kiniwa Y Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation BMC Cancer 2021 21 287 10.1186/s12885-021-08016-y 33731038
Kiniwa, Y. et al. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation. BMC Cancer 21, 287 (2021).33731038 10.1186/s12885-021-08016-y
69. Hall CS Circulating tumor cells in stage IV melanoma patients J. Am. Coll. Surg. 2018 227 116 124 10.1016/j.jamcollsurg.2018.04.026 29746918
Hall, C. S. et al. Circulating tumor cells in stage IV melanoma patients. J. Am. Coll. Surg. 227, 116–124 (2018).29746918 10.1016/j.jamcollsurg.2018.04.026
70. Hoshimoto S Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial J. Clin. Oncol. 2012 30 3819 3826 10.1200/JCO.2011.40.0887 23008288
Hoshimoto, S. et al. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J. Clin. Oncol. 30, 3819–3826 (2012).23008288 10.1200/JCO.2011.40.0887
71. Lin SY Prospective molecular profiling of circulating tumor cells from patients with melanoma receiving combinatorial immunotherapy Clin. Chem. 2020 66 169 177 10.1373/clinchem.2019.307140 31672856
Lin, S. Y. et al. Prospective molecular profiling of circulating tumor cells from patients with melanoma receiving combinatorial immunotherapy. Clin. Chem. 66, 169–177 (2020).31672856 10.1373/clinchem.2019.307140
72. Chambers AF Groom AC MacDonald IC Dissemination and growth of cancer cells in metastatic sites Nat. Rev. Cancer 2002 2 563 572 10.1038/nrc865 12154349
Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563–572 (2002).12154349 10.1038/nrc865
73. Mehlen P Puisieux A Metastasis: a question of life or death Nat. Rev. Cancer 2006 6 449 458 10.1038/nrc1886 16723991
Mehlen, P. & Puisieux, A. Metastasis: a question of life or death. Nat. Rev. Cancer 6, 449–458 (2006).16723991 10.1038/nrc1886
74. Merino D Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer Nat. Commun. 2019 10 766 10.1038/s41467-019-08595-2 30770823
Merino, D. et al. Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nat. Commun. 10, 766 (2019).30770823 10.1038/s41467-019-08595-2
75. Lambert AW Pattabiraman DR Weinberg RA Emerging biological principles of metastasis Cell 2017 168 670 691 10.1016/j.cell.2016.11.037 28187288
Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017).28187288 10.1016/j.cell.2016.11.037
76. Baccelli I Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay Nat. Biotechnol. 2013 31 539 544 10.1038/nbt.2576 23609047
Baccelli, I. et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31, 539–544 (2013).23609047 10.1038/nbt.2576
77. Mani SA The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 2008 133 704 715 10.1016/j.cell.2008.03.027 18485877
Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).18485877 10.1016/j.cell.2008.03.027
78. Batlle E The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells Nat. Cell Biol. 2000 2 84 89 10.1038/35000034 10655587
Batlle, E. et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2, 84–89 (2000).10655587 10.1038/35000034
79. Yang J Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis Cell 2004 117 927 939 10.1016/j.cell.2004.06.006 15210113
Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927–939 (2004).15210113 10.1016/j.cell.2004.06.006
80. Fischer KR Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance Nature 2015 527 472 476 10.1038/nature15748 26560033
Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472–476 (2015).26560033 10.1038/nature15748
81. Zheng X Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer Nature 2015 527 525 530 10.1038/nature16064 26560028
Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015).26560028 10.1038/nature16064
82. Padmanaban V E-cadherin is required for metastasis in multiple models of breast cancer Nature 2019 573 439 444 10.1038/s41586-019-1526-3 31485072
Padmanaban, V. et al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature 573, 439–444 (2019).31485072 10.1038/s41586-019-1526-3
83. Tsai JH Donaher JL Murphy DA Chau S Yang J Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis Cancer Cell 2012 22 725 736 10.1016/j.ccr.2012.09.022 23201165
Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725–736 (2012).23201165 10.1016/j.ccr.2012.09.022
84. Yu M Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition Science 2013 339 580 584 10.1126/science.1228522 23372014
Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580–584 (2013).23372014 10.1126/science.1228522
85. Giordano A Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer Mol. Cancer Ther. 2012 11 2526 2534 10.1158/1535-7163.MCT-12-0460 22973057
Giordano, A. et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol. Cancer Ther. 11, 2526–2534 (2012).22973057 10.1158/1535-7163.MCT-12-0460
86. Rhim AD EMT and dissemination precede pancreatic tumor formation Cell 2012 148 349 361 10.1016/j.cell.2011.11.025 22265420
Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361 (2012).22265420 10.1016/j.cell.2011.11.025
87. Strauss R Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity PLoS One 2011 6 e16186 10.1371/journal.pone.0016186 21264259
Strauss, R. et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 6, e16186 (2011).21264259 10.1371/journal.pone.0016186
88. Brabletz T To differentiate or not–routes towards metastasis Nat. Rev. Cancer 2012 12 425 436 10.1038/nrc3265 22576165
Brabletz, T. To differentiate or not–routes towards metastasis. Nat. Rev. Cancer 12, 425–436 (2012).22576165 10.1038/nrc3265
89. Friedl P Locker J Sahai E Segall JE Classifying collective cancer cell invasion Nat. Cell Biol. 2012 14 777 783 10.1038/ncb2548 22854810
Friedl, P., Locker, J., Sahai, E. & Segall, J. E. Classifying collective cancer cell invasion. Nat. Cell Biol. 14, 777–783 (2012).22854810 10.1038/ncb2548
90. Liotta LA Saidel MG Kleinerman J The significance of hematogenous tumor cell clumps in the metastatic process Cancer Res. 1976 36 889 894 1253177
Liotta, L. A., Saidel, M. G. & Kleinerman, J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 36, 889–894 (1976).1253177
91. Cleary AS Leonard TL Gestl SA Gunther EJ Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers Nature 2014 508 113 117 10.1038/nature13187 24695311
Cleary, A. S., Leonard, T. L., Gestl, S. A. & Gunther, E. J. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508, 113–117 (2014).24695311 10.1038/nature13187
92. Gundem G The evolutionary history of lethal metastatic prostate cancer Nature 2015 520 353 357 10.1038/nature14347 25830880
Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353–357 (2015).25830880 10.1038/nature14347
93. Maddipati R Stanger BZ Pancreatic cancer metastases harbor evidence of polyclonality Cancer Discov. 2015 5 1086 1097 10.1158/2159-8290.CD-15-0120 26209539
Maddipati, R. & Stanger, B. Z. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 5, 1086–1097 (2015).26209539 10.1158/2159-8290.CD-15-0120
94. McFadden DG Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing Cell 2014 156 1298 1311 10.1016/j.cell.2014.02.031 24630729
McFadden, D. G. et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156, 1298–1311 (2014).24630729 10.1016/j.cell.2014.02.031
95. Eirew P Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution Nature 2015 518 422 426 10.1038/nature13952 25470049
Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422–426 (2015).25470049 10.1038/nature13952
96. Miller BE Miller FR Heppner GH Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate Cancer Res. 1981 41 4378 4381 7306965
Miller, B. E., Miller, F. R. & Heppner, G. H. Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate. Cancer Res. 41, 4378–4381 (1981).7306965
97. Aceto N Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis Cell 2014 158 1110 1122 10.1016/j.cell.2014.07.013 25171411
Aceto, N. et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110–1122 (2014).25171411 10.1016/j.cell.2014.07.013
98. Liu X Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models Cancer Discov. 2019 9 96 113 10.1158/2159-8290.CD-18-0065 30361447
Liu, X. et al. Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. Cancer Discov. 9, 96–113 (2019).30361447 10.1158/2159-8290.CD-18-0065
99. Aceto N Toner M Maheswaran S Haber DA En route to metastasis: circulating tumor cell clusters and epithelial-to-mesenchymal transition Trends Cancer 2015 1 44 52 10.1016/j.trecan.2015.07.006 28741562
Aceto, N., Toner, M., Maheswaran, S. & Haber, D. A. En route to metastasis: circulating tumor cell clusters and epithelial-to-mesenchymal transition. Trends Cancer 1, 44–52 (2015).28741562 10.1016/j.trecan.2015.07.006
100. Taftaf R ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer Nat. Commun. 2021 12 4867 10.1038/s41467-021-25189-z 34381029
Taftaf, R. et al. ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nat. Commun. 12, 4867 (2021).34381029 10.1038/s41467-021-25189-z
101. Chimonidou M DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells Clin. Chem. 2011 57 1169 1177 10.1373/clinchem.2011.165902 21700955
Chimonidou, M. et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin. Chem. 57, 1169–1177 (2011).21700955 10.1373/clinchem.2011.165902
102. Zhao Q Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis Mol. Cancer 2010 9 154 10.1186/1476-4598-9-154 20565834
Zhao, Q. et al. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol. Cancer 9, 154 (2010).20565834 10.1186/1476-4598-9-154
103. Li C Neural EGFL like 1 as a potential pro-chondrogenic, anti-inflammatory dual-functional disease-modifying osteoarthritis drug Biomaterials 2020 226 119541 10.1016/j.biomaterials.2019.119541 31634652
Li, C. et al. Neural EGFL like 1 as a potential pro-chondrogenic, anti-inflammatory dual-functional disease-modifying osteoarthritis drug. Biomaterials 226, 119541 (2020).31634652 10.1016/j.biomaterials.2019.119541
104. Cheung KJ Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters Proc. Natl Acad. Sci. USA 2016 113 E854 E863 10.1073/pnas.1508541113 26831077
Cheung, K. J. et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc. Natl Acad. Sci. USA 113, E854–E863 (2016).26831077 10.1073/pnas.1508541113
105. Zhang L The identification and characterization of breast cancer CTCs competent for brain metastasis Sci. Transl. Med. 2013 5 180ra148 10.1126/scitranslmed.3005109
Zhang, L. et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci. Transl. Med. 5, 180ra148 (2013).10.1126/scitranslmed.3005109
106. Haynes BF Telen MJ Hale LP Denning SM CD44–a molecule involved in leukocyte adherence and T-cell activation Immunol. Today 1989 10 423 428 10.1016/0167-5699(89)90040-6 2695102
Haynes, B. F., Telen, M. J., Hale, L. P. & Denning, S. M. CD44–a molecule involved in leukocyte adherence and T-cell activation. Immunol. Today 10, 423–428 (1989).2695102 10.1016/0167-5699(89)90040-6
107. Labelle M Begum S Hynes RO Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis Cancer Cell 2011 20 576 590 10.1016/j.ccr.2011.09.009 22094253
Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576–590 (2011).22094253 10.1016/j.ccr.2011.09.009
108. Labelle M Begum S Hynes RO Platelets guide the formation of early metastatic niches Proc. Natl Acad. Sci. USA 2014 111 E3053 E3061 10.1073/pnas.1411082111 25024172
Labelle, M., Begum, S. & Hynes, R. O. Platelets guide the formation of early metastatic niches. Proc. Natl Acad. Sci. USA 111, E3053–E3061 (2014).25024172 10.1073/pnas.1411082111
109. Labernadie A A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion Nat. Cell Biol. 2017 19 224 237 10.1038/ncb3478 28218910
Labernadie, A. et al. A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat. Cell Biol. 19, 224–237 (2017).28218910 10.1038/ncb3478
110. Sprouse, M. L. et al. PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/nodal signaling. Int. J. Mol. Sci. 20, 1916 (2019).
111. Szczerba BM Neutrophils escort circulating tumour cells to enable cell cycle progression Nature 2019 566 553 557 10.1038/s41586-019-0915-y 30728496
Szczerba, B. M. et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature 566, 553–557 (2019).30728496 10.1038/s41586-019-0915-y
112. Labelle M Hynes RO The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination Cancer Discov. 2012 2 1091 1099 10.1158/2159-8290.CD-12-0329 23166151
Labelle, M. & Hynes, R. O. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2, 1091–1099 (2012).23166151 10.1158/2159-8290.CD-12-0329
113. Haemmerle M Platelets reduce anoikis and promote metastasis by activating YAP1 signaling Nat. Commun. 2017 8 310 10.1038/s41467-017-00411-z 28827520
Haemmerle, M. et al. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat. Commun. 8, 310 (2017).28827520 10.1038/s41467-017-00411-z
114. Russell JO Monga SP Wnt/β-catenin signaling in liver development, homeostasis, and pathobiology Annu Rev. Pathol. 2018 13 351 378 10.1146/annurev-pathol-020117-044010 29125798
Russell, J. O. & Monga, S. P. Wnt/β-catenin signaling in liver development, homeostasis, and pathobiology. Annu Rev. Pathol. 13, 351–378 (2018).29125798 10.1146/annurev-pathol-020117-044010
115. Schumacher D Strilic B Sivaraj KK Wettschureck N Offermanns S Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor Cancer Cell 2013 24 130 137 10.1016/j.ccr.2013.05.008 23810565
Schumacher, D., Strilic, B., Sivaraj, K. K., Wettschureck, N. & Offermanns, S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24, 130–137 (2013).23810565 10.1016/j.ccr.2013.05.008
116. Rachidi, S. et al. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci. Immunol. 2, eaai7911 (2017).
117. Placke T Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells Cancer Res. 2012 72 440 448 10.1158/0008-5472.CAN-11-1872 22127925
Placke, T. et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 72, 440–448 (2012).22127925 10.1158/0008-5472.CAN-11-1872
118. Cools-Lartigue J Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis J. Clin. Investig. 2013 123 3446 3458 10.1172/JCI67484 23863628
Cools-Lartigue, J. et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Investig. 123, 3446–3458 (2013).23863628 10.1172/JCI67484
119. Spiegel A Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells Cancer Discov. 2016 6 630 649 10.1158/2159-8290.CD-15-1157 27072748
Spiegel, A. et al. Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov. 6, 630–649 (2016).27072748 10.1158/2159-8290.CD-15-1157
120. Coffelt SB IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis Nature 2015 522 345 348 10.1038/nature14282 25822788
Coffelt, S. B. et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345–348 (2015).25822788 10.1038/nature14282
121. Schuster E Better together: circulating tumor cell clustering in metastatic cancer Trends Cancer 2021 7 1020 1032 10.1016/j.trecan.2021.07.001 34481763
Schuster, E. et al. Better together: circulating tumor cell clustering in metastatic cancer. Trends Cancer 7, 1020–1032 (2021).34481763 10.1016/j.trecan.2021.07.001
122. Gaggioli C Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells Nat. Cell Biol. 2007 9 1392 1400 10.1038/ncb1658 18037882
Gaggioli, C. et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 9, 1392–1400 (2007).18037882 10.1038/ncb1658
123. Au SH Clusters of circulating tumor cells traverse capillary-sized vessels Proc. Natl Acad. Sci. USA 2016 113 4947 4952 10.1073/pnas.1524448113 27091969
Au, S. H. et al. Clusters of circulating tumor cells traverse capillary-sized vessels. Proc. Natl Acad. Sci. USA 113, 4947–4952 (2016).27091969 10.1073/pnas.1524448113
124. Duda DG Malignant cells facilitate lung metastasis by bringing their own soil Proc. Natl Acad. Sci. USA 2010 107 21677 21682 10.1073/pnas.1016234107 21098274
Duda, D. G. et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl Acad. Sci. USA 107, 21677–21682 (2010).21098274 10.1073/pnas.1016234107
125. Rejniak KA Circulating tumor cells: when a solid tumor meets a fluid microenvironment Adv. Exp. Med. Biol. 2016 936 93 106 10.1007/978-3-319-42023-3_5 27739044
Rejniak, K. A. Circulating tumor cells: when a solid tumor meets a fluid microenvironment. Adv. Exp. Med. Biol. 936, 93–106 (2016).27739044 10.1007/978-3-319-42023-3_5
126. Diamantopoulou Z The metastatic spread of breast cancer accelerates during sleep Nature 2022 607 156 162 10.1038/s41586-022-04875-y 35732738
Diamantopoulou, Z. et al. The metastatic spread of breast cancer accelerates during sleep. Nature 607, 156–162 (2022).35732738 10.1038/s41586-022-04875-y
127. Schernhammer ES Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study J. Natl Cancer Inst. 2001 93 1563 1568 10.1093/jnci/93.20.1563 11604480
Schernhammer, E. S. et al. Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J. Natl Cancer Inst. 93, 1563–1568 (2001).11604480 10.1093/jnci/93.20.1563
128. Zhu X In vivo flow cytometry reveals a circadian rhythm of circulating tumor cells Light Sci. Appl. 2021 10 110 10.1038/s41377-021-00542-5 34045431
Zhu, X. et al. In vivo flow cytometry reveals a circadian rhythm of circulating tumor cells. Light Sci. Appl. 10, 110 (2021).34045431 10.1038/s41377-021-00542-5
129. Lauriola M Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment Nat. Commun. 2014 5 5073 10.1038/ncomms6073 25278152
Lauriola, M. et al. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nat. Commun. 5, 5073 (2014).25278152 10.1038/ncomms6073
130. Travis, R. C. et al. Night shift work and breast cancer incidence: three prospective studies and meta-analysis of published studies. J. Natl Cancer Inst. 108, djw169 (2016).
131. Giacchetti S Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group J. Clin. Oncol. 2006 24 3562 3569 10.1200/JCO.2006.06.1440 16877722
Giacchetti, S. et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J. Clin. Oncol. 24, 3562–3569 (2006).16877722 10.1200/JCO.2006.06.1440
132. Sephton SE Diurnal cortisol rhythm as a predictor of lung cancer survival Brain Behav. Immun. 2013 30 S163 S170 10.1016/j.bbi.2012.07.019 22884416
Sephton, S. E. et al. Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav. Immun. 30, S163–S170 (2013).22884416 10.1016/j.bbi.2012.07.019
133. Lévi F Zidani R Misset JL Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy Lancet 1997 350 681 686 10.1016/S0140-6736(97)03358-8 9291901
Lévi, F., Zidani, R. & Misset, J. L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350, 681–686 (1997).9291901 10.1016/S0140-6736(97)03358-8
134. Yokobori T Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis Cancer Res. 2013 73 2059 2069 10.1158/0008-5472.CAN-12-0326 23378342
Yokobori, T. et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 73, 2059–2069 (2013).23378342 10.1158/0008-5472.CAN-12-0326
135. Adorno-Cruz V Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance Cancer Res. 2015 75 924 929 10.1158/0008-5472.CAN-14-3225 25604264
Adorno-Cruz, V. et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 75, 924–929 (2015).25604264 10.1158/0008-5472.CAN-14-3225
136. de Sousa e Melo F A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer Nature 2017 543 676 680 10.1038/nature21713 28358093
de Sousa e Melo, F. et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature 543, 676–680 (2017).28358093 10.1038/nature21713
137. Tsao SC Characterising the phenotypic evolution of circulating tumour cells during treatment Nat. Commun. 2018 9 1482 10.1038/s41467-018-03725-8 29662054
Tsao, S. C. et al. Characterising the phenotypic evolution of circulating tumour cells during treatment. Nat. Commun. 9, 1482 (2018).29662054 10.1038/s41467-018-03725-8
138. Hata AN Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition Nat. Med. 2016 22 262 269 10.1038/nm.4040 26828195
Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262–269 (2016).26828195 10.1038/nm.4040
139. Paoletti C Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer Clin. Cancer Res. 2015 21 2487 2498 10.1158/1078-0432.CCR-14-1913 25381338
Paoletti, C. et al. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin. Cancer Res. 21, 2487–2498 (2015).25381338 10.1158/1078-0432.CCR-14-1913
140. Hou JM Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer J. Clin. Oncol. 2012 30 525 532 10.1200/JCO.2010.33.3716 22253462
Hou, J. M. et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol. 30, 525–532 (2012).22253462 10.1200/JCO.2010.33.3716
141. Chang MC Clinical significance of circulating tumor microemboli as a prognostic marker in patients with pancreatic ductal adenocarcinoma Clin. Chem. 2016 62 505 513 10.1373/clinchem.2015.248260 26861552
Chang, M. C. et al. Clinical significance of circulating tumor microemboli as a prognostic marker in patients with pancreatic ductal adenocarcinoma. Clin. Chem. 62, 505–513 (2016).26861552 10.1373/clinchem.2015.248260
142. Hodgkinson CL Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer Nat. Med. 2014 20 897 903 10.1038/nm.3600 24880617
Hodgkinson, C. L. et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat. Med. 20, 897–903 (2014).24880617 10.1038/nm.3600
143. Kilgour E Rothwell DG Brady G Dive C Liquid biopsy-based biomarkers of treatment response and resistance Cancer Cell 2020 37 485 495 10.1016/j.ccell.2020.03.012 32289272
Kilgour, E., Rothwell, D. G., Brady, G. & Dive, C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell 37, 485–495 (2020).32289272 10.1016/j.ccell.2020.03.012
144. Aktas B Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients Breast Cancer Res. 2009 11 R46 10.1186/bcr2333 19589136
Aktas, B. et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11, R46 (2009).19589136 10.1186/bcr2333
145. Pantel K Brakenhoff RH Brandt B Detection, clinical relevance and specific biological properties of disseminating tumour cells Nat. Rev. Cancer 2008 8 329 340 10.1038/nrc2375 18404148
Pantel, K., Brakenhoff, R. H. & Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 8, 329–340 (2008).18404148 10.1038/nrc2375
146. Liu R The prognostic role of a gene signature from tumorigenic breast-cancer cells N. Engl. J. Med. 2007 356 217 226 10.1056/NEJMoa063994 17229949
Liu, R. et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217–226 (2007).17229949 10.1056/NEJMoa063994
147. Korkaya H Paulson A Iovino F Wicha MS HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion Oncogene 2008 27 6120 6130 10.1038/onc.2008.207 18591932
Korkaya, H., Paulson, A., Iovino, F. & Wicha, M. S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27, 6120–6130 (2008).18591932 10.1038/onc.2008.207
148. Papadaki MA Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer BMC Cancer 2014 14 651 10.1186/1471-2407-14-651 25182808
Papadaki, M. A. et al. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer 14, 651 (2014).25182808 10.1186/1471-2407-14-651
149. Theodoropoulos PA Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer Cancer Lett. 2010 288 99 106 10.1016/j.canlet.2009.06.027 19619935
Theodoropoulos, P. A. et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 288, 99–106 (2010).19619935 10.1016/j.canlet.2009.06.027
150. Abraham BK Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis Clin. Cancer Res. 2005 11 1154 1159 10.1158/1078-0432.1154.11.3 15709183
Abraham, B. K. et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 11, 1154–1159 (2005).15709183 10.1158/1078-0432.1154.11.3
151. Trumpp A Wiestler OD Mechanisms of disease: cancer stem cells–targeting the evil twin Nat. Clin. Pract. Oncol. 2008 5 337 347 10.1038/ncponc1110 18431377
Trumpp, A. & Wiestler, O. D. Mechanisms of disease: cancer stem cells–targeting the evil twin. Nat. Clin. Pract. Oncol. 5, 337–347 (2008).18431377 10.1038/ncponc1110
152. Honeth G The CD44+/CD24- phenotype is enriched in basal-like breast tumors Breast Cancer Res. 2008 10 R53 10.1186/bcr2108 18559090
Honeth, G. et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10, R53 (2008).18559090 10.1186/bcr2108
153. Mylona E The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas Hum. Pathol. 2008 39 1096 1102 10.1016/j.humpath.2007.12.003 18495204
Mylona, E. et al. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum. Pathol. 39, 1096–1102 (2008).18495204 10.1016/j.humpath.2007.12.003
154. Jamal-Hanjani M Tracking the evolution of non-small-cell lung cancer N. Engl. J. Med. 2017 376 2109 2121 10.1056/NEJMoa1616288 28445112
Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).28445112 10.1056/NEJMoa1616288
155. Turajlic S Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal Cell 2018 173 595 610.e511 10.1016/j.cell.2018.03.043 29656894
Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 173, 595–610.e511 (2018).29656894 10.1016/j.cell.2018.03.043
156. Chemi F Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse Nat. Med. 2019 25 1534 1539 10.1038/s41591-019-0593-1 31591595
Chemi, F. et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat. Med. 25, 1534–1539 (2019).31591595 10.1038/s41591-019-0593-1
157. Visal TH den Hollander P Cristofanilli M Mani SA Circulating tumour cells in the -omics era: how far are we from achieving the ‘singularity’? Br. J. Cancer 2022 127 173 184 10.1038/s41416-022-01768-9 35273384
Visal, T. H., den Hollander, P., Cristofanilli, M. & Mani, S. A. Circulating tumour cells in the -omics era: how far are we from achieving the ‘singularity’? Br. J. Cancer 127, 173–184 (2022).35273384 10.1038/s41416-022-01768-9
158. Pantel K Alix-Panabières C Liquid biopsy and minimal residual disease—latest advances and implications for cure Nat. Rev. Clin. Oncol. 2019 16 409 424 10.1038/s41571-019-0187-3 30796368
Pantel, K. & Alix-Panabières, C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat. Rev. Clin. Oncol. 16, 409–424 (2019).30796368 10.1038/s41571-019-0187-3
159. Müller V Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study Breast Cancer Res. 2012 14 R118 10.1186/bcr3243 22894854
Müller, V. et al. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 14, R118 (2012).22894854 10.1186/bcr3243
160. Wang L Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells Semin Oncol. 2016 43 464 475 10.1053/j.seminoncol.2016.06.004 27663478
Wang, L. et al. Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells. Semin Oncol. 43, 464–475 (2016).27663478 10.1053/j.seminoncol.2016.06.004
161. Gleghorn JP Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody Lab Chip 2010 10 27 29 10.1039/B917959C 20024046
Gleghorn, J. P. et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 10, 27–29 (2010).20024046 10.1039/B917959C
162. Karabacak NM Microfluidic, marker-free isolation of circulating tumor cells from blood samples Nat. Protoc. 2014 9 694 710 10.1038/nprot.2014.044 24577360
Karabacak, N. M. et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat. Protoc. 9, 694–710 (2014).24577360 10.1038/nprot.2014.044
163. Krol I Detection of clustered circulating tumour cells in early breast cancer Br. J. Cancer 2021 125 23 27 10.1038/s41416-021-01327-8 33762721
Krol, I. et al. Detection of clustered circulating tumour cells in early breast cancer. Br. J. Cancer 125, 23–27 (2021).33762721 10.1038/s41416-021-01327-8
164. Harb W Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay Transl. Oncol. 2013 6 528 538 10.1593/tlo.13367 24151533
Harb, W. et al. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl. Oncol. 6, 528–538 (2013).24151533 10.1593/tlo.13367
165. Donato C Hypoxia triggers the intravasation of clustered circulating tumor cells Cell Rep. 2020 32 108105 10.1016/j.celrep.2020.108105 32905777
Donato, C. et al. Hypoxia triggers the intravasation of clustered circulating tumor cells. Cell Rep. 32, 108105 (2020).32905777 10.1016/j.celrep.2020.108105
166. Saucedo-Zeni N A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire Int. J. Oncol. 2012 41 1241 1250 22825490
Saucedo-Zeni, N. et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int. J. Oncol. 41, 1241–1250 (2012).22825490
167. Eifler RL Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept Cytom. B Clin. Cytom. 2011 80 100 111 10.1002/cyto.b.20560
Eifler, R. L. et al. Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytom. B Clin. Cytom. 80, 100–111 (2011).10.1002/cyto.b.20560
168. Crosbie PA Circulating tumor cells detected in the tumor-draining pulmonary vein are associated with disease recurrence after surgical resection of NSCLC J. Thorac. Oncol. 2016 11 1793 1797 10.1016/j.jtho.2016.06.017 27468936
Crosbie, P. A. et al. Circulating tumor cells detected in the tumor-draining pulmonary vein are associated with disease recurrence after surgical resection of NSCLC. J. Thorac. Oncol. 11, 1793–1797 (2016).27468936 10.1016/j.jtho.2016.06.017
169. Wang Y Navin NE Advances and applications of single-cell sequencing technologies Mol. Cell 2015 58 598 609 10.1016/j.molcel.2015.05.005 26000845
Wang, Y. & Navin, N. E. Advances and applications of single-cell sequencing technologies. Mol. Cell 58, 598–609 (2015).26000845 10.1016/j.molcel.2015.05.005
170. Gawad C Koh W Quake SR Single-cell genome sequencing: current state of the science Nat. Rev. Genet. 2016 17 175 188 10.1038/nrg.2015.16 26806412
Gawad, C., Koh, W. & Quake, S. R. Single-cell genome sequencing: current state of the science. Nat. Rev. Genet. 17, 175–188 (2016).26806412 10.1038/nrg.2015.16
171. Abouleila Y Live single cell mass spectrometry reveals cancer-specific metabolic profiles of circulating tumor cells Cancer Sci. 2019 110 697 706 10.1111/cas.13915 30549153
Abouleila, Y. et al. Live single cell mass spectrometry reveals cancer-specific metabolic profiles of circulating tumor cells. Cancer Sci. 110, 697–706 (2019).30549153 10.1111/cas.13915
172. Donato C Buczak K Schmidt A Aceto N Mass spectrometry analysis of circulating breast cancer cells from a Xenograft mouse model STAR Protoc. 2021 2 100480 10.1016/j.xpro.2021.100480 33982014
Donato, C., Buczak, K., Schmidt, A. & Aceto, N. Mass spectrometry analysis of circulating breast cancer cells from a Xenograft mouse model. STAR Protoc. 2, 100480 (2021).33982014 10.1016/j.xpro.2021.100480
173. Armbrecht L Quantification of protein secretion from circulating tumor cells in microfluidic chambers Adv. Sci. 2020 7 1903237 10.1002/advs.201903237
Armbrecht, L. et al. Quantification of protein secretion from circulating tumor cells in microfluidic chambers. Adv. Sci. 7, 1903237 (2020).10.1002/advs.201903237
174. Yu M Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility Science 2014 345 216 220 10.1126/science.1253533 25013076
Yu, M. et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216–220 (2014).25013076 10.1126/science.1253533
175. Khoo BL Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device Nat. Protoc. 2018 13 34 58 10.1038/nprot.2017.125 29215634
Khoo, B. L. et al. Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device. Nat. Protoc. 13, 34–58 (2018).29215634 10.1038/nprot.2017.125
176. Fokas E Engenhart-Cabillic R Daniilidis K Rose F An HX Metastasis: the seed and soil theory gains identity Cancer Metastasis Rev. 2007 26 705 715 10.1007/s10555-007-9088-5 17786535
Fokas, E., Engenhart-Cabillic, R., Daniilidis, K., Rose, F. & An, H. X. Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev. 26, 705–715 (2007).17786535 10.1007/s10555-007-9088-5
177. Chaffer CL Weinberg RA A perspective on cancer cell metastasis Science 2011 331 1559 1564 10.1126/science.1203543 21436443
Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559–1564 (2011).21436443 10.1126/science.1203543
178. Genna, A. et al. EMT-Associated heterogeneity in circulating tumor cells: sticky friends on the road to metastasis. Cancers 12, 1632 (2020).
179. Silva Paiva R Gomes I Casimiro S Fernandes I Costa L c-Met expression in renal cell carcinoma with bone metastases J. Bone Oncol. 2020 25 100315 10.1016/j.jbo.2020.100315 33024658
Silva Paiva, R., Gomes, I., Casimiro, S., Fernandes, I. & Costa, L. c-Met expression in renal cell carcinoma with bone metastases. J. Bone Oncol. 25, 100315 (2020).33024658 10.1016/j.jbo.2020.100315
180. D’Oronzo S Brown J Coleman R The role of biomarkers in the management of bone-homing malignancies J. Bone Oncol. 2017 9 1 9 10.1016/j.jbo.2017.09.001 28948139
D’Oronzo, S., Brown, J. & Coleman, R. The role of biomarkers in the management of bone-homing malignancies. J. Bone Oncol. 9, 1–9 (2017).28948139 10.1016/j.jbo.2017.09.001
181. Majidpoor J Mortezaee K Steps in metastasis: an updated review Med Oncol. 2021 38 3 10.1007/s12032-020-01447-w 33394200
Majidpoor, J. & Mortezaee, K. Steps in metastasis: an updated review. Med Oncol. 38, 3 (2021).33394200 10.1007/s12032-020-01447-w
182. Zhu, L. et al. Characterization of stem-like circulating tumor cells in pancreatic cancer. Diagnostics 10, 305 (2020).
183. Fabisiewicz A Grzybowska E CTC clusters in cancer progression and metastasis Med. Oncol. 2017 34 12 10.1007/s12032-016-0875-0 28012133
Fabisiewicz, A. & Grzybowska, E. CTC clusters in cancer progression and metastasis. Med. Oncol. 34, 12 (2017).28012133 10.1007/s12032-016-0875-0
184. Obenauf AC Massague J Surviving at a distance: organ-specific metastasis Trends Cancer 2015 1 76 91 10.1016/j.trecan.2015.07.009 28741564
Obenauf, A. C. & Massague, J. Surviving at a distance: organ-specific metastasis. Trends Cancer 1, 76–91 (2015).28741564 10.1016/j.trecan.2015.07.009
185. Ring A Nguyen-Strauli BD Wicki A Aceto N Biology, vulnerabilities and clinical applications of circulating tumour cells Nat. Rev. Cancer 2023 23 95 111 10.1038/s41568-022-00536-4 36494603
Ring, A., Nguyen-Strauli, B. D., Wicki, A. & Aceto, N. Biology, vulnerabilities and clinical applications of circulating tumour cells. Nat. Rev. Cancer 23, 95–111 (2023).36494603 10.1038/s41568-022-00536-4
186. Novikov NM Zolotaryova SY Gautreau AM Denisov EV Mutational drivers of cancer cell migration and invasion Br. J. Cancer 2021 124 102 114 10.1038/s41416-020-01149-0 33204027
Novikov, N. M., Zolotaryova, S. Y., Gautreau, A. M. & Denisov, E. V. Mutational drivers of cancer cell migration and invasion. Br. J. Cancer 124, 102–114 (2021).33204027 10.1038/s41416-020-01149-0
187. Trepat X Chen Z Jacobson K Cell migration Compr. Physiol. 2012 2 2369 2392 10.1002/cphy.c110012 23720251
Trepat, X., Chen, Z. & Jacobson, K. Cell migration. Compr. Physiol. 2, 2369–2392 (2012).23720251 10.1002/cphy.c110012
188. Fanfone, D. et al. Confined migration promotes cancer metastasis through resistance to anoikis and increased invasiveness. Elife 11, e73150 (2022).
189. Muscella A Vetrugno C Cossa LG Marsigliante S TGF-β1 activates RSC96 Schwann cells migration and invasion through MMP-2 and MMP-9 activities J. Neurochem. 2020 153 525 538 10.1111/jnc.14913 31729763
Muscella, A., Vetrugno, C., Cossa, L. G. & Marsigliante, S. TGF-β1 activates RSC96 Schwann cells migration and invasion through MMP-2 and MMP-9 activities. J. Neurochem. 153, 525–538 (2020).31729763 10.1111/jnc.14913
190. Wan G SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3β/β-catenin pathway Cell Signal 2019 59 1 12 10.1016/j.cellsig.2019.03.004 30844429
Wan, G. et al. SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3β/β-catenin pathway. Cell Signal 59, 1–12 (2019).30844429 10.1016/j.cellsig.2019.03.004
191. Bonnans C Chou J Werb Z Remodelling the extracellular matrix in development and disease Nat. Rev. Mol. Cell Biol. 2014 15 786 801 10.1038/nrm3904 25415508
Bonnans, C., Chou, J. & Werb, Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 15, 786–801 (2014).25415508 10.1038/nrm3904
192. Theocharis AD Skandalis SS Gialeli C Karamanos NK Extracellular matrix structure Adv. Drug Deliv. Rev. 2016 97 4 27 10.1016/j.addr.2015.11.001 26562801
Theocharis, A. D., Skandalis, S. S., Gialeli, C. & Karamanos, N. K. Extracellular matrix structure. Adv. Drug Deliv. Rev. 97, 4–27 (2016).26562801 10.1016/j.addr.2015.11.001
193. Insua-Rodríguez J Oskarsson T The extracellular matrix in breast cancer Adv. Drug Deliv. Rev. 2016 97 41 55 10.1016/j.addr.2015.12.017 26743193
Insua-Rodríguez, J. & Oskarsson, T. The extracellular matrix in breast cancer. Adv. Drug Deliv. Rev. 97, 41–55 (2016).26743193 10.1016/j.addr.2015.12.017
194. Lambert AW Weinberg RA Linking EMT programmes to normal and neoplastic epithelial stem cells Nat. Rev. Cancer 2021 21 325 338 10.1038/s41568-021-00332-6 33547455
Lambert, A. W. & Weinberg, R. A. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat. Rev. Cancer 21, 325–338 (2021).33547455 10.1038/s41568-021-00332-6
195. Zhou P The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer Mol. Cancer 2017 16 52 10.1186/s12943-017-0624-9 28245823
Zhou, P. et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Mol. Cancer 16, 52 (2017).28245823 10.1186/s12943-017-0624-9
196. Deshmukh, A. P. et al. Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing. Proc. Natl Acad. Sci. USA 118, e2102050118 (2021).
197. Meng J USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma Theranostics 2019 9 573 587 10.7150/thno.27654 30809294
Meng, J. et al. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma. Theranostics 9, 573–587 (2019).30809294 10.7150/thno.27654
198. Dai X CBP-mediated Slug acetylation stabilizes Slug and promotes EMT and migration of breast cancer cells Sci. China Life Sci. 2021 64 563 574 10.1007/s11427-020-1736-5 32737855
Dai, X. et al. CBP-mediated Slug acetylation stabilizes Slug and promotes EMT and migration of breast cancer cells. Sci. China Life Sci. 64, 563–574 (2021).32737855 10.1007/s11427-020-1736-5
199. Yoon H Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis Oncogene 2021 40 1957 1973 10.1038/s41388-021-01685-w 33603171
Yoon, H. et al. Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene 40, 1957–1973 (2021).33603171 10.1038/s41388-021-01685-w
200. Ingruber, J. et al. KLF4, Slug and EMT in head and neck squamous cell carcinoma. Cells 10, 539(2021).
201. Schinke H SLUG-related partial epithelial-to-mesenchymal transition is a transcriptomic prognosticator of head and neck cancer survival Mol. Oncol. 2022 16 347 367 10.1002/1878-0261.13075 34382739
Schinke, H. et al. SLUG-related partial epithelial-to-mesenchymal transition is a transcriptomic prognosticator of head and neck cancer survival. Mol. Oncol. 16, 347–367 (2022).34382739 10.1002/1878-0261.13075
202. Cho ES Kang HE Kim NH Yook JI Therapeutic implications of cancer epithelial-mesenchymal transition (EMT) Arch. Pharm. Res. 2019 42 14 24 10.1007/s12272-018-01108-7 30649699
Cho, E. S., Kang, H. E., Kim, N. H. & Yook, J. I. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT). Arch. Pharm. Res. 42, 14–24 (2019).30649699 10.1007/s12272-018-01108-7
203. Kuburich NA den Hollander P Pietz JT Mani SA Vimentin and cytokeratin: good alone, bad together Semin. Cancer Biol. 2022 86 816 826 10.1016/j.semcancer.2021.12.006 34953942
Kuburich, N. A., den Hollander, P., Pietz, J. T. & Mani, S. A. Vimentin and cytokeratin: good alone, bad together. Semin. Cancer Biol. 86, 816–826 (2022).34953942 10.1016/j.semcancer.2021.12.006
204. Satelli A Li S Vimentin in cancer and its potential as a molecular target for cancer therapy Cell Mol. Life Sci. 2011 68 3033 3046 10.1007/s00018-011-0735-1 21637948
Satelli, A. & Li, S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol. Life Sci. 68, 3033–3046 (2011).21637948 10.1007/s00018-011-0735-1
205. Serrano-Gomez SJ Maziveyi M Alahari SK Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications Mol. Cancer 2016 15 18 10.1186/s12943-016-0502-x 26905733
Serrano-Gomez, S. J., Maziveyi, M. & Alahari, S. K. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol. Cancer 15, 18 (2016).26905733 10.1186/s12943-016-0502-x
206. Francart ME Epithelial-mesenchymal plasticity and circulating tumor cells: travel companions to metastases Dev. Dyn. 2018 247 432 450 10.1002/dvdy.24506 28407379
Francart, M. E. et al. Epithelial-mesenchymal plasticity and circulating tumor cells: travel companions to metastases. Dev. Dyn. 247, 432–450 (2018).28407379 10.1002/dvdy.24506
207. Nowak, E. & Bednarek, I. Aspects of the epigenetic regulation of emt related to cancer metastasis. Cells 10, 3435 (2021).
208. Loh, C. Y. et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells 8, 1118 (2019).
209. Imran M Luteolin, a flavonoid, as an anticancer agent: a review Biomed. Pharmacother. 2019 112 108612 10.1016/j.biopha.2019.108612 30798142
Imran, M. et al. Luteolin, a flavonoid, as an anticancer agent: a review. Biomed. Pharmacother. 112, 108612 (2019).30798142 10.1016/j.biopha.2019.108612
210. Keller L Werner S Pantel K Biology and clinical relevance of EpCAM Cell Stress 2019 3 165 180 10.15698/cst2019.06.188 31225512
Keller, L., Werner, S. & Pantel, K. Biology and clinical relevance of EpCAM. Cell Stress 3, 165–180 (2019).31225512 10.15698/cst2019.06.188
211. Usman, S. et al. Vimentin is at the heart of epithelial-mesenchymal transition (EMT) mediated metastasis. Cancers 13 (2021).
212. Friedl P Alexander S Cancer invasion and the microenvironment: plasticity and reciprocity Cell 2011 147 992 1009 10.1016/j.cell.2011.11.016 22118458
Friedl, P. & Alexander, S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147, 992–1009 (2011).22118458 10.1016/j.cell.2011.11.016
213. Friedl, P. & Mayor, R. Tuning collective cell migration by cell-cell junction regulation. Cold Spring Harb. Perspect. Biol. 9, a029199 (2017).
214. Shankar J Nabi IR Actin cytoskeleton regulation of epithelial mesenchymal transition in metastatic cancer cells PLoS One 2015 10 e0119954 10.1371/journal.pone.0119954 25756282
Shankar, J. & Nabi, I. R. Actin cytoskeleton regulation of epithelial mesenchymal transition in metastatic cancer cells. PLoS One 10, e0119954 (2015).25756282 10.1371/journal.pone.0119954
215. Bordin M D’Atri F Guillemot L Citi S Histone deacetylase inhibitors up-regulate the expression of tight junction proteins Mol. Cancer Res. 2004 2 692 701 10.1158/1541-7786.692.2.12 15634758
Bordin, M., D’Atri, F., Guillemot, L. & Citi, S. Histone deacetylase inhibitors up-regulate the expression of tight junction proteins. Mol. Cancer Res. 2, 692–701 (2004).15634758 10.1158/1541-7786.692.2.12
216. Samulitis BK Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors Cancer Biol. Ther. 2015 16 43 51 10.4161/15384047.2014.986967 25485960
Samulitis, B. K. et al. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol. Ther. 16, 43–51 (2015).25485960 10.4161/15384047.2014.986967
217. Rolando M Contractile actin cables induced by Bacillus anthracis lethal toxin depend on the histone acetylation machinery Cytoskeleton 2015 72 542 556 10.1002/cm.21256 26403219
Rolando, M. et al. Contractile actin cables induced by Bacillus anthracis lethal toxin depend on the histone acetylation machinery. Cytoskeleton 72, 542–556 (2015).26403219 10.1002/cm.21256
218. Jiang J Redox regulation in tumor cell epithelial-mesenchymal transition: molecular basis and therapeutic strategy Signal Transduct. Target Ther. 2017 2 17036 10.1038/sigtrans.2017.36 29263924
Jiang, J. et al. Redox regulation in tumor cell epithelial-mesenchymal transition: molecular basis and therapeutic strategy. Signal Transduct. Target Ther. 2, 17036 (2017).29263924 10.1038/sigtrans.2017.36
219. Ottaviani S TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression Nat. Commun. 2018 9 1845 10.1038/s41467-018-03962-x 29748571
Ottaviani, S. et al. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Nat. Commun. 9, 1845 (2018).29748571 10.1038/s41467-018-03962-x
220. Przybyla L Lakins JN Weaver VM Tissue mechanics orchestrate Wnt-dependent human embryonic stem cell differentiation Cell Stem Cell 2016 19 462 475 10.1016/j.stem.2016.06.018 27452175
Przybyla, L., Lakins, J. N. & Weaver, V. M. Tissue mechanics orchestrate Wnt-dependent human embryonic stem cell differentiation. Cell Stem Cell 19, 462–475 (2016).27452175 10.1016/j.stem.2016.06.018
221. Li Z Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis Cancer Res. 2022 82 1321 1339 10.1158/0008-5472.CAN-21-2576 35078818
Li, Z. et al. Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. Cancer Res. 82, 1321–1339 (2022).35078818 10.1158/0008-5472.CAN-21-2576
222. Nagase H Visse R Murphy G Structure and function of matrix metalloproteinases and TIMPs Cardiovasc Res. 2006 69 562 573 10.1016/j.cardiores.2005.12.002 16405877
Nagase, H., Visse, R. & Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 69, 562–573 (2006).16405877 10.1016/j.cardiores.2005.12.002
223. Niland, S., Riscanevo, A. X. & Eble, J. A. Matrix metalloproteinases shape the tumor microenvironment in cancer progression. Int. J. Mol. Sci. 23, 146 (2021).
224. Zhang Y Melatonin modulates IL-1β-induced extracellular matrix remodeling in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration and inflammation Aging 2019 11 10499 10512 10.18632/aging.102472 31772145
Zhang, Y. et al. Melatonin modulates IL-1β-induced extracellular matrix remodeling in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration and inflammation. Aging 11, 10499–10512 (2019).31772145 10.18632/aging.102472
225. Magnan L In vivo remodeling of human cell-assembled extracellular matrix yarns Biomaterials 2021 273 120815 10.1016/j.biomaterials.2021.120815 33894404
Magnan, L. et al. In vivo remodeling of human cell-assembled extracellular matrix yarns. Biomaterials 273, 120815 (2021).33894404 10.1016/j.biomaterials.2021.120815
226. Jafari G Genetics of extracellular matrix remodeling during organ growth using the Caenorhabditis elegans pharynx model Genetics 2010 186 969 982 10.1534/genetics.110.120519 20805556
Jafari, G. et al. Genetics of extracellular matrix remodeling during organ growth using the Caenorhabditis elegans pharynx model. Genetics 186, 969–982 (2010).20805556 10.1534/genetics.110.120519
227. Gucciardo F Pirson S Baudin L Lebeau A Noël A uPARAP/Endo180: a multifaceted protein of mesenchymal cells Cell Mol. Life Sci. 2022 79 255 10.1007/s00018-022-04249-7 35460056
Gucciardo, F., Pirson, S., Baudin, L., Lebeau, A. & Noël, A. uPARAP/Endo180: a multifaceted protein of mesenchymal cells. Cell Mol. Life Sci. 79, 255 (2022).35460056 10.1007/s00018-022-04249-7
228. Kunze, P. et al. Multiphoton microscopy reveals DAPK1-dependent extracellular matrix remodeling in a chorioallantoic membrane (CAM) model. Cancers 14, 2364 (2022).
229. Shmakova, A. A. et al. Urokinase receptor uPAR downregulation in neuroblastoma leads to dormancy, chemoresistance and metastasis. Cancers 14, 994 (2022).
230. Ismail, A. A., Shaker, B. T. & Bajou, K. The plasminogen-activator plasmin system in physiological and pathophysiological angiogenesis. Int. J. Mol. Sci. 23, 337 (2021).
231. Ingram KG Curtis CD Silasi-Mansat R Lupu F Griffin CT The NuRD chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis PLoS Genet. 2013 9 e1004031 10.1371/journal.pgen.1004031 24348274
Ingram, K. G., Curtis, C. D., Silasi-Mansat, R., Lupu, F. & Griffin, C. T. The NuRD chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis. PLoS Genet. 9, e1004031 (2013).24348274 10.1371/journal.pgen.1004031
232. Hamidi H Ivaska J Every step of the way: integrins in cancer progression and metastasis Nat. Rev. Cancer 2018 18 533 548 10.1038/s41568-018-0038-z 30002479
Hamidi, H. & Ivaska, J. Every step of the way: integrins in cancer progression and metastasis. Nat. Rev. Cancer 18, 533–548 (2018).30002479 10.1038/s41568-018-0038-z
233. Vining KH Mechanical checkpoint regulates monocyte differentiation in fibrotic niches Nat. Mater. 2022 21 939 950 10.1038/s41563-022-01293-3 35817965
Vining, K. H. et al. Mechanical checkpoint regulates monocyte differentiation in fibrotic niches. Nat. Mater. 21, 939–950 (2022).35817965 10.1038/s41563-022-01293-3
234. Wang X Succinylation inhibits the enzymatic hydrolysis of the extracellular matrix protein fibrillin 1 and promotes gastric cancer progression Adv. Sci. 2022 9 e2200546 10.1002/advs.202200546
Wang, X. et al. Succinylation inhibits the enzymatic hydrolysis of the extracellular matrix protein fibrillin 1 and promotes gastric cancer progression. Adv. Sci. 9, e2200546 (2022).10.1002/advs.202200546
235. Leiva O The role of extracellular matrix stiffness in megakaryocyte and platelet development and function Am. J. Hematol. 2018 93 430 441 10.1002/ajh.25008 29247535
Leiva, O. et al. The role of extracellular matrix stiffness in megakaryocyte and platelet development and function. Am. J. Hematol. 93, 430–441 (2018).29247535 10.1002/ajh.25008
236. Schüler SC Extensive remodeling of the extracellular matrix during aging contributes to age-dependent impairments of muscle stem cell functionality Cell Rep. 2021 35 109223 10.1016/j.celrep.2021.109223 34107247
Schüler, S. C. et al. Extensive remodeling of the extracellular matrix during aging contributes to age-dependent impairments of muscle stem cell functionality. Cell Rep. 35, 109223 (2021).34107247 10.1016/j.celrep.2021.109223
237. Hynes RO Naba A Overview of the matrisome–an inventory of extracellular matrix constituents and functions Cold Spring Harb. Perspect. Biol. 2012 4 a004903 10.1101/cshperspect.a004903 21937732
Hynes, R. O. & Naba, A. Overview of the matrisome–an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 4, a004903 (2012).21937732 10.1101/cshperspect.a004903
238. Godinho SA Oncogene-like induction of cellular invasion from centrosome amplification Nature 2014 510 167 171 10.1038/nature13277 24739973
Godinho, S. A. et al. Oncogene-like induction of cellular invasion from centrosome amplification. Nature 510, 167–171 (2014).24739973 10.1038/nature13277
239. Sawabata N Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood? Surg. Today 2016 46 1402 1409 10.1007/s00595-016-1318-4 26951195
Sawabata, N. et al. Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood? Surg. Today 46, 1402–1409 (2016).26951195 10.1007/s00595-016-1318-4
240. Camara O Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells World J. Surg. Oncol. 2006 4 67 10.1186/1477-7819-4-67 17002789
Camara, O. et al. Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J. Surg. Oncol. 4, 67 (2006).17002789 10.1186/1477-7819-4-67
241. Hapach LA Phenotypic heterogeneity and metastasis of breast cancer cells Cancer Res 2021 81 3649 3663 10.1158/0008-5472.CAN-20-1799 33975882
Hapach, L. A. et al. Phenotypic heterogeneity and metastasis of breast cancer cells. Cancer Res 81, 3649–3663 (2021).33975882 10.1158/0008-5472.CAN-20-1799
242. Chang, P. H. et al. Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer. Proc. Natl Acad. Sci. USA 118, e2014408118 (2021).
243. Jin K Luo Z Zhang B Pang Z Biomimetic nanoparticles for inflammation targeting Acta Pharm. Sin. B 2018 8 23 33 10.1016/j.apsb.2017.12.002 29872620
Jin, K., Luo, Z., Zhang, B. & Pang, Z. Biomimetic nanoparticles for inflammation targeting. Acta Pharm. Sin. B 8, 23–33 (2018).29872620 10.1016/j.apsb.2017.12.002
244. Kapeleris J Cancer stemness contributes to cluster formation of colon cancer cells and high metastatic potentials Clin. Exp. Pharm. Physiol. 2020 47 838 847 10.1111/1440-1681.13247
Kapeleris, J. et al. Cancer stemness contributes to cluster formation of colon cancer cells and high metastatic potentials. Clin. Exp. Pharm. Physiol. 47, 838–847 (2020).10.1111/1440-1681.13247
245. Martínez-León E Fibronectin stimulates human sperm capacitation through the cyclic AMP/protein kinase A pathway Hum. Reprod. 2015 30 2138 2151 10.1093/humrep/dev154 26109618
Martínez-León, E. et al. Fibronectin stimulates human sperm capacitation through the cyclic AMP/protein kinase A pathway. Hum. Reprod. 30, 2138–2151 (2015).26109618 10.1093/humrep/dev154
246. Castellano L Evaluation of α5β1 integrin as a candidate marker for fertility in bull sperm samples Theriogenology 2021 168 66 74 10.1016/j.theriogenology.2021.04.001 33862426
Castellano, L. et al. Evaluation of α5β1 integrin as a candidate marker for fertility in bull sperm samples. Theriogenology 168, 66–74 (2021).33862426 10.1016/j.theriogenology.2021.04.001
247. Kim MY Tumor self-seeding by circulating cancer cells Cell 2009 139 1315 1326 10.1016/j.cell.2009.11.025 20064377
Kim, M. Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315–1326 (2009).20064377 10.1016/j.cell.2009.11.025
248. Divella R Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer Anticancer Res. 2013 33 1491 1497 23564790
Divella, R. et al. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer. Anticancer Res. 33, 1491–1497 (2013).23564790
249. Varol R Acousto-holographic reconstruction of whole-cell stiffness maps Nat. Commun. 2022 13 7351 10.1038/s41467-022-35075-x 36446776
Varol, R. et al. Acousto-holographic reconstruction of whole-cell stiffness maps. Nat. Commun. 13, 7351 (2022).36446776 10.1038/s41467-022-35075-x
250. Hynes WF Examining metastatic behavior within 3D bioprinted vasculature for the validation of a 3D computational flow model Sci. Adv. 2020 6 eabb3308 10.1126/sciadv.abb3308 32923637
Hynes, W. F. et al. Examining metastatic behavior within 3D bioprinted vasculature for the validation of a 3D computational flow model. Sci. Adv. 6, eabb3308 (2020).32923637 10.1126/sciadv.abb3308
251. Dong C Wang H Zhang Z Zhang T Liu B Carboxybetaine methacrylate oligomer modified nylon for circulating tumor cells capture J. Colloid Interface Sci. 2014 432 135 143 10.1016/j.jcis.2014.07.003 25086387
Dong, C., Wang, H., Zhang, Z., Zhang, T. & Liu, B. Carboxybetaine methacrylate oligomer modified nylon for circulating tumor cells capture. J. Colloid Interface Sci. 432, 135–143 (2014).25086387 10.1016/j.jcis.2014.07.003
252. Yang MH Imrali A Heeschen C Circulating cancer stem cells: the importance to select Chin. J. Cancer Res 2015 27 437 449 26543330
Yang, M. H., Imrali, A. & Heeschen, C. Circulating cancer stem cells: the importance to select. Chin. J. Cancer Res 27, 437–449 (2015).26543330
253. Huang Q Fluid shear stress and tumor metastasis Am. J. Cancer Res 2018 8 763 777 29888101
Huang, Q. et al. Fluid shear stress and tumor metastasis. Am. J. Cancer Res 8, 763–777 (2018).29888101
254. Wong SY Hynes RO Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 2006 5 812 817 10.4161/cc.5.8.2646 16627996
Wong, S. Y. & Hynes, R. O. Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 5, 812–817 (2006).16627996 10.4161/cc.5.8.2646
255. Dianat-Moghadam, H. et al. The role of circulating tumor cells in the metastatic cascade: biology, technical challenges, and clinical relevance. Cancers 12, 867 (2020).
256. Badia-Ramentol, J., Linares, J., Gómez-Llonin, A. & Calon, A. Minimal residual disease, metastasis and immunity. Biomolecules 11, 130(2021).
257. Li H Tissue factor: a neglected role in cancer biology J. Thromb. Thrombolysis 2022 54 97 108 10.1007/s11239-022-02662-0 35763169
Li, H. et al. Tissue factor: a neglected role in cancer biology. J. Thromb. Thrombolysis 54, 97–108 (2022).35763169 10.1007/s11239-022-02662-0
258. Lian S Xie X Lu Y Jia L Checkpoint CD47 function on tumor metastasis and immune therapy Onco Targets Ther. 2019 12 9105 9114 10.2147/OTT.S220196 31806995
Lian, S., Xie, X., Lu, Y. & Jia, L. Checkpoint CD47 function on tumor metastasis and immune therapy. Onco Targets Ther. 12, 9105–9114 (2019).31806995 10.2147/OTT.S220196
259. Lozar T Gersak K Cemazar M Kuhar CG Jesenko T The biology and clinical potential of circulating tumor cells Radio. Oncol. 2019 53 131 147 10.2478/raon-2019-0024
Lozar, T., Gersak, K., Cemazar, M., Kuhar, C. G. & Jesenko, T. The biology and clinical potential of circulating tumor cells. Radio. Oncol. 53, 131–147 (2019).10.2478/raon-2019-0024
260. Nguyen DX Bos PD Massagué J Metastasis: from dissemination to organ-specific colonization Nat. Rev. Cancer 2009 9 274 284 10.1038/nrc2622 19308067
Nguyen, D. X., Bos, P. D. & Massagué, J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274–284 (2009).19308067 10.1038/nrc2622
261. Liu SJ Dang HX Lim DA Feng FY Maher CA Long noncoding RNAs in cancer metastasis Nat. Rev. Cancer 2021 21 446 460 10.1038/s41568-021-00353-1 33953369
Liu, S. J., Dang, H. X., Lim, D. A., Feng, F. Y. & Maher, C. A. Long noncoding RNAs in cancer metastasis. Nat. Rev. Cancer 21, 446–460 (2021).33953369 10.1038/s41568-021-00353-1
262. Tucci P Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer Proc. Natl Acad. Sci. USA 2012 109 15312 15317 10.1073/pnas.1110977109 22949650
Tucci, P. et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl Acad. Sci. USA 109, 15312–15317 (2012).22949650 10.1073/pnas.1110977109
263. Vasilaki E Ras and TGF-β signaling enhance cancer progression by promoting the ΔNp63 transcriptional program Sci. Signal 2016 9 ra84 10.1126/scisignal.aag3232 27555661
Vasilaki, E. et al. Ras and TGF-β signaling enhance cancer progression by promoting the ΔNp63 transcriptional program. Sci. Signal 9, ra84 (2016).27555661 10.1126/scisignal.aag3232
264. Bakir B Chiarella AM Pitarresi JR Rustgi AK EMT, MET, plasticity, and tumor metastasis Trends Cell Biol. 2020 30 764 776 10.1016/j.tcb.2020.07.003 32800658
Bakir, B., Chiarella, A. M., Pitarresi, J. R. & Rustgi, A. K. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 30, 764–776 (2020).32800658 10.1016/j.tcb.2020.07.003
265. Lee YC The dynamic roles of the bladder tumour microenvironment Nat. Rev. Urol. 2022 19 515 533 10.1038/s41585-022-00608-y 35764795
Lee, Y. C. et al. The dynamic roles of the bladder tumour microenvironment. Nat. Rev. Urol. 19, 515–533 (2022).35764795 10.1038/s41585-022-00608-y
266. Zhang KL Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer Theranostics 2021 11 6560 6572 10.7150/thno.55609 33995676
Zhang, K. L. et al. Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer. Theranostics 11, 6560–6572 (2021).33995676 10.7150/thno.55609
267. Tsai JH Yang J Epithelial-mesenchymal plasticity in carcinoma metastasis Genes Dev. 2013 27 2192 2206 10.1101/gad.225334.113 24142872
Tsai, J. H. & Yang, J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27, 2192–2206 (2013).24142872 10.1101/gad.225334.113
268. Nimmakayala RK Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma Oncogene 2021 40 215 231 10.1038/s41388-020-01518-2 33110235
Nimmakayala, R. K. et al. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Oncogene 40, 215–231 (2021).33110235 10.1038/s41388-020-01518-2
269. Fedele, M., Sgarra, R., Battista, S., Cerchia, L. & Manfioletti, G. The epithelial-mesenchymal transition at the crossroads between metabolism and tumor progression. Int. J. Mol. Sci. 23, 800 (2022).
270. Basturk O A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas Am. J. Surg. Pathol. 2015 39 1730 1741 10.1097/PAS.0000000000000533 26559377
Basturk, O. et al. A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am. J. Surg. Pathol. 39, 1730–1741 (2015).26559377 10.1097/PAS.0000000000000533
271. Peinado H Pre-metastatic niches: organ-specific homes for metastases Nat. Rev. Cancer 2017 17 302 317 10.1038/nrc.2017.6 28303905
Peinado, H. et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer 17, 302–317 (2017).28303905 10.1038/nrc.2017.6
272. Massague J Obenauf AC Metastatic colonization by circulating tumour cells Nature 2016 529 298 306 10.1038/nature17038 26791720
Massague, J. & Obenauf, A. C. Metastatic colonization by circulating tumour cells. Nature 529, 298–306 (2016).26791720 10.1038/nature17038
273. Sun YF Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma Nat. Commun. 2021 12 4091 10.1038/s41467-021-24386-0 34215748
Sun, Y. F. et al. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nat. Commun. 12, 4091 (2021).34215748 10.1038/s41467-021-24386-0
274. Ebright RY Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis Science 2020 367 1468 1473 10.1126/science.aay0939 32029688
Ebright, R. Y. et al. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science 367, 1468–1473 (2020).32029688 10.1126/science.aay0939
275. Austin RG Huang TJ Wu M Armstrong AJ Zhang T Clinical utility of non-EpCAM based circulating tumor cell assays Adv. Drug Deliv. Rev. 2018 125 132 142 10.1016/j.addr.2018.01.013 29366804
Austin, R. G., Huang, T. J., Wu, M., Armstrong, A. J. & Zhang, T. Clinical utility of non-EpCAM based circulating tumor cell assays. Adv. Drug Deliv. Rev. 125, 132–142 (2018).29366804 10.1016/j.addr.2018.01.013
276. Agnoletto C Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts Biomark. Res. 2018 6 31 10.1186/s40364-018-0145-8 30450210
Agnoletto, C. et al. Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts. Biomark. Res. 6, 31 (2018).30450210 10.1186/s40364-018-0145-8
277. Ligthart ST Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer Ann. Oncol. 2013 24 1231 1238 10.1093/annonc/mds625 23275633
Ligthart, S. T. et al. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann. Oncol. 24, 1231–1238 (2013).23275633 10.1093/annonc/mds625
278. Kallergi G Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients Breast Cancer Res. 2015 17 113 10.1186/s13058-015-0624-x 26285572
Kallergi, G. et al. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res. 17, 113 (2015).26285572 10.1186/s13058-015-0624-x
279. Müller V Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program ESMO Open 2021 6 100299 10.1016/j.esmoop.2021.100299 34839105
Müller, V. et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 6, 100299 (2021).34839105 10.1016/j.esmoop.2021.100299
280. Zhang Z YOD1 serves as a potential prognostic biomarker for pancreatic cancer Cancer Cell Int. 2022 22 203 10.1186/s12935-022-02616-9 35642058
Zhang, Z. et al. YOD1 serves as a potential prognostic biomarker for pancreatic cancer. Cancer Cell Int. 22, 203 (2022).35642058 10.1186/s12935-022-02616-9
281. Braun AC Circulating tumor cells in desmoid tumors: new perspectives Front. Oncol. 2021 11 622626 10.3389/fonc.2021.622626 34595102
Braun, A. C. et al. Circulating tumor cells in desmoid tumors: new perspectives. Front. Oncol. 11, 622626 (2021).34595102 10.3389/fonc.2021.622626
282. Mego M Vitamin D and circulating tumor cells in primary breast cancer Front. Oncol. 2022 12 950451 10.3389/fonc.2022.950451 36158648
Mego, M. et al. Vitamin D and circulating tumor cells in primary breast cancer. Front. Oncol. 12, 950451 (2022).36158648 10.3389/fonc.2022.950451
283. Lu Y S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells Pharm. Res. 2019 139 535 549 10.1016/j.phrs.2018.10.020
Lu, Y. et al. S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells. Pharm. Res. 139, 535–549 (2019).10.1016/j.phrs.2018.10.020
284. Silva-Carvalho A GVHD-derived plasma as a priming strategy of mesenchymal stem cells Stem Cell Res. Ther. 2020 11 156 10.1186/s13287-020-01659-x 32299501
Silva-Carvalho, A. et al. GVHD-derived plasma as a priming strategy of mesenchymal stem cells. Stem Cell Res. Ther. 11, 156 (2020).32299501 10.1186/s13287-020-01659-x
285. Wei C Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis Mol. Cancer 2019 18 64 10.1186/s12943-019-0976-4 30927925
Wei, C. et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol. Cancer 18, 64 (2019).30927925 10.1186/s12943-019-0976-4
286. Klusa, D. et al. Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy. Int. J. Cancer 152 , 2639–2654 (2023).
287. Mehdipour P Javan F Jouibari MF Khaleghi M Mehrazin M Evolutionary model of brain tumor circulating cells: cellular galaxy World J. Clin. Oncol. 2021 12 13 30 10.5306/wjco.v12.i1.13 33552936
Mehdipour, P., Javan, F., Jouibari, M. F., Khaleghi, M. & Mehrazin, M. Evolutionary model of brain tumor circulating cells: cellular galaxy. World J. Clin. Oncol. 12, 13–30 (2021).33552936 10.5306/wjco.v12.i1.13
288. Jung YY Ha IJ Um JY Sethi G Ahn KS Fangchinoline diminishes STAT3 activation by stimulating oxidative stress and targeting SHP-1 protein in multiple myeloma model J. Adv. Res. 2022 35 245 257 10.1016/j.jare.2021.03.008 35024200
Jung, Y. Y., Ha, I. J., Um, J. Y., Sethi, G. & Ahn, K. S. Fangchinoline diminishes STAT3 activation by stimulating oxidative stress and targeting SHP-1 protein in multiple myeloma model. J. Adv. Res. 35, 245–257 (2022).35024200 10.1016/j.jare.2021.03.008
289. Huang Q Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation J. Exp. Clin. Cancer Res. 2020 39 25 10.1186/s13046-020-1533-0 32000836
Huang, Q. et al. Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation. J. Exp. Clin. Cancer Res. 39, 25 (2020).32000836 10.1186/s13046-020-1533-0
290. Strati A A comprehensive molecular analysis of in vivo isolated EpCAM-positive circulating tumor cells in breast cancer Clin. Chem. 2021 67 1395 1405 10.1093/clinchem/hvab099 34322698
Strati, A. et al. A comprehensive molecular analysis of in vivo isolated EpCAM-positive circulating tumor cells in breast cancer. Clin. Chem. 67, 1395–1405 (2021).34322698 10.1093/clinchem/hvab099
291. Balamurugan, K. et al. Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer. JCI Insight 8, e156057 (2023).
292. Mathenge EG Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model Neoplasia 2014 16 950 960 10.1016/j.neo.2014.09.004 25425969
Mathenge, E. G. et al. Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model. Neoplasia 16, 950–960 (2014).25425969 10.1016/j.neo.2014.09.004
293. Christensen E Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity Clin. Cancer Res. 2009 15 5576 5583 10.1158/1078-0432.CCR-09-0245 19706801
Christensen, E. et al. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin. Cancer Res. 15, 5576–5583 (2009).19706801 10.1158/1078-0432.CCR-09-0245
294. Long Y Self-delivery micellar nanoparticles prevent premetastatic niche formation by interfering with the early recruitment and vascular destruction of granulocytic myeloid-derived suppressor cells Nano Lett. 2020 20 2219 2229 10.1021/acs.nanolett.9b03883 31823615
Long, Y. et al. Self-delivery micellar nanoparticles prevent premetastatic niche formation by interfering with the early recruitment and vascular destruction of granulocytic myeloid-derived suppressor cells. Nano Lett. 20, 2219–2229 (2020).31823615 10.1021/acs.nanolett.9b03883
295. Liu M Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients Mol. Oncol. 2020 14 865 881 10.1002/1878-0261.12643 31981446
Liu, M. et al. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients. Mol. Oncol. 14, 865–881 (2020).31981446 10.1002/1878-0261.12643
296. Wang X CTC immune escape mediated by PD-L1 Med. Hypotheses 2016 93 138 139 10.1016/j.mehy.2016.05.022 27372873
Wang, X. et al. CTC immune escape mediated by PD-L1. Med. Hypotheses 93, 138–139 (2016).27372873 10.1016/j.mehy.2016.05.022
297. Yılmaz, M., Kaplan, F., Mender, I., Gryaznov, S. M. & Dikmen, Z. G. Cancer stem cells and anti-tumor immunity. Curr Stem Cell Res. Ther. 18, 445–459 (2022).
298. Darga EP PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer PLoS One 2021 16 e0260124 10.1371/journal.pone.0260124 34780566
Darga, E. P. et al. PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS One 16, e0260124 (2021).34780566 10.1371/journal.pone.0260124
299. Zhang T Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer Biomark. Res. 2021 9 14 10.1186/s40364-021-00267-y 33602330
Zhang, T. et al. Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomark. Res. 9, 14 (2021).33602330 10.1186/s40364-021-00267-y
300. Ao H Xin Z Jian Z Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma Biomark. Res. 2021 9 91 10.1186/s40364-021-00348-y 34930486
Ao, H., Xin, Z. & Jian, Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. Biomark. Res. 9, 91 (2021).34930486 10.1186/s40364-021-00348-y
301. Indini, A., Rijavec, E. & Grossi, F. Circulating biomarkers of response and toxicity of immunotherapy in advanced non-small cell lung cancer (NSCLC): a comprehensive review. Cancers 13, 1794 (2021).
302. Mohammad Alizadeh AH Hajilooi M Ranjbar M Fallahian F Mousavi SM Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B World J. Gastroenterol. 2006 12 630 635 10.3748/wjg.v12.i4.630 16489681
Mohammad Alizadeh, A. H., Hajilooi, M., Ranjbar, M., Fallahian, F. & Mousavi, S. M. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B. World J. Gastroenterol. 12, 630–635 (2006).16489681 10.3748/wjg.v12.i4.630
303. Wang X Cell by cell immuno- and cancer marker profiling of non-small cell lung cancer tissue: checkpoint marker expression on CD103+, CD4+ T-cells predicts circulating tumor cells Transl. Oncol. 2021 14 100953 10.1016/j.tranon.2020.100953 33217647
Wang, X. et al. Cell by cell immuno- and cancer marker profiling of non-small cell lung cancer tissue: checkpoint marker expression on CD103+, CD4+ T-cells predicts circulating tumor cells. Transl. Oncol. 14, 100953 (2021).33217647 10.1016/j.tranon.2020.100953
304. Arnoletti JP Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation PLoS One 2022 17 e0265725 10.1371/journal.pone.0265725 35316296
Arnoletti, J. P. et al. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation. PLoS One 17, e0265725 (2022).35316296 10.1371/journal.pone.0265725
305. Po JW Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status PLoS One 2019 14 e0211866 10.1371/journal.pone.0211866 30735560
Po, J. W. et al. Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. PLoS One 14, e0211866 (2019).30735560 10.1371/journal.pone.0211866
306. Bootsma M Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma J. Clin. Oncol. 2022 40 3633 3641 10.1200/JCO.22.00219 35617646
Bootsma, M. et al. Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma. J. Clin. Oncol. 40, 3633–3641 (2022).35617646 10.1200/JCO.22.00219
307. Kong D Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis Oncoimmunology 2021 10 1938476 10.1080/2162402X.2021.1938476 34211802
Kong, D. et al. Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis. Oncoimmunology 10, 1938476 (2021).34211802 10.1080/2162402X.2021.1938476
308. Bergmann S Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC) Oncoimmunology 2020 9 1738798 10.1080/2162402X.2020.1738798 32391189
Bergmann, S. et al. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). Oncoimmunology 9, 1738798 (2020).32391189 10.1080/2162402X.2020.1738798
309. Zhong X Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy Mol. Cancer 2020 19 15 10.1186/s12943-020-1141-9 31980023
Zhong, X. et al. Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. Mol. Cancer 19, 15 (2020).31980023 10.1186/s12943-020-1141-9
310. Guo S The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis Mol. Cancer 2023 22 193 10.1186/s12943-023-01909-5 38037077
Guo, S. et al. The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis. Mol. Cancer 22, 193 (2023).38037077 10.1186/s12943-023-01909-5
311. Kang YT On-chip biogenesis of circulating NK cell-derived exosomes in non-small cell lung cancer exhibits antitumoral activity Adv. Sci. 2021 8 2003747 10.1002/advs.202003747
Kang, Y. T. et al. On-chip biogenesis of circulating NK cell-derived exosomes in non-small cell lung cancer exhibits antitumoral activity. Adv. Sci. 8, 2003747 (2021).10.1002/advs.202003747
312. Termini R Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma Clin. Cancer Res. 2022 28 4771 4781 10.1158/1078-0432.CCR-22-1594 36074126
Termini, R. et al. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma. Clin. Cancer Res. 28, 4771–4781 (2022).36074126 10.1158/1078-0432.CCR-22-1594
313. Lou, C., Wu, K., Shi, J., Dai, Z. & Xu, Q. N-cadherin protects oral cancer cells from NK cell killing in the circulation by inducing NK cell functional exhaustion via the KLRG1 receptor. J. Immunother. Cancer 10, e005061 (2022).
314. Yu W Exosome-based liquid biopsies in cancer: opportunities and challenges Ann. Oncol. 2021 32 466 477 10.1016/j.annonc.2021.01.074 33548389
Yu, W. et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann. Oncol. 32, 466–477 (2021).33548389 10.1016/j.annonc.2021.01.074
315. Wagner KT Nash TR Liu B Vunjak-Novakovic G Radisic M Extracellular vesicles in cardiac regeneration: potential applications for tissues-on-a-chip Trends Biotechnol. 2021 39 755 773 10.1016/j.tibtech.2020.08.005 32958383
Wagner, K. T., Nash, T. R., Liu, B., Vunjak-Novakovic, G. & Radisic, M. Extracellular vesicles in cardiac regeneration: potential applications for tissues-on-a-chip. Trends Biotechnol. 39, 755–773 (2021).32958383 10.1016/j.tibtech.2020.08.005
316. Jerabkova-Roda K Dupas A Osmani N Hyenne V Goetz JG Circulating extracellular vesicles and tumor cells: sticky partners in metastasis Trends Cancer 2022 8 799 805 10.1016/j.trecan.2022.05.002 35644773
Jerabkova-Roda, K., Dupas, A., Osmani, N., Hyenne, V. & Goetz, J. G. Circulating extracellular vesicles and tumor cells: sticky partners in metastasis. Trends Cancer 8, 799–805 (2022).35644773 10.1016/j.trecan.2022.05.002
317. Chen VL Xu D Wicha MS Lok AS Parikh ND Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review Clin. Gastroenterol. Hepatol. 2020 18 2879 2902.e2879 10.1016/j.cgh.2020.04.019 32289533
Chen, V. L., Xu, D., Wicha, M. S., Lok, A. S. & Parikh, N. D. Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review. Clin. Gastroenterol. Hepatol. 18, 2879–2902.e2879 (2020).32289533 10.1016/j.cgh.2020.04.019
318. Raza A Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer J. Exp. Clin. Cancer Res. 2022 41 99 10.1186/s13046-022-02318-0 35292091
Raza, A. et al. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. J. Exp. Clin. Cancer Res. 41, 99 (2022).35292091 10.1186/s13046-022-02318-0
319. Vaidyanathan R Soon RH Zhang P Jiang K Lim CT Cancer diagnosis: from tumor to liquid biopsy and beyond Lab. Chip 2018 19 11 34 30480287
Vaidyanathan, R., Soon, R. H., Zhang, P., Jiang, K. & Lim, C. T. Cancer diagnosis: from tumor to liquid biopsy and beyond. Lab. Chip 19, 11–34 (2018).30480287
320. Brozos-Vázquez EM Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy Cancer Immunol. Immunother. 2021 70 1177 1188 10.1007/s00262-020-02752-z 33113004
Brozos-Vázquez, E. M. et al. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. Cancer Immunol. Immunother. 70, 1177–1188 (2021).33113004 10.1007/s00262-020-02752-z
321. Lo HC Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis Nat. Cancer 2020 1 709 722 10.1038/s43018-020-0068-9 35122036
Lo, H. C. et al. Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis. Nat. Cancer 1, 709–722 (2020).35122036 10.1038/s43018-020-0068-9
322. Pereira-Veiga T Schneegans S Pantel K Wikman H Circulating tumor cell-blood cell crosstalk: biology and clinical relevance Cell Rep. 2022 40 111298 10.1016/j.celrep.2022.111298 36044866
Pereira-Veiga, T., Schneegans, S., Pantel, K. & Wikman, H. Circulating tumor cell-blood cell crosstalk: biology and clinical relevance. Cell Rep. 40, 111298 (2022).36044866 10.1016/j.celrep.2022.111298
323. Poulet G Massias J Taly V Liquid biopsy: general concepts Acta Cytol. 2019 63 449 455 10.1159/000499337 31091522
Poulet, G., Massias, J. & Taly, V. Liquid biopsy: general concepts. Acta Cytol. 63, 449–455 (2019).31091522 10.1159/000499337
324. Razmara AM Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer Clin. Exp. Metastasis 2020 37 413 424 10.1007/s10585-020-10033-3 32335861
Razmara, A. M. et al. Tumor shedding and metastatic progression after tumor excision in patient-derived orthotopic xenograft models of triple-negative breast cancer. Clin. Exp. Metastasis 37, 413–424 (2020).32335861 10.1007/s10585-020-10033-3
325. Toss A Mu Z Fernandez S Cristofanilli M CTC enumeration and characterization: moving toward personalized medicine Ann. Transl. Med. 2014 2 108 25489582
Toss, A., Mu, Z., Fernandez, S. & Cristofanilli, M. CTC enumeration and characterization: moving toward personalized medicine. Ann. Transl. Med. 2, 108 (2014).25489582
326. von Felden J Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection Oncotarget 2017 8 89978 89987 10.18632/oncotarget.21208 29163804
von Felden, J. et al. Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. Oncotarget 8, 89978–89987 (2017).29163804 10.18632/oncotarget.21208
327. Beinse G Circulating tumor cell count and thrombosis in metastatic breast cancer J. Thromb. Haemost. 2017 15 1981 1988 10.1111/jth.13792 28779538
Beinse, G. et al. Circulating tumor cell count and thrombosis in metastatic breast cancer. J. Thromb. Haemost. 15, 1981–1988 (2017).28779538 10.1111/jth.13792
328. Bidard FC Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials Cancer Metastasis Rev. 2013 32 179 188 10.1007/s10555-012-9398-0 23129208
Bidard, F. C. et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 32, 179–188 (2013).23129208 10.1007/s10555-012-9398-0
329. Stott SL Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer Sci. Transl. Med. 2010 2 25ra23 10.1126/scitranslmed.3000403 20424012
Stott, S. L. et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Transl. Med. 2, 25ra23 (2010).20424012 10.1126/scitranslmed.3000403
330. Nieswandt B Hafner M Echtenacher B Männel DN Lysis of tumor cells by natural killer cells in mice is impeded by platelets Cancer Res. 1999 59 1295 1300 10096562
Nieswandt, B., Hafner, M., Echtenacher, B. & Männel, D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59, 1295–1300 (1999).10096562
331. Lizama BN Chu CT Neuronal autophagy and mitophagy in Parkinson’s disease Mol. Asp. Med. 2021 82 100972 10.1016/j.mam.2021.100972
Lizama, B. N. & Chu, C. T. Neuronal autophagy and mitophagy in Parkinson’s disease. Mol. Asp. Med. 82, 100972 (2021).10.1016/j.mam.2021.100972
332. Nikanjam M Kato S Kurzrock R Liquid biopsy: current technology and clinical applications J. Hematol. Oncol. 2022 15 131 10.1186/s13045-022-01351-y 36096847
Nikanjam, M., Kato, S. & Kurzrock, R. Liquid biopsy: current technology and clinical applications. J. Hematol. Oncol. 15, 131 (2022).36096847 10.1186/s13045-022-01351-y
333. Fridrichova, I., Kalinkova, L. & Ciernikova, S. Clinical relevancy of circulating tumor cells in breast cancer: epithelial or mesenchymal characteristics, single cells or clusters? Int. J. Mol. Sci. 23, 12141 (2022).
334. Ma S Current progress in CAR-T cell therapy for solid tumors Int. J. Biol. Sci. 2019 15 2548 2560 10.7150/ijbs.34213 31754328
Ma, S. et al. Current progress in CAR-T cell therapy for solid tumors. Int. J. Biol. Sci. 15, 2548–2560 (2019).31754328 10.7150/ijbs.34213
335. Patel SA Vanharanta S Epigenetic determinants of metastasis Mol. Oncol. 2017 11 79 96 10.1016/j.molonc.2016.09.008 27756687
Patel, S. A. & Vanharanta, S. Epigenetic determinants of metastasis. Mol. Oncol. 11, 79–96 (2017).27756687 10.1016/j.molonc.2016.09.008
336. Pal S Tyler JK Epigenetics and aging Sci. Adv. 2016 2 e1600584 10.1126/sciadv.1600584 27482540
Pal, S. & Tyler, J. K. Epigenetics and aging. Sci. Adv. 2, e1600584 (2016).27482540 10.1126/sciadv.1600584
337. Chabanon RM Morel D Postel-Vinay S Exploiting epigenetic vulnerabilities in solid tumors: novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers Semin. Cancer Biol. 2020 61 180 198 10.1016/j.semcancer.2019.09.018 31568814
Chabanon, R. M., Morel, D. & Postel-Vinay, S. Exploiting epigenetic vulnerabilities in solid tumors: novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers. Semin. Cancer Biol. 61, 180–198 (2020).31568814 10.1016/j.semcancer.2019.09.018
338. Zhao L Wu X Zheng J Dong D DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution Oncogene 2021 40 1884 1895 10.1038/s41388-021-01657-0 33564067
Zhao, L., Wu, X., Zheng, J. & Dong, D. DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution. Oncogene 40, 1884–1895 (2021).33564067 10.1038/s41388-021-01657-0
339. Chen H Single-cell DNA methylome analysis of circulating tumor cells Chin. J. Cancer Res. 2021 33 391 404 10.21147/j.issn.1000-9604.2021.03.10 34321835
Chen, H. et al. Single-cell DNA methylome analysis of circulating tumor cells. Chin. J. Cancer Res. 33, 391–404 (2021).34321835 10.21147/j.issn.1000-9604.2021.03.10
340. Li J Gregory SG Garcia-Blanco MA Armstrong AJ Using circulating tumor cells to inform on prostate cancer biology and clinical utility Crit. Rev. Clin. Lab. Sci. 2015 52 191 210 10.3109/10408363.2015.1023430 26079252
Li, J., Gregory, S. G., Garcia-Blanco, M. A. & Armstrong, A. J. Using circulating tumor cells to inform on prostate cancer biology and clinical utility. Crit. Rev. Clin. Lab. Sci. 52, 191–210 (2015).26079252 10.3109/10408363.2015.1023430
341. Xiong G Hsp47 promotes cancer metastasis by enhancing collagen-dependent cancer cell-platelet interaction Proc. Natl Acad. Sci. USA 2020 117 3748 3758 10.1073/pnas.1911951117 32015106
Xiong, G. et al. Hsp47 promotes cancer metastasis by enhancing collagen-dependent cancer cell-platelet interaction. Proc. Natl Acad. Sci. USA 117, 3748–3758 (2020).32015106 10.1073/pnas.1911951117
342. Ntzifa, A. et al. DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatment. Cancers 13, 5974 (2021).
343. Sun K Ultrasensitive nanopore sensing of mucin 1 and circulating tumor cells in whole blood of breast cancer patients by analyte-triggered triplex-DNA release ACS Appl. Mater. Interfaces 2021 13 21030 21039 10.1021/acsami.1c03538 33905228
Sun, K. et al. Ultrasensitive nanopore sensing of mucin 1 and circulating tumor cells in whole blood of breast cancer patients by analyte-triggered triplex-DNA release. ACS Appl. Mater. Interfaces 13, 21030–21039 (2021).33905228 10.1021/acsami.1c03538
344. Gerlinger M Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 2012 366 883 892 10.1056/NEJMoa1113205 22397650
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).22397650 10.1056/NEJMoa1113205
345. McGranahan N Swanton C Clonal heterogeneity and tumor evolution: past, present, and the future Cell 2017 168 613 628 10.1016/j.cell.2017.01.018 28187284
McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628 (2017).28187284 10.1016/j.cell.2017.01.018
346. Yu M Metastasis stemming from circulating tumor cell clusters Trends Cell Biol. 2019 29 275 276 10.1016/j.tcb.2019.02.001 30799250
Yu, M. Metastasis stemming from circulating tumor cell clusters. Trends Cell Biol. 29, 275–276 (2019).30799250 10.1016/j.tcb.2019.02.001
347. Bertamini L High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma J. Clin. Oncol. 2022 40 3120 3131 10.1200/JCO.21.01393 35666982
Bertamini, L. et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J. Clin. Oncol. 40, 3120–3131 (2022).35666982 10.1200/JCO.21.01393
348. Yuan H SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways Cancer Cell 2020 38 350 365.e357 10.1016/j.ccell.2020.05.022 32619406
Yuan, H. et al. SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways. Cancer Cell 38, 350–365.e357 (2020).32619406 10.1016/j.ccell.2020.05.022
349. Duan R Du W Guo W EZH2: a novel target for cancer treatment J. Hematol. Oncol. 2020 13 104 10.1186/s13045-020-00937-8 32723346
Duan, R., Du, W. & Guo, W. EZH2: a novel target for cancer treatment. J. Hematol. Oncol. 13, 104 (2020).32723346 10.1186/s13045-020-00937-8
350. Hemminki A Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer Nat. Genet. 1994 8 405 410 10.1038/ng1294-405 7894494
Hemminki, A. et al. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat. Genet. 8, 405–410 (1994).7894494 10.1038/ng1294-405
351. Galm O Herman JG Baylin SB The fundamental role of epigenetics in hematopoietic malignancies Blood Rev. 2006 20 1 13 10.1016/j.blre.2005.01.006 16426940
Galm, O., Herman, J. G. & Baylin, S. B. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 20, 1–13 (2006).16426940 10.1016/j.blre.2005.01.006
352. Esteller M Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis Cancer Res. 2000 60 2368 2371 10811111
Esteller, M. et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60, 2368–2371 (2000).10811111
353. Hadjimichael C Common stemness regulators of embryonic and cancer stem cells World J. Stem Cells 2015 7 1150 1184 10.4252/wjsc.v7.i9.1150 26516408
Hadjimichael, C. et al. Common stemness regulators of embryonic and cancer stem cells. World J. Stem Cells 7, 1150–1184 (2015).26516408 10.4252/wjsc.v7.i9.1150
354. Yang J Guidelines and definitions for research on epithelial-mesenchymal transition Nat. Rev. Mol. Cell Biol. 2020 21 341 352 10.1038/s41580-020-0237-9 32300252
Yang, J. et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 21, 341–352 (2020).32300252 10.1038/s41580-020-0237-9
355. Lyberopoulou A Identification of methylation profiles of cancer-related genes in circulating tumor cells population Anticancer Res. 2017 37 1105 1112 10.21873/anticanres.11423 28314271
Lyberopoulou, A. et al. Identification of methylation profiles of cancer-related genes in circulating tumor cells population. Anticancer Res. 37, 1105–1112 (2017).28314271 10.21873/anticanres.11423
356. Pixberg CF Analysis of DNA methylation in single circulating tumor cells Oncogene 2017 36 3223 3231 10.1038/onc.2016.480 28068321
Pixberg, C. F. et al. Analysis of DNA methylation in single circulating tumor cells. Oncogene 36, 3223–3231 (2017).28068321 10.1038/onc.2016.480
357. Zavridou M Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma Sci. Rep. 2020 10 6551 10.1038/s41598-020-63055-y 32300118
Zavridou, M. et al. Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma. Sci. Rep. 10, 6551 (2020).32300118 10.1038/s41598-020-63055-y
358. Robertson KD DNA methylation, methyltransferases, and cancer Oncogene 2001 20 3139 3155 10.1038/sj.onc.1204341 11420731
Robertson, K. D. DNA methylation, methyltransferases, and cancer. Oncogene 20, 3139–3155 (2001).11420731 10.1038/sj.onc.1204341
359. Sasidharan Nair V DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer Clin. Epigenet. 2018 10 78 10.1186/s13148-018-0512-1
Sasidharan Nair, V. et al. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin. Epigenet. 10, 78 (2018).10.1186/s13148-018-0512-1
360. Sasidharan Nair V Toor SM Taha RZ Shaath H Elkord E DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer Clin. Epigenet. 2018 10 104 10.1186/s13148-018-0539-3
Sasidharan Nair, V., Toor, S. M., Taha, R. Z., Shaath, H. & Elkord, E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin. Epigenet. 10, 104 (2018).10.1186/s13148-018-0539-3
361. McCracken, L. C. et al. Development of a physical shoulder simulator for the training of basic arthroscopic skills. Int. J. Med. Robot. 14 (2018).
362. Andersen, F. H. [Not Available]. Tidsskr Nor Laegeforen 137 (2017).
363. Ota M Fukuda M Highly efficient on-chip excitation of orthogonal-polarized gap plasmons for a dense polarization multiplexing circuit Opt. Express 2018 26 21778 21783 10.1364/OE.26.021778 30130879
Ota, M. & Fukuda, M. Highly efficient on-chip excitation of orthogonal-polarized gap plasmons for a dense polarization multiplexing circuit. Opt. Express 26, 21778–21783 (2018).30130879 10.1364/OE.26.021778
364. Elashi AA Sasidharan Nair V Taha RZ Shaath H Elkord E DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients Oncoimmunology 2019 8 e1542918 10.1080/2162402X.2018.1542918 30713804
Elashi, A. A., Sasidharan Nair, V., Taha, R. Z., Shaath, H. & Elkord, E. DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients. Oncoimmunology 8, e1542918 (2019).30713804 10.1080/2162402X.2018.1542918
365. Marwitz S Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression Clin. Epigenet. 2017 9 51 10.1186/s13148-017-0354-2
Marwitz, S. et al. Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression. Clin. Epigenet. 9, 51 (2017).10.1186/s13148-017-0354-2
366. Franzen A PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas Oncotarget 2018 9 641 650 10.18632/oncotarget.23080 29416641
Franzen, A. et al. PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. Oncotarget 9, 641–650 (2018).29416641 10.18632/oncotarget.23080
367. Goltz D Gevensleben H Dietrich J Dietrich D PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients Oncoimmunology 2017 6 e1257454 10.1080/2162402X.2016.1257454 28197377
Goltz, D., Gevensleben, H., Dietrich, J. & Dietrich, D. PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. Oncoimmunology 6, e1257454 (2017).28197377 10.1080/2162402X.2016.1257454
368. Goltz D PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia Leukemia 2017 31 738 743 10.1038/leu.2016.328 27840427
Goltz, D. et al. PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia. Leukemia 31, 738–743 (2017).27840427 10.1038/leu.2016.328
369. Jiang JH Circulating tumor cell methylation profiles reveal the classification and evolution of non-small cell lung cancer Transl. Lung Cancer Res. 2022 11 224 237 10.21037/tlcr-22-50 35280307
Jiang, J. H. et al. Circulating tumor cell methylation profiles reveal the classification and evolution of non-small cell lung cancer. Transl. Lung Cancer Res. 11, 224–237 (2022).35280307 10.21037/tlcr-22-50
370. Cheng SB Three-dimensional scaffold chip with thermosensitive coating for capture and reversible release of individual and cluster of circulating tumor cells Anal. Chem. 2017 89 7924 7932 10.1021/acs.analchem.7b00905 28661138
Cheng, S. B. et al. Three-dimensional scaffold chip with thermosensitive coating for capture and reversible release of individual and cluster of circulating tumor cells. Anal. Chem. 89, 7924–7932 (2017).28661138 10.1021/acs.analchem.7b00905
371. Cao Y Gao HL Chen JN Chen ZY Yang L Identification and characterization of conjugated linolenic acid isomers by Ag+-HPLC and NMR J. Agric. Food Chem. 2006 54 9004 9009 10.1021/jf0616199 17117784
Cao, Y., Gao, H. L., Chen, J. N., Chen, Z. Y. & Yang, L. Identification and characterization of conjugated linolenic acid isomers by Ag+-HPLC and NMR. J. Agric. Food Chem. 54, 9004–9009 (2006).17117784 10.1021/jf0616199
372. Puga AV From mono- to poly-substituted frameworks: a way of tuning the acidic character of C(c)-H in o-carborane derivatives Chemistry 2009 15 9755 9763 10.1002/chem.200900925 19697374
Puga, A. V. et al. From mono- to poly-substituted frameworks: a way of tuning the acidic character of C(c)-H in o-carborane derivatives. Chemistry 15, 9755–9763 (2009).19697374 10.1002/chem.200900925
373. Xu LH First report of pear blossom blast caused by Pseudomonas syringae pv. syringae in China Plant Dis. 2008 92 832 10.1094/PDIS-92-5-0832C 30769615
Xu, L. H. et al. First report of pear blossom blast caused by Pseudomonas syringae pv. syringae in China. Plant Dis. 92, 832 (2008).30769615 10.1094/PDIS-92-5-0832C
374. Feng H Homogeneous pancreatic cancer spheroids mimic growth pattern of circulating tumor cell clusters and macrometastases: displaying heterogeneity and crater-like structure on inner layer J. Cancer Res. Clin. Oncol. 2017 143 1771 1786 10.1007/s00432-017-2434-2 28497169
Feng, H. et al. Homogeneous pancreatic cancer spheroids mimic growth pattern of circulating tumor cell clusters and macrometastases: displaying heterogeneity and crater-like structure on inner layer. J. Cancer Res. Clin. Oncol. 143, 1771–1786 (2017).28497169 10.1007/s00432-017-2434-2
375. Liu X EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer Theranostics 2021 11 6632 6643 10.7150/thno.57706 33995681
Liu, X. et al. EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer. Theranostics 11, 6632–6643 (2021).33995681 10.7150/thno.57706
376. Woo HJ Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation Theranostics 2022 12 3676 3689 10.7150/thno.72511 35664056
Woo, H. J. et al. Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation. Theranostics 12, 3676–3689 (2022).35664056 10.7150/thno.72511
377. Ma F Jiang S Zhang CY Recent advances in histone modification and histone modifying enzyme assays Expert Rev. Mol. Diagn. 2019 19 27 36 10.1080/14737159.2019.1559053 30563379
Ma, F., Jiang, S. & Zhang, C. Y. Recent advances in histone modification and histone modifying enzyme assays. Expert Rev. Mol. Diagn. 19, 27–36 (2019).30563379 10.1080/14737159.2019.1559053
378. Dawson MA Kouzarides T Cancer epigenetics: from mechanism to therapy Cell 2012 150 12 27 10.1016/j.cell.2012.06.013 22770212
Dawson, M. A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27 (2012).22770212 10.1016/j.cell.2012.06.013
379. Bhaumik SR Smith E Shilatifard A Covalent modifications of histones during development and disease pathogenesis Nat. Struct. Mol. Biol. 2007 14 1008 1016 10.1038/nsmb1337 17984963
Bhaumik, S. R., Smith, E. & Shilatifard, A. Covalent modifications of histones during development and disease pathogenesis. Nat. Struct. Mol. Biol. 14, 1008–1016 (2007).17984963 10.1038/nsmb1337
380. Kebede AF Schneider R Daujat S Novel types and sites of histone modifications emerge as players in the transcriptional regulation contest FEBS J. 2015 282 1658 1674 10.1111/febs.13047 25220185
Kebede, A. F., Schneider, R. & Daujat, S. Novel types and sites of histone modifications emerge as players in the transcriptional regulation contest. FEBS J. 282, 1658–1674 (2015).25220185 10.1111/febs.13047
381. Feinberg AP Koldobskiy MA Göndör A Epigenetic modulators, modifiers and mediators in cancer aetiology and progression Nat. Rev. Genet. 2016 17 284 299 10.1038/nrg.2016.13 26972587
Feinberg, A. P., Koldobskiy, M. A. & Göndör, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 17, 284–299 (2016).26972587 10.1038/nrg.2016.13
382. Bannister AJ Kouzarides T Regulation of chromatin by histone modifications Cell Res. 2011 21 381 395 10.1038/cr.2011.22 21321607
Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 21, 381–395 (2011).21321607 10.1038/cr.2011.22
383. Verma A EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis Nat. Commun. 2022 13 7344 10.1038/s41467-022-35059-x 36446780
Verma, A. et al. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. Nat. Commun. 13, 7344 (2022).36446780 10.1038/s41467-022-35059-x
384. Piunti A Shilatifard A Epigenetic balance of gene expression by Polycomb and COMPASS families Science 2016 352 aad9780 10.1126/science.aad9780 27257261
Piunti, A. & Shilatifard, A. Epigenetic balance of gene expression by Polycomb and COMPASS families. Science 352, aad9780 (2016).27257261 10.1126/science.aad9780
385. Kang-Decker N Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency Cancer Cell 2004 5 177 189 10.1016/S1535-6108(04)00022-4 14998493
Kang-Decker, N. et al. Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell 5, 177–189 (2004).14998493 10.1016/S1535-6108(04)00022-4
386. Narita T Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release Mol. Cell 2021 81 2166 2182.e2166 10.1016/j.molcel.2021.03.008 33765415
Narita, T. et al. Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release. Mol. Cell 81, 2166–2182.e2166 (2021).33765415 10.1016/j.molcel.2021.03.008
387. Hogg SJ Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition Mol. Cell 2021 81 2183 2200.e2113 10.1016/j.molcel.2021.04.015 34019788
Hogg, S. J. et al. Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Mol. Cell 81, 2183–2200.e2113 (2021).34019788 10.1016/j.molcel.2021.04.015
388. Mansour MR Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element Science 2014 346 1373 1377 10.1126/science.1259037 25394790
Mansour, M. R. et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373–1377 (2014).25394790 10.1126/science.1259037
389. Tsang FH Aberrant super-enhancer landscape in human hepatocellular carcinoma Hepatology 2019 69 2502 2517 10.1002/hep.30544 30723918
Tsang, F. H. et al. Aberrant super-enhancer landscape in human hepatocellular carcinoma. Hepatology 69, 2502–2517 (2019).30723918 10.1002/hep.30544
390. Kadoch C Crabtree GR Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics Sci. Adv. 2015 1 e1500447 10.1126/sciadv.1500447 26601204
Kadoch, C. & Crabtree, G. R. Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci. Adv. 1, e1500447 (2015).26601204 10.1126/sciadv.1500447
391. Stern C Boveri and the early days of genetics Nature 1950 166 446 10.1038/166446a0 14775717
Stern, C. Boveri and the early days of genetics. Nature 166, 446 (1950).14775717 10.1038/166446a0
392. Lazzerini-Denchi E Sfeir A Stop pulling my strings—what telomeres taught us about the DNA damage response Nat. Rev. Mol. Cell Biol. 2016 17 364 378 10.1038/nrm.2016.43 27165790
Lazzerini-Denchi, E. & Sfeir, A. Stop pulling my strings—what telomeres taught us about the DNA damage response. Nat. Rev. Mol. Cell Biol. 17, 364–378 (2016).27165790 10.1038/nrm.2016.43
393. Li SKH Martin A Mismatch repair and colon cancer: mechanisms and therapies explored Trends Mol. Med. 2016 22 274 289 10.1016/j.molmed.2016.02.003 26970951
Li, S. K. H. & Martin, A. Mismatch repair and colon cancer: mechanisms and therapies explored. Trends Mol. Med. 22, 274–289 (2016).26970951 10.1016/j.molmed.2016.02.003
394. Ogiwara H Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors Oncogene 2011 30 2135 2146 10.1038/onc.2010.592 21217779
Ogiwara, H. et al. Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors. Oncogene 30, 2135–2146 (2011).21217779 10.1038/onc.2010.592
395. Qi W BRG1 promotes the repair of DNA double-strand breaks by facilitating the replacement of RPA with RAD51 J. Cell Sci. 2015 128 317 330 25395584
Qi, W. et al. BRG1 promotes the repair of DNA double-strand breaks by facilitating the replacement of RPA with RAD51. J. Cell Sci. 128, 317–330 (2015).25395584
396. Chen Y A PARP1-BRG1-SIRT1 axis promotes HR repair by reducing nucleosome density at DNA damage sites Nucleic Acids Res. 2019 47 8563 8580 31291457
Chen, Y. et al. A PARP1-BRG1-SIRT1 axis promotes HR repair by reducing nucleosome density at DNA damage sites. Nucleic Acids Res. 47, 8563–8580 (2019).31291457
397. Brownlee PM Meisenberg C Downs JA The SWI/SNF chromatin remodelling complex: its role in maintaining genome stability and preventing tumourigenesis DNA Repair 2015 32 127 133 10.1016/j.dnarep.2015.04.023 25981841
Brownlee, P. M., Meisenberg, C. & Downs, J. A. The SWI/SNF chromatin remodelling complex: its role in maintaining genome stability and preventing tumourigenesis. DNA Repair 32, 127–133 (2015).25981841 10.1016/j.dnarep.2015.04.023
398. Watanabe R SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability Cancer Res. 2014 74 2465 2475 10.1158/0008-5472.CAN-13-3608 24788099
Watanabe, R. et al. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability. Cancer Res. 74, 2465–2475 (2014).24788099 10.1158/0008-5472.CAN-13-3608
399. Zhao B ARID1A promotes genomic stability through protecting telomere cohesion Nat. Commun. 2019 10 4067 10.1038/s41467-019-12037-4 31492885
Zhao, B. et al. ARID1A promotes genomic stability through protecting telomere cohesion. Nat. Commun. 10, 4067 (2019).31492885 10.1038/s41467-019-12037-4
400. Kakarougkas A Requirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin Mol. Cell 2014 55 723 732 10.1016/j.molcel.2014.06.028 25066234
Kakarougkas, A. et al. Requirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin. Mol. Cell 55, 723–732 (2014).25066234 10.1016/j.molcel.2014.06.028
401. Ahel D Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1 Science 2009 325 1240 1243 10.1126/science.1177321 19661379
Ahel, D. et al. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science 325, 1240–1243 (2009).19661379 10.1126/science.1177321
402. Verma P ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells Nat. Cell Biol. 2021 23 160 171 10.1038/s41556-020-00624-3 33462394
Verma, P. et al. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells. Nat. Cell Biol. 23, 160–171 (2021).33462394 10.1038/s41556-020-00624-3
403. Hnisz D Activation of proto-oncogenes by disruption of chromosome neighborhoods Science 2016 351 1454 1458 10.1126/science.aad9024 26940867
Hnisz, D. et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science 351, 1454–1458 (2016).26940867 10.1126/science.aad9024
404. Flavahan WA Insulator dysfunction and oncogene activation in IDH mutant gliomas Nature 2016 529 110 114 10.1038/nature16490 26700815
Flavahan, W. A. et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529, 110–114 (2016).26700815 10.1038/nature16490
405. Ooi WF Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma Gut 2020 69 1039 1052 10.1136/gutjnl-2018-317612 31542774
Ooi, W. F. et al. Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma. Gut 69, 1039–1052 (2020).31542774 10.1136/gutjnl-2018-317612
406. Cho SW Promoter of lncRNA gene PVT1 is a tumorsuppressor DNA boundary element Cell 2018 173 1398 1412.e1322 10.1016/j.cell.2018.03.068 29731168
Cho, S. W. et al. Promoter of lncRNA gene PVT1 is a tumorsuppressor DNA boundary element. Cell 173, 1398–1412.e1322 (2018).29731168 10.1016/j.cell.2018.03.068
407. Rubio-Perez C In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities Cancer Cell 2015 27 382 396 10.1016/j.ccell.2015.02.007 25759023
Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382–396 (2015).25759023 10.1016/j.ccell.2015.02.007
408. Marshall AD CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic Oncogene 2017 36 4100 4110 10.1038/onc.2017.25 28319062
Marshall, A. D. et al. CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic. Oncogene 36, 4100–4110 (2017).28319062 10.1038/onc.2017.25
409. Gonzalez-Perez A IntOGen-mutations identifies cancer drivers across tumor types Nat. Methods 2013 10 1081 1082 10.1038/nmeth.2642 24037244
Gonzalez-Perez, A. et al. IntOGen-mutations identifies cancer drivers across tumor types. Nat. Methods 10, 1081–1082 (2013).24037244 10.1038/nmeth.2642
410. Damaschke NA CTCF loss mediates unique DNA hypermethylation landscapes in human cancers Clin. Epigenet. 2020 12 80 10.1186/s13148-020-00869-7
Damaschke, N. A. et al. CTCF loss mediates unique DNA hypermethylation landscapes in human cancers. Clin. Epigenet. 12, 80 (2020).10.1186/s13148-020-00869-7
411. Kemp CJ CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer Cell Rep. 2014 7 1020 1029 10.1016/j.celrep.2014.04.004 24794443
Kemp, C. J. et al. CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Rep. 7, 1020–1029 (2014).24794443 10.1016/j.celrep.2014.04.004
412. Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, eaan2507 (2017).
413. Martin TD The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation Science 2021 373 1327 1335 10.1126/science.abg5784 34529489
Martin, T. D. et al. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science 373, 1327–1335 (2021).34529489 10.1126/science.abg5784
414. Oreskovic, E. et al. Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1. Proc. Natl Acad. Sci. USA 119, e2120540119 (2022).
415. Sun L Decreased expression of acetyl-CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma Cancer Sci. 2017 108 1338 1346 10.1111/cas.13252 28387999
Sun, L. et al. Decreased expression of acetyl-CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. Cancer Sci. 108, 1338–1346 (2017).28387999 10.1111/cas.13252
416. Liang Y Cadmium promotes breast cancer cell proliferation, migration and invasion by inhibiting ACSS2/ATG5-mediated autophagy Environ. Pollut. 2021 273 116504 10.1016/j.envpol.2021.116504 33486244
Liang, Y. et al. Cadmium promotes breast cancer cell proliferation, migration and invasion by inhibiting ACSS2/ATG5-mediated autophagy. Environ. Pollut. 273, 116504 (2021).33486244 10.1016/j.envpol.2021.116504
417. Horibata Y Ando H Itoh M Sugimoto H Enzymatic and transcriptional regulation of the cytoplasmic acetyl-CoA hydrolase ACOT12 J. Lipid Res. 2013 54 2049 2059 10.1194/jlr.M030163 23709691
Horibata, Y., Ando, H., Itoh, M. & Sugimoto, H. Enzymatic and transcriptional regulation of the cytoplasmic acetyl-CoA hydrolase ACOT12. J. Lipid Res. 54, 2049–2059 (2013).23709691 10.1194/jlr.M030163
418. Lu M ACOT12-dependent alteration of Acetyl-CoA drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial-mesenchymal transition Cell Metab. 2019 29 886 900.e885 10.1016/j.cmet.2018.12.019 30661930
Lu, M. et al. ACOT12-dependent alteration of Acetyl-CoA drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial-mesenchymal transition. Cell Metab. 29, 886–900.e885 (2019).30661930 10.1016/j.cmet.2018.12.019
419. Zhou X ACOT12-mediated acetyl-CoA hydrolysis suppresses intrahepatic cholangiocarcinoma metastasis by inhibiting epithelial-mesenchymal transition J. Cancer 2022 13 1734 1744 10.7150/jca.62169 35399720
Zhou, X. et al. ACOT12-mediated acetyl-CoA hydrolysis suppresses intrahepatic cholangiocarcinoma metastasis by inhibiting epithelial-mesenchymal transition. J. Cancer 13, 1734–1744 (2022).35399720 10.7150/jca.62169
420. Shen Y Wei W Zhou DX Histone acetylation enzymes coordinate metabolism and gene expression Trends Plant Sci. 2015 20 614 621 10.1016/j.tplants.2015.07.005 26440431
Shen, Y., Wei, W. & Zhou, D. X. Histone acetylation enzymes coordinate metabolism and gene expression. Trends Plant Sci. 20, 614–621 (2015).26440431 10.1016/j.tplants.2015.07.005
421. Haque ME The GCN5: its biological functions and therapeutic potentials Clin. Sci. 2021 135 231 257 10.1042/CS20200986
Haque, M. E. et al. The GCN5: its biological functions and therapeutic potentials. Clin. Sci. 135, 231–257 (2021).10.1042/CS20200986
422. Wang X Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma Nat. Commun. 2020 11 1141 10.1038/s41467-020-14870-4 32111827
Wang, X. et al. Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma. Nat. Commun. 11, 1141 (2020).32111827 10.1038/s41467-020-14870-4
423. Liu J Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells J. Transl. Med 2016 14 7 10.1186/s12967-015-0753-0 26747087
Liu, J. et al. Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells. J. Transl. Med 14, 7 (2016).26747087 10.1186/s12967-015-0753-0
424. Cheng C HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target Cell Death Dis. 2021 12 137 10.1038/s41419-021-03417-0 33542203
Cheng, C. et al. HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target. Cell Death Dis. 12, 137 (2021).33542203 10.1038/s41419-021-03417-0
425. Tang X HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration Nucleic Acids Res. 2020 48 2912 2923 10.1093/nar/gkaa039 31970414
Tang, X. et al. HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration. Nucleic Acids Res. 48, 2912–2923 (2020).31970414 10.1093/nar/gkaa039
426. Ding S DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway EBioMedicine 2022 81 104100 10.1016/j.ebiom.2022.104100 35689852
Ding, S. et al. DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway. EBioMedicine 81, 104100 (2022).35689852 10.1016/j.ebiom.2022.104100
427. Wen Y Histone deacetylase (HDAC) 11 inhibits matrix metalloproteinase (MMP) 3 expression to suppress colorectal cancer metastasis J. Cancer 2022 13 1923 1932 10.7150/jca.66914 35399729
Wen, Y. et al. Histone deacetylase (HDAC) 11 inhibits matrix metalloproteinase (MMP) 3 expression to suppress colorectal cancer metastasis. J. Cancer 13, 1923–1932 (2022).35399729 10.7150/jca.66914
428. Leslie PL Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes Nat. Commun. 2019 10 4192 10.1038/s41467-019-12222-5 31519896
Leslie, P. L. et al. Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. Nat. Commun. 10, 4192 (2019).31519896 10.1038/s41467-019-12222-5
429. Bayik D Lathia JD Cancer stem cell-immune cell crosstalk in tumour progression Nat. Rev. Cancer 2021 21 526 536 10.1038/s41568-021-00366-w 34103704
Bayik, D. & Lathia, J. D. Cancer stem cell-immune cell crosstalk in tumour progression. Nat. Rev. Cancer 21, 526–536 (2021).34103704 10.1038/s41568-021-00366-w
430. Hsu JM STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion Nat. Commun. 2018 9 1908 10.1038/s41467-018-04313-6 29765039
Hsu, J. M. et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat. Commun. 9, 1908 (2018).29765039 10.1038/s41467-018-04313-6
431. Meder L Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer Cancer Res. 2018 78 4270 4281 10.1158/0008-5472.CAN-17-2176 29776963
Meder, L. et al. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res. 78, 4270–4281 (2018).29776963 10.1158/0008-5472.CAN-17-2176
432. Shirahata A Hibi K Serum vimentin methylation as a potential marker for colorectal cancer Anticancer Res. 2014 34 4121 4125 25075038
Shirahata, A. & Hibi, K. Serum vimentin methylation as a potential marker for colorectal cancer. Anticancer Res. 34, 4121–4125 (2014).25075038
433. Welte T Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation Nat. Cell Biol. 2016 18 632 644 10.1038/ncb3355 27183469
Welte, T. et al. Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat. Cell Biol. 18, 632–644 (2016).27183469 10.1038/ncb3355
434. Ai L Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation Mol. Cancer 2019 18 88 10.1186/s12943-019-1011-5 30979371
Ai, L. et al. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. Mol. Cancer 18, 88 (2019).30979371 10.1186/s12943-019-1011-5
435. Lee CR Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-β during murine colitis Cell Rep. 2016 17 3219 3232 10.1016/j.celrep.2016.11.062 28009291
Lee, C. R. et al. Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-β during murine colitis. Cell Rep. 17, 3219–3232 (2016).28009291 10.1016/j.celrep.2016.11.062
436. Liu S Regulatory T cells promote glioma cell stemness through TGF-β-NF-κB-IL6-STAT3 signaling Cancer Immunol. Immunother. 2021 70 2601 2616 10.1007/s00262-021-02872-0 33576874
Liu, S. et al. Regulatory T cells promote glioma cell stemness through TGF-β-NF-κB-IL6-STAT3 signaling. Cancer Immunol. Immunother. 70, 2601–2616 (2021).33576874 10.1007/s00262-021-02872-0
437. Xu Y Sox2 communicates with Tregs through CCL1 to promote the stemness property of breast cancer cells Stem Cells 2017 35 2351 2365 10.1002/stem.2720 29044882
Xu, Y. et al. Sox2 communicates with Tregs through CCL1 to promote the stemness property of breast cancer cells. Stem Cells 35, 2351–2365 (2017).29044882 10.1002/stem.2720
438. Rezalotfi A Ahmadian E Aazami H Solgi G Ebrahimi M Gastric cancer stem cells effect on Th17/Treg balance; a bench to beside perspective Front Oncol. 2019 9 226 10.3389/fonc.2019.00226 31024835
Rezalotfi, A., Ahmadian, E., Aazami, H., Solgi, G. & Ebrahimi, M. Gastric cancer stem cells effect on Th17/Treg balance; a bench to beside perspective. Front Oncol. 9, 226 (2019).31024835 10.3389/fonc.2019.00226
439. Oh, E., Hong, J. & Yun, C. O. Regulatory T cells induce metastasis by increasing Tgf-β and enhancing the epithelial–mesenchymal transition. Cells 8, 1387(2019).
440. Beck B A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours Nature 2011 478 399 403 10.1038/nature10525 22012397
Beck, B. et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478, 399–403 (2011).22012397 10.1038/nature10525
441. Castriconi R NK cells recognize and kill human glioblastoma cells with stem cell-like properties J. Immunol. 2009 182 3530 3539 10.4049/jimmunol.0802845 19265131
Castriconi, R. et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 182, 3530–3539 (2009).19265131 10.4049/jimmunol.0802845
442. Tallerico R Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules J. Immunol. 2013 190 2381 2390 10.4049/jimmunol.1201542 23345327
Tallerico, R. et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J. Immunol. 190, 2381–2390 (2013).23345327 10.4049/jimmunol.1201542
443. Jewett A Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell-mediated lysis of cancer stem cells Curr. Drug Deliv. 2012 9 5 16 10.2174/156720112798375989 22023212
Jewett, A. et al. Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell-mediated lysis of cancer stem cells. Curr. Drug Deliv. 9, 5–16 (2012).22023212 10.2174/156720112798375989
444. Akhter MZ Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype Oncogene 2018 37 2089 2103 10.1038/s41388-017-0106-y 29379166
Akhter, M. Z. et al. Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype. Oncogene 37, 2089–2103 (2018).29379166 10.1038/s41388-017-0106-y
445. Zhong Y Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells Cancer Lett. 2010 299 150 160 10.1016/j.canlet.2010.08.013 20846785
Zhong, Y. et al. Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells. Cancer Lett. 299, 150–160 (2010).20846785 10.1016/j.canlet.2010.08.013
446. Malladi S Metastatic latency and immune evasion through autocrine inhibition of WNT Cell 2016 165 45 60 10.1016/j.cell.2016.02.025 27015306
Malladi, S. et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165, 45–60 (2016).27015306 10.1016/j.cell.2016.02.025
447. Sainz B Jr Martín B Tatari M Heeschen C Guerra S ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells Cancer Res. 2014 74 7309 7320 10.1158/0008-5472.CAN-14-1354 25368022
Sainz, B. Jr, Martín, B., Tatari, M., Heeschen, C. & Guerra, S. ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res. 74, 7309–7320 (2014).25368022 10.1158/0008-5472.CAN-14-1354
448. Martin-Hijano L Sainz B Jr The interactions between cancer stem cells and the innate interferon signaling pathway Front. Immunol. 2020 11 526 10.3389/fimmu.2020.00526 32296435
Martin-Hijano, L. & Sainz, B. Jr The interactions between cancer stem cells and the innate interferon signaling pathway. Front. Immunol. 11, 526 (2020).32296435 10.3389/fimmu.2020.00526
449. Zhu Y Influence of interferon-α on the expression of the cancer stem cell markers in pancreatic carcinoma cells Exp. Cell Res. 2014 324 146 156 10.1016/j.yexcr.2014.03.020 24726912
Zhu, Y. et al. Influence of interferon-α on the expression of the cancer stem cell markers in pancreatic carcinoma cells. Exp. Cell Res. 324, 146–156 (2014).24726912 10.1016/j.yexcr.2014.03.020
450. Wilson EB Blockade of chronic type I interferon signaling to control persistent LCMV infection Science 2013 340 202 207 10.1126/science.1235208 23580528
Wilson, E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202–207 (2013).23580528 10.1126/science.1235208
451. Teijaro JR Persistent LCMV infection is controlled by blockade of type I interferon signaling Science 2013 340 207 211 10.1126/science.1235214 23580529
Teijaro, J. R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207–211 (2013).23580529 10.1126/science.1235214
452. Musella M Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B Nat. Immunol. 2022 23 1379 1392 10.1038/s41590-022-01290-3 36002648
Musella, M. et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat. Immunol. 23, 1379–1392 (2022).36002648 10.1038/s41590-022-01290-3
453. de Almeida Nagata DE Regulation of tumor-associated myeloid cell activity by CBP/EP300 bromodomain modulation of H3K27 acetylation Cell Rep. 2019 27 269 281.e264 10.1016/j.celrep.2019.03.008 30943407
de Almeida Nagata, D. E. et al. Regulation of tumor-associated myeloid cell activity by CBP/EP300 bromodomain modulation of H3K27 acetylation. Cell Rep. 27, 269–281.e264 (2019).30943407 10.1016/j.celrep.2019.03.008
454. Szade K Where hematopoietic stem cells live: the bone marrow niche Antioxid. Redox Signal 2018 29 191 204 10.1089/ars.2017.7419 29113449
Szade, K. et al. Where hematopoietic stem cells live: the bone marrow niche. Antioxid. Redox Signal 29, 191–204 (2018).29113449 10.1089/ars.2017.7419
455. Du L Loss of sirt4 promotes the self-renewal of breast cancer stem cells Theranostics 2020 10 9458 9476 10.7150/thno.44688 32863939
Du, L. et al. Loss of sirt4 promotes the self-renewal of breast cancer stem cells. Theranostics 10, 9458–9476 (2020).32863939 10.7150/thno.44688
456. Ma Y SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis Free Radic. Biol. Med. 2019 134 458 467 10.1016/j.freeradbiomed.2019.01.030 30703481
Ma, Y. et al. SIRT5-mediated SDHA desuccinylation promotes clear cell renal cell carcinoma tumorigenesis. Free Radic. Biol. Med. 134, 458–467 (2019).30703481 10.1016/j.freeradbiomed.2019.01.030
457. Song M Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer Cancer Res. 2019 79 3737 3748 10.1158/0008-5472.CAN-19-0596 31085700
Song, M. et al. Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer. Cancer Res. 79, 3737–3748 (2019).31085700 10.1158/0008-5472.CAN-19-0596
458. Eisenhauer EA New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer 2009 45 228 247 10.1016/j.ejca.2008.10.026 19097774
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).19097774 10.1016/j.ejca.2008.10.026
459. Anderson RL A framework for the development of effective anti-metastatic agents Nat. Rev. Clin. Oncol. 2019 16 185 204 10.1038/s41571-018-0134-8 30514977
Anderson, R. L. et al. A framework for the development of effective anti-metastatic agents. Nat. Rev. Clin. Oncol. 16, 185–204 (2019).30514977 10.1038/s41571-018-0134-8
460. Zhao ZM Early and multiple origins of metastatic lineages within primary tumors Proc. Natl Acad. Sci. USA 2016 113 2140 2145 10.1073/pnas.1525677113 26858460
Zhao, Z. M. et al. Early and multiple origins of metastatic lineages within primary tumors. Proc. Natl Acad. Sci. USA 113, 2140–2145 (2016).26858460 10.1073/pnas.1525677113
461. Hosseini H Early dissemination seeds metastasis in breast cancer Nature 2016 540 552 558 10.1038/nature20785 27974799
Hosseini, H. et al. Early dissemination seeds metastasis in breast cancer. Nature 540, 552–558 (2016).27974799 10.1038/nature20785
462. Harper KL Mechanism of early dissemination and metastasis in Her2(+) mammary cancer Nature 2016 540 588 592 10.1038/nature20609 27974798
Harper, K. L. et al. Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature 540, 588–592 (2016).27974798 10.1038/nature20609
463. Hüsemann Y Systemic spread is an early step in breast cancer Cancer Cell 2008 13 58 68 10.1016/j.ccr.2007.12.003 18167340
Hüsemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58–68 (2008).18167340 10.1016/j.ccr.2007.12.003
464. Parsons S Maldonado EB Prasad V Comparison of drugs used for adjuvant and metastatic therapy of colon, breast, and non-small cell lung cancers JAMA Netw. Open 2020 3 e202488 10.1001/jamanetworkopen.2020.2488 32275321
Parsons, S., Maldonado, E. B. & Prasad, V. Comparison of drugs used for adjuvant and metastatic therapy of colon, breast, and non-small cell lung cancers. JAMA Netw. Open 3, e202488 (2020).32275321 10.1001/jamanetworkopen.2020.2488
465. Groppa, E. et al. EphrinB2/EphB4 signaling regulates non-sprouting angiogenesis by VEGF. EMBO Rep. 19, e45054 (2018).
466. Scheidmann MC An in vivo CRISPR screen identifies stepwise genetic dependencies of metastatic progression Cancer Res 2022 82 681 694 10.1158/0008-5472.CAN-21-3908 34916221
Scheidmann, M. C. et al. An in vivo CRISPR screen identifies stepwise genetic dependencies of metastatic progression. Cancer Res 82, 681–694 (2022).34916221 10.1158/0008-5472.CAN-21-3908
467. Gligorijevic B N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors J. Cell Sci. 2012 125 724 734 10.1242/jcs.092726 22389406
Gligorijevic, B. et al. N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. J. Cell Sci. 125, 724–734 (2012).22389406 10.1242/jcs.092726
468. Xu XR Yousef GM Ni H Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents Blood 2018 131 1777 1789 10.1182/blood-2017-05-743187 29519806
Xu, X. R., Yousef, G. M. & Ni, H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood 131, 1777–1789 (2018).29519806 10.1182/blood-2017-05-743187
469. Leong HS Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis Cell Rep. 2014 8 1558 1570 10.1016/j.celrep.2014.07.050 25176655
Leong, H. S. et al. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep. 8, 1558–1570 (2014).25176655 10.1016/j.celrep.2014.07.050
470. Choi JW Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells Cancer Res. 2015 75 4474 4482 10.1158/0008-5472.CAN-15-0684 26527605
Choi, J. W. et al. Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells. Cancer Res. 75, 4474–4482 (2015).26527605 10.1158/0008-5472.CAN-15-0684
471. Mitchell MJ Wayne E Rana K Schaffer CB King MR TRAIL-coated leukocytes that kill cancer cells in the circulation Proc. Natl Acad. Sci. USA 2014 111 930 935 10.1073/pnas.1316312111 24395803
Mitchell, M. J., Wayne, E., Rana, K., Schaffer, C. B. & King, M. R. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc. Natl Acad. Sci. USA 111, 930–935 (2014).24395803 10.1073/pnas.1316312111
472. Cooke NM Spillane CD Sheils O O’Leary J Kenny D Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion BMC Cancer 2015 15 627 10.1186/s12885-015-1634-x 26353776
Cooke, N. M., Spillane, C. D., Sheils, O., O’Leary, J. & Kenny, D. Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion. BMC Cancer 15, 627 (2015).26353776 10.1186/s12885-015-1634-x
473. Bambace NM Holmes CE The platelet contribution to cancer progression J. Thromb. Haemost. 2011 9 237 249 10.1111/j.1538-7836.2010.04131.x 21040448
Bambace, N. M. & Holmes, C. E. The platelet contribution to cancer progression. J. Thromb. Haemost. 9, 237–249 (2011).21040448 10.1111/j.1538-7836.2010.04131.x
474. Elia I Doglioni G Fendt SM Metabolic hallmarks of metastasis formation Trends Cell Biol. 2018 28 673 684 10.1016/j.tcb.2018.04.002 29747903
Elia, I., Doglioni, G. & Fendt, S. M. Metabolic hallmarks of metastasis formation. Trends Cell Biol. 28, 673–684 (2018).29747903 10.1016/j.tcb.2018.04.002
475. Mazel M Frequent expression of PD-L1 on circulating breast cancer cells Mol. Oncol. 2015 9 1773 1782 10.1016/j.molonc.2015.05.009 26093818
Mazel, M. et al. Frequent expression of PD-L1 on circulating breast cancer cells. Mol. Oncol. 9, 1773–1782 (2015).26093818 10.1016/j.molonc.2015.05.009
476. Elia I Breast cancer cells rely on environmental pyruvate to shape the metastatic niche Nature 2019 568 117 121 10.1038/s41586-019-0977-x 30814728
Elia, I. et al. Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature 568, 117–121 (2019).30814728 10.1038/s41586-019-0977-x
477. Elia I Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells Nat. Commun. 2017 8 15267 10.1038/ncomms15267 28492237
Elia, I. et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat. Commun. 8, 15267 (2017).28492237 10.1038/ncomms15267
478. Chen HN EpCAM signaling promotes tumor progression and protein stability of PD-L1 through the EGFR pathway Cancer Res. 2020 80 5035 5050 10.1158/0008-5472.CAN-20-1264 32978170
Chen, H. N. et al. EpCAM signaling promotes tumor progression and protein stability of PD-L1 through the EGFR pathway. Cancer Res. 80, 5035–5050 (2020).32978170 10.1158/0008-5472.CAN-20-1264
479. Müller P Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade Sci. Transl. Med. 2015 7 315ra188 10.1126/scitranslmed.aac4925 26606967
Müller, P. et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl. Med. 7, 315ra188 (2015).26606967 10.1126/scitranslmed.aac4925
480. Dombroski JA Jyotsana N Crews DW Zhang Z King MR Fabrication and characterization of tumor nano-lysate as a preventative vaccine for breast cancer Langmuir 2020 36 6531 6539 10.1021/acs.langmuir.0c00947 32437619
Dombroski, J. A., Jyotsana, N., Crews, D. W., Zhang, Z. & King, M. R. Fabrication and characterization of tumor nano-lysate as a preventative vaccine for breast cancer. Langmuir 36, 6531–6539 (2020).32437619 10.1021/acs.langmuir.0c00947
481. Parkins KM Engineering circulating tumor cells as novel cancer theranostics Theranostics 2020 10 7925 7937 10.7150/thno.44259 32685030
Parkins, K. M. et al. Engineering circulating tumor cells as novel cancer theranostics. Theranostics 10, 7925–7937 (2020).32685030 10.7150/thno.44259
482. Scher HI Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data Lancet Oncol. 2009 10 233 239 10.1016/S1470-2045(08)70340-1 19213602
Scher, H. I. et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 10, 233–239 (2009).19213602 10.1016/S1470-2045(08)70340-1
483. Aggarwal C Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer Ann. Oncol. 2013 24 420 428 10.1093/annonc/mds336 23028040
Aggarwal, C. et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann. Oncol. 24, 420–428 (2013).23028040 10.1093/annonc/mds336
484. Sparano J Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial JAMA Oncol. 2018 4 1700 1706 10.1001/jamaoncol.2018.2574 30054636
Sparano, J. et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4, 1700–1706 (2018).30054636 10.1001/jamaoncol.2018.2574
485. Rack, B. et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J. Natl. Cancer Inst. 106, dju066(2014).
486. Cristofanilli M Circulating tumor cells, disease progression, and survival in metastatic breast cancer N. Engl. J. Med. 2004 351 781 791 10.1056/NEJMoa040766 15317891
Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781–791 (2004).15317891 10.1056/NEJMoa040766
487. Cohen SJ Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer Clin. Colorectal Cancer 2006 6 125 132 10.3816/CCC.2006.n.029 16945168
Cohen, S. J. et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 6, 125–132 (2006).16945168 10.3816/CCC.2006.n.029
488. de Bono JS Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin. Cancer Res. 2008 14 6302 6309 10.1158/1078-0432.CCR-08-0872 18829513
de Bono, J. S. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302–6309 (2008).18829513 10.1158/1078-0432.CCR-08-0872
489. Danila DC Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin. Cancer Res. 2007 13 7053 7058 10.1158/1078-0432.CCR-07-1506 18056182
Danila, D. C. et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13, 7053–7058 (2007).18056182 10.1158/1078-0432.CCR-07-1506
490. Wallwiener M Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients BMC Cancer 2014 14 512 10.1186/1471-2407-14-512 25015676
Wallwiener, M. et al. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer 14, 512 (2014).25015676 10.1186/1471-2407-14-512
491. Smerage JB Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500 J. Clin. Oncol. 2014 32 3483 3489 10.1200/JCO.2014.56.2561 24888818
Smerage, J. B. et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J. Clin. Oncol. 32, 3483–3489 (2014).24888818 10.1200/JCO.2014.56.2561
492. Liu MC First-line doublet chemotherapy for metastatic triple-negative breast cancer: circulating tumor cell analysis of the tnAcity trial Cancer Manag. Res. 2019 11 10427 10433 10.2147/CMAR.S208712 31849532
Liu, M. C. et al. First-line doublet chemotherapy for metastatic triple-negative breast cancer: circulating tumor cell analysis of the tnAcity trial. Cancer Manag. Res. 11, 10427–10433 (2019).31849532 10.2147/CMAR.S208712
493. Liu MC Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer J. Clin. Oncol. 2009 27 5153 5159 10.1200/JCO.2008.20.6664 19752342
Liu, M. C. et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 27, 5153–5159 (2009).19752342 10.1200/JCO.2008.20.6664
494. Thery L Circulating tumor cells in early breast cancer JNCI Cancer Spectr. 2019 3 pkz026 10.1093/jncics/pkz026 31360902
Thery, L. et al. Circulating tumor cells in early breast cancer. JNCI Cancer Spectr. 3, pkz026 (2019).31360902 10.1093/jncics/pkz026
495. Bidard FC Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial JAMA Oncol. 2021 7 34 41 10.1001/jamaoncol.2020.5660 33151266
Bidard, F. C. et al. Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial. JAMA Oncol. 7, 34–41 (2021).33151266 10.1001/jamaoncol.2020.5660
496. Cabel L Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial Br. J. Cancer 2021 124 1207 1213 10.1038/s41416-020-01227-3 33473163
Cabel, L. et al. Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. Br. J. Cancer 124, 1207–1213 (2021).33473163 10.1038/s41416-020-01227-3
497. Georgoulias V Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study Ann. Oncol. 2012 23 1744 1750 10.1093/annonc/mds020 22377561
Georgoulias, V. et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann. Oncol. 23, 1744–1750 (2012).22377561 10.1093/annonc/mds020
498. Jacot W Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial Breast Cancer Res. 2019 21 121 10.1186/s13058-019-1215-z 31727113
Jacot, W. et al. Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast Cancer Res. 21, 121 (2019).31727113 10.1186/s13058-019-1215-z
499. Pestrin M Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study Breast Cancer Res. Treat. 2012 134 283 289 10.1007/s10549-012-2045-1 22476856
Pestrin, M. et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res. Treat. 134, 283–289 (2012).22476856 10.1007/s10549-012-2045-1
500. Armstrong AJ Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study J. Clin. Oncol. 2019 37 1120 1129 10.1200/JCO.18.01731 30865549
Armstrong, A. J. et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J. Clin. Oncol. 37, 1120–1129 (2019).30865549 10.1200/JCO.18.01731
501. Antonarakis ES AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N. Engl. J. Med. 2014 371 1028 1038 10.1056/NEJMoa1315815 25184630
Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).25184630 10.1056/NEJMoa1315815
502. Parker C Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 2020 31 1119 1134 10.1016/j.annonc.2020.06.011 32593798
Parker, C. et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1119–1134 (2020).32593798 10.1016/j.annonc.2020.06.011
503. Belderbos BPS Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer Eur. J. Cancer 2019 121 48 54 10.1016/j.ejca.2019.08.005 31542641
Belderbos, B. P. S. et al. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. Eur. J. Cancer 121, 48–54 (2019).31542641 10.1016/j.ejca.2019.08.005
504. Isebia KT CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients Eur. J. Cancer 2022 177 33 44 10.1016/j.ejca.2022.09.032 36323051
Isebia, K. T. et al. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients. Eur. J. Cancer 177, 33–44 (2022).36323051 10.1016/j.ejca.2022.09.032
505. Khoo BL Liquid biopsy and therapeutic response: circulating tumor cell cultures for evaluation of anticancer treatment Sci. Adv. 2016 2 e1600274 10.1126/sciadv.1600274 27453941
Khoo, B. L. et al. Liquid biopsy and therapeutic response: circulating tumor cell cultures for evaluation of anticancer treatment. Sci. Adv. 2, e1600274 (2016).27453941 10.1126/sciadv.1600274
506. Khoo BL Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy Oncotarget 2015 6 15578 15593 10.18632/oncotarget.3903 26008969
Khoo, B. L. et al. Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget 6, 15578–15593 (2015).26008969 10.18632/oncotarget.3903
507. Madhavan D Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer Clin. Cancer Res. 2012 18 5972 5982 10.1158/1078-0432.CCR-12-1407 22952344
Madhavan, D. et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 18, 5972–5982 (2012).22952344 10.1158/1078-0432.CCR-12-1407
508. Cabel L Circulating tumor cells: clinical validity and utility Int. J. Clin. Oncol. 2017 22 421 430 10.1007/s10147-017-1105-2 28238187
Cabel, L. et al. Circulating tumor cells: clinical validity and utility. Int. J. Clin. Oncol. 22, 421–430 (2017).28238187 10.1007/s10147-017-1105-2
509. Widschwendter M The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer Genome Med. 2017 9 116 10.1186/s13073-017-0500-7 29268796
Widschwendter, M. et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. 9, 116 (2017).29268796 10.1186/s13073-017-0500-7
510. Kneip C SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma J. Thorac. Oncol. 2011 6 1632 1638 10.1097/JTO.0b013e318220ef9a 21694641
Kneip, C. et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J. Thorac. Oncol. 6, 1632–1638 (2011).21694641 10.1097/JTO.0b013e318220ef9a
511. Hulbert A Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum Clin. Cancer Res. 2017 23 1998 2005 10.1158/1078-0432.CCR-16-1371 27729459
Hulbert, A. et al. Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum. Clin. Cancer Res. 23, 1998–2005 (2017).27729459 10.1158/1078-0432.CCR-16-1371
512. Mazor T Pankov A Song JS Costello JF Intratumoral Heterogeneity of the Epigenome Cancer Cell 2016 29 440 451 10.1016/j.ccell.2016.03.009 27070699
Mazor, T., Pankov, A., Song, J. S. & Costello, J. F. Intratumoral Heterogeneity of the Epigenome. Cancer Cell 29, 440–451 (2016).27070699 10.1016/j.ccell.2016.03.009
513. Suvilesh KN Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses Mol. Cancer 2022 21 73 10.1186/s12943-022-01553-5 35279152
Suvilesh, K. N. et al. Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses. Mol. Cancer 21, 73 (2022).35279152 10.1186/s12943-022-01553-5
514. Han HJ Fibronectin regulates anoikis resistance via cell aggregate formation Cancer Lett. 2021 508 59 72 10.1016/j.canlet.2021.03.011 33771684
Han, H. J. et al. Fibronectin regulates anoikis resistance via cell aggregate formation. Cancer Lett. 508, 59–72 (2021).33771684 10.1016/j.canlet.2021.03.011
515. Wang C HOTAIR lncRNA SNPs rs920778 and rs1899663 are associated with smoking, male gender, and squamous cell carcinoma in a Chinese lung cancer population Acta Pharm. Sin. 2018 39 1797 1803 10.1038/s41401-018-0083-x
Wang, C. et al. HOTAIR lncRNA SNPs rs920778 and rs1899663 are associated with smoking, male gender, and squamous cell carcinoma in a Chinese lung cancer population. Acta Pharm. Sin. 39, 1797–1803 (2018).10.1038/s41401-018-0083-x
516. Onstenk W Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer Oncotarget 2016 7 59058 59069 10.18632/oncotarget.10175 27340863
Onstenk, W. et al. Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer. Oncotarget 7, 59058–59069 (2016).27340863 10.18632/oncotarget.10175
517. Barros-Filho MC Marchi FA Pinto CA Rogatto SR Kowalski LP High diagnostic accuracy based on CLDN10, HMGA2, and LAMB3 transcripts in papillary thyroid carcinoma J. Clin. Endocrinol. Metab. 2015 100 E890 E899 10.1210/jc.2014-4053 25867809
Barros-Filho, M. C., Marchi, F. A., Pinto, C. A., Rogatto, S. R. & Kowalski, L. P. High diagnostic accuracy based on CLDN10, HMGA2, and LAMB3 transcripts in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 100, E890–E899 (2015).25867809 10.1210/jc.2014-4053
518. Vasantharajan SS The epigenetic landscape of circulating tumour cells Biochim. Biophys. Acta Rev. Cancer 2021 1875 188514 10.1016/j.bbcan.2021.188514 33497709
Vasantharajan, S. S. et al. The epigenetic landscape of circulating tumour cells. Biochim. Biophys. Acta Rev. Cancer 1875, 188514 (2021).33497709 10.1016/j.bbcan.2021.188514
519. Dong S Hypermethylated PCDHGB7 as a universal cancer only marker and its application in early cervical cancer screening Clin. Transl. Med. 2021 11 e457 10.1002/ctm2.457 34185407
Dong, S. et al. Hypermethylated PCDHGB7 as a universal cancer only marker and its application in early cervical cancer screening. Clin. Transl. Med. 11, e457 (2021).34185407 10.1002/ctm2.457
520. Dubois F Bergot E Zalcman G Levallet G RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review Cell Death Dis. 2019 10 928 10.1038/s41419-019-2169-x 31804463
Dubois, F., Bergot, E., Zalcman, G. & Levallet, G. RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review. Cell Death Dis. 10, 928 (2019).31804463 10.1038/s41419-019-2169-x
521. Hiddinga BI Pauwels P Janssens A van Meerbeeck JPO 6)-Methylguanine-DNA methyltransferase (MGMT): a drugable target in lung cancer? Lung Cancer 2017 107 91 99 10.1016/j.lungcan.2016.07.014 27492578
Hiddinga, B. I., Pauwels, P., Janssens, A. & van Meerbeeck, J. P. O. 6)-Methylguanine-DNA methyltransferase (MGMT): a drugable target in lung cancer? Lung Cancer 107, 91–99 (2017).27492578 10.1016/j.lungcan.2016.07.014
522. Punnoose EA PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients Br. J. Cancer 2015 113 1225 1233 10.1038/bjc.2015.332 26379078
Punnoose, E. A. et al. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br. J. Cancer 113, 1225–1233 (2015).26379078 10.1038/bjc.2015.332
523. Keller L Pantel K Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells Nat. Rev. Cancer 2019 19 553 567 10.1038/s41568-019-0180-2 31455893
Keller, L. & Pantel, K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat. Rev. Cancer 19, 553–567 (2019).31455893 10.1038/s41568-019-0180-2
524. Frenel JS Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial Ann. Oncol. 2022 33 1021 1028 10.1016/j.annonc.2022.06.011 35772665
Frenel, J. S. et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann. Oncol. 33, 1021–1028 (2022).35772665 10.1016/j.annonc.2022.06.011
525. Koyanagi K Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients Cancer Res. 2006 66 6111 6117 10.1158/0008-5472.CAN-05-4198 16778184
Koyanagi, K. et al. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 66, 6111–6117 (2006).16778184 10.1158/0008-5472.CAN-05-4198
526. Warton K Samimi G Methylation of cell-free circulating DNA in the diagnosis of cancer Front. Mol. Biosci. 2015 2 13 10.3389/fmolb.2015.00013 25988180
Warton, K. & Samimi, G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Front. Mol. Biosci. 2, 13 (2015).25988180 10.3389/fmolb.2015.00013
527. Church TR Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer Gut 2014 63 317 325 10.1136/gutjnl-2012-304149 23408352
Church, T. R. et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63, 317–325 (2014).23408352 10.1136/gutjnl-2012-304149
528. Osaka M Rowley JD Zeleznik-Le NJ MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25) Proc. Natl Acad. Sci. USA 1999 96 6428 6433 10.1073/pnas.96.11.6428 10339604
Osaka, M., Rowley, J. D. & Zeleznik-Le, N. J. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc. Natl Acad. Sci. USA 96, 6428–6433 (1999).10339604 10.1073/pnas.96.11.6428
529. Sun J Zheng MY Li YW Zhang SW Structure and function of Septin 9 and its role in human malignant tumors World J. Gastrointest. Oncol. 2020 12 619 631 10.4251/wjgo.v12.i6.619 32699577
Sun, J., Zheng, M. Y., Li, Y. W. & Zhang, S. W. Structure and function of Septin 9 and its role in human malignant tumors. World J. Gastrointest. Oncol. 12, 619–631 (2020).32699577 10.4251/wjgo.v12.i6.619
530. Song L Li Y SEPT9: a specific circulating biomarker for colorectal cancer Adv. Clin. Chem. 2015 72 171 204 10.1016/bs.acc.2015.07.004 26471083
Song, L. & Li, Y. SEPT9: a specific circulating biomarker for colorectal cancer. Adv. Clin. Chem. 72, 171–204 (2015).26471083 10.1016/bs.acc.2015.07.004
531. Cai G A multilocus blood-based assay targeting circulating tumor DNA methylation enables early detection and early relapse prediction of colorectal cancer Gastroenterology 2021 161 2053 2056.e2052 10.1053/j.gastro.2021.08.054 34487783
Cai, G. et al. A multilocus blood-based assay targeting circulating tumor DNA methylation enables early detection and early relapse prediction of colorectal cancer. Gastroenterology 161, 2053–2056.e2052 (2021).34487783 10.1053/j.gastro.2021.08.054
532. Roperch JP Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer BMC Cancer 2013 13 566 10.1186/1471-2407-13-566 24289328
Roperch, J. P. et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer 13, 566 (2013).24289328 10.1186/1471-2407-13-566
533. Park JK The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer Pancreas 2012 41 95 101 10.1097/MPA.0b013e318221c903 21778928
Park, J. K. et al. The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer. Pancreas 41, 95–101 (2012).21778928 10.1097/MPA.0b013e318221c903
534. Matsui S Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients Oncol. Rep. 2016 36 2225 2235 10.3892/or.2016.5004 27499429
Matsui, S. et al. Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients. Oncol. Rep. 36, 2225–2235 (2016).27499429 10.3892/or.2016.5004
535. Moore SR Distinctions between sex and time in patterns of DNA methylation across puberty BMC Genom. 2020 21 389 10.1186/s12864-020-06789-3
Moore, S. R. et al. Distinctions between sex and time in patterns of DNA methylation across puberty. BMC Genom. 21, 389 (2020).10.1186/s12864-020-06789-3
536. Bell CG DNA methylation aging clocks: challenges and recommendations Genome Biol. 2019 20 249 10.1186/s13059-019-1824-y 31767039
Bell, C. G. et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol. 20, 249 (2019).31767039 10.1186/s13059-019-1824-y
537. Mazzone PJ Screening for lung cancer: CHEST guideline and expert panel report Chest 2018 153 954 985 10.1016/j.chest.2018.01.016 29374513
Mazzone, P. J. et al. Screening for lung cancer: CHEST guideline and expert panel report. Chest 153, 954–985 (2018).29374513 10.1016/j.chest.2018.01.016
538. Cho N Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy JAMA Oncol. 2017 3 1495 1502 10.1001/jamaoncol.2017.1256 28655029
Cho, N. et al. Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. JAMA Oncol. 3, 1495–1502 (2017).28655029 10.1001/jamaoncol.2017.1256
539. Gupta S Screening for colorectal cancer Hematol. Oncol. Clin. North Am. 2022 36 393 414 10.1016/j.hoc.2022.02.001 35501176
Gupta, S. Screening for colorectal cancer. Hematol. Oncol. Clin. North Am. 36, 393–414 (2022).35501176 10.1016/j.hoc.2022.02.001
540. Yi JM Novel methylation biomarker panel for the early detection of pancreatic cancer Clin. Cancer Res. 2013 19 6544 6555 10.1158/1078-0432.CCR-12-3224 24088737
Yi, J. M. et al. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin. Cancer Res. 19, 6544–6555 (2013).24088737 10.1158/1078-0432.CCR-12-3224
541. Singh N Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients J. Cancer Res. Clin. Oncol. 2020 146 897 907 10.1007/s00432-020-03169-y 32146565
Singh, N. et al. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients. J. Cancer Res. Clin. Oncol. 146, 897–907 (2020).32146565 10.1007/s00432-020-03169-y
542. Shinjo K A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer PLoS One 2020 15 e0233782 10.1371/journal.pone.0233782 32520974
Shinjo, K. et al. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer. PLoS One 15, e0233782 (2020).32520974 10.1371/journal.pone.0233782
543. Schott S HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: a case control study Oncotarget 2017 8 67614 67625 10.18632/oncotarget.18757 28978057
Schott, S. et al. HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: a case control study. Oncotarget 8, 67614–67625 (2017).28978057 10.18632/oncotarget.18757
544. Fujimoto Y Combination of CA19-9 and blood free-circulating methylated RUNX3 may be useful to diagnose stage I pancreatic cancer Oncology 2021 99 234 239 10.1159/000511940 33440396
Fujimoto, Y. et al. Combination of CA19-9 and blood free-circulating methylated RUNX3 may be useful to diagnose stage I pancreatic cancer. Oncology 99, 234–239 (2021).33440396 10.1159/000511940
545. Ying L Methylation-based cell-free DNA signature for early detection of pancreatic cancer Pancreas 2021 50 1267 1273 10.1097/MPA.0000000000001919 34860810
Ying, L. et al. Methylation-based cell-free DNA signature for early detection of pancreatic cancer. Pancreas 50, 1267–1273 (2021).34860810 10.1097/MPA.0000000000001919
546. Eissa MAL Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood Clin. Epigenet. 2019 11 59 10.1186/s13148-019-0650-0
Eissa, M. A. L. et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin. Epigenet. 11, 59 (2019).10.1186/s13148-019-0650-0
547. Kelwick R Desanlis I Wheeler GN Edwards DR The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family Genome Biol. 2015 16 113 10.1186/s13059-015-0676-3 26025392
Kelwick, R., Desanlis, I., Wheeler, G. N. & Edwards, D. R. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. Genome Biol. 16, 113 (2015).26025392 10.1186/s13059-015-0676-3
548. Kota J Hancock J Kwon J Korc M Pancreatic cancer: stroma and its current and emerging targeted therapies Cancer Lett. 2017 391 38 49 10.1016/j.canlet.2016.12.035 28093284
Kota, J., Hancock, J., Kwon, J. & Korc, M. Pancreatic cancer: stroma and its current and emerging targeted therapies. Cancer Lett. 391, 38–49 (2017).28093284 10.1016/j.canlet.2016.12.035
549. Mastoraki S KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer Mol. Oncol. 2021 15 2412 2422 10.1002/1878-0261.12848 33159839
Mastoraki, S. et al. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. Mol. Oncol. 15, 2412–2422 (2021).33159839 10.1002/1878-0261.12848
550. Liu Y Methylation of serum SST gene is an independent prognostic marker in colorectal cancer Am. J. Cancer Res. 2016 6 2098 2108 27725914
Liu, Y. et al. Methylation of serum SST gene is an independent prognostic marker in colorectal cancer. Am. J. Cancer Res. 6, 2098–2108 (2016).27725914
551. Fujita N Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients Oncology 2012 83 273 282 10.1159/000342083 22964822
Fujita, N. et al. Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology 83, 273–282 (2012).22964822 10.1159/000342083
552. Tserpeli, V. et al. Prognostic significance of SLFN11 methylation in plasma cell-free DNA in advanced high-grade serous ovarian cancer. Cancers 14 (2021).
553. Matthaios D Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer Oncol. Lett. 2016 12 748 756 10.3892/ol.2016.4649 27347211
Matthaios, D. et al. Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncol. Lett. 12, 748–756 (2016).27347211 10.3892/ol.2016.4649
554. Karamitrousis EI Prognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in cell-free DNA of advanced gastric cancer patients Technol. Cancer Res. Treat. 2021 20 1533033820973279 10.1177/1533033820973279 33928818
Karamitrousis, E. I. et al. Prognostic role of RASSF1A, SOX17 and Wif-1 promoter methylation status in cell-free DNA of advanced gastric cancer patients. Technol. Cancer Res. Treat. 20, 1533033820973279 (2021).33928818 10.1177/1533033820973279
555. Deng QK Lei YG Lin YL Ma JG Li WP Prognostic value of protocadherin10 (PCDH10) methylation in serum of prostate cancer patients Med. Sci. Monit. 2016 22 516 521 10.12659/MSM.897179 26881880
Deng, Q. K., Lei, Y. G., Lin, Y. L., Ma, J. G. & Li, W. P. Prognostic value of protocadherin10 (PCDH10) methylation in serum of prostate cancer patients. Med. Sci. Monit. 22, 516–521 (2016).26881880 10.12659/MSM.897179
556. Mansouri A MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges Neuro Oncol. 2019 21 167 178 10.1093/neuonc/noy132 30189035
Mansouri, A. et al. MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neuro Oncol. 21, 167–178 (2019).30189035 10.1093/neuonc/noy132
557. Fuster-Garcia E MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas Eur. Radio. 2021 31 1738 1747 10.1007/s00330-020-07297-4
Fuster-Garcia, E. et al. MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas. Eur. Radio. 31, 1738–1747 (2021).10.1007/s00330-020-07297-4
558. Luo G Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter Biochim. Biophys. Acta Rev. Cancer 2021 1875 188409 10.1016/j.bbcan.2020.188409 32827580
Luo, G. et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter. Biochim. Biophys. Acta Rev. Cancer 1875, 188409 (2021).32827580 10.1016/j.bbcan.2020.188409
559. Xu X Xiao Y Hong B Hao B Qian Y Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer Cancer Biomark. 2019 25 251 257 10.3233/CBM-190067 31282407
Xu, X., Xiao, Y., Hong, B., Hao, B. & Qian, Y. Combined detection of CA19-9 and B7-H4 in the diagnosis and prognosis of pancreatic cancer. Cancer Biomark. 25, 251–257 (2019).31282407 10.3233/CBM-190067
560. Rieser CJ CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time Ann. Surg. Oncol. 2018 25 3483 3491 10.1245/s10434-018-6521-7 29786131
Rieser, C. J. et al. CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time. Ann. Surg. Oncol. 25, 3483–3491 (2018).29786131 10.1245/s10434-018-6521-7
561. Mujica VR Barkin JS Go VL Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants Pancreas 2000 21 329 332 10.1097/00006676-200011000-00001 11075985
Mujica, V. R., Barkin, J. S. & Go, V. L. Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants. Pancreas 21, 329–332 (2000).11075985 10.1097/00006676-200011000-00001
562. Luo G New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer Pancreatology 2018 18 971 976 10.1016/j.pan.2018.08.003 30131287
Luo, G. et al. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology 18, 971–976 (2018).30131287 10.1016/j.pan.2018.08.003
563. Stastny I Aberrantly methylated cfDNA in body fluids as a promising diagnostic tool for early detection of breast cancer Clin. Breast Cancer 2020 20 e711 e722 10.1016/j.clbc.2020.05.009 32792225
Stastny, I. et al. Aberrantly methylated cfDNA in body fluids as a promising diagnostic tool for early detection of breast cancer. Clin. Breast Cancer 20, e711–e722 (2020).32792225 10.1016/j.clbc.2020.05.009
564. Ignatiadis M Sledge GW Jeffrey SS Liquid biopsy enters the clinic—implementation issues and future challenges Nat. Rev. Clin. Oncol. 2021 18 297 312 10.1038/s41571-020-00457-x 33473219
Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat. Rev. Clin. Oncol. 18, 297–312 (2021).33473219 10.1038/s41571-020-00457-x
565. Nakayama G p16INK4a methylation in serum as a follow-up marker for recurrence of colorectal cancer Anticancer Res. 2011 31 1643 1646 21617221
Nakayama, G. et al. p16INK4a methylation in serum as a follow-up marker for recurrence of colorectal cancer. Anticancer Res. 31, 1643–1646 (2011).21617221
566. Jin S Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy Proc. Natl Acad. Sci. USA 2021 118 e2017421118 10.1073/pnas.2017421118 33495330
Jin, S. et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc. Natl Acad. Sci. USA 118, e2017421118 (2021).33495330 10.1073/pnas.2017421118
567. Hutóczki G Virga J Birkó Z Klekner A Novel concepts of glioblastoma therapy concerning its heterogeneity Int. J. Mol. Sci. 2021 22 10005 10.3390/ijms221810005 34576168
Hutóczki, G., Virga, J., Birkó, Z. & Klekner, A. Novel concepts of glioblastoma therapy concerning its heterogeneity. Int. J. Mol. Sci. 22, 10005 (2021).34576168 10.3390/ijms221810005
568. Nunes SP Henrique R Jerónimo C Paramio JM DNA methylation as a therapeutic target for bladder cancer Cells 2020 9 1850 10.3390/cells9081850 32784599
Nunes, S. P., Henrique, R., Jerónimo, C. & Paramio, J. M. DNA methylation as a therapeutic target for bladder cancer. Cells 9, 1850 (2020).32784599 10.3390/cells9081850
569. Wong KK DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications Cell Oncol. 2020 43 779 792 10.1007/s13402-020-00526-4
Wong, K. K. DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications. Cell Oncol. 43, 779–792 (2020).10.1007/s13402-020-00526-4
570. Wong KK DNMT1: a key drug target in triple-negative breast cancer Semin. Cancer Biol. 2021 72 198 213 10.1016/j.semcancer.2020.05.010 32461152
Wong, K. K. DNMT1: a key drug target in triple-negative breast cancer. Semin. Cancer Biol. 72, 198–213 (2021).32461152 10.1016/j.semcancer.2020.05.010
571. Morin RD Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat. Genet. 2010 42 181 185 10.1038/ng.518 20081860
Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).20081860 10.1038/ng.518
572. Morschhauser F Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial Lancet Oncol. 2020 21 1433 1442 10.1016/S1470-2045(20)30441-1 33035457
Morschhauser, F. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21, 1433–1442 (2020).33035457 10.1016/S1470-2045(20)30441-1
573. Honma D Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor Cancer Sci. 2017 108 2069 2078 10.1111/cas.13326 28741798
Honma, D. et al. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. Cancer Sci. 108, 2069–2078 (2017).28741798 10.1111/cas.13326
574. Izutsu K An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma Blood 2023 141 1159 1168 10.1182/blood.2022016862 36150143
Izutsu, K. et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood 141, 1159–1168 (2023).36150143 10.1182/blood.2022016862
575. Okada Y hDOT1L links histone methylation to leukemogenesis Cell 2005 121 167 178 10.1016/j.cell.2005.02.020 15851025
Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167–178 (2005).15851025 10.1016/j.cell.2005.02.020
576. Lonetti A Inhibition of methyltransferase DOT1L sensitizes to sorafenib treatment AML cells irrespective of MLL-rearrangements: a novel therapeutic strategy for pediatric AML Cancers 2020 12 1972 10.3390/cancers12071972 32698374
Lonetti, A. et al. Inhibition of methyltransferase DOT1L sensitizes to sorafenib treatment AML cells irrespective of MLL-rearrangements: a novel therapeutic strategy for pediatric AML. Cancers 12, 1972 (2020).32698374 10.3390/cancers12071972
577. Shen DD LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer Mol. Cancer 2022 21 75 10.1186/s12943-022-01557-1 35296335
Shen, D. D. et al. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer. Mol. Cancer 21, 75 (2022).35296335 10.1186/s12943-022-01557-1
578. Fang Y Liao G Yu B LSD1/KDM1A inhibitors in clinical trials: advances and prospects J. Hematol. Oncol. 2019 12 129 10.1186/s13045-019-0811-9 31801559
Fang, Y., Liao, G. & Yu, B. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J. Hematol. Oncol. 12, 129 (2019).31801559 10.1186/s13045-019-0811-9
579. Hollebecque A Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed/refractory non-hodgkin lymphoma Clin. Cancer Res. 2021 27 438 446 10.1158/1078-0432.CCR-20-2380 33046517
Hollebecque, A. et al. Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed/refractory non-hodgkin lymphoma. Clin. Cancer Res. 27, 438–446 (2021).33046517 10.1158/1078-0432.CCR-20-2380
580. Perillo B Tramontano A Pezone A Migliaccio A LSD1: more than demethylation of histone lysine residues Exp. Mol. Med. 2020 52 1936 1947 10.1038/s12276-020-00542-2 33318631
Perillo, B., Tramontano, A., Pezone, A. & Migliaccio, A. LSD1: more than demethylation of histone lysine residues. Exp. Mol. Med. 52, 1936–1947 (2020).33318631 10.1038/s12276-020-00542-2
581. Wang J The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation Nat. Genet. 2009 41 125 129 10.1038/ng.268 19098913
Wang, J. et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41, 125–129 (2009).19098913 10.1038/ng.268
582. Xu S Wang X Yang Y Li Y Wu S LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer Cell Death Dis. 2021 12 282 10.1038/s41419-021-03556-4 33731702
Xu, S., Wang, X., Yang, Y., Li, Y. & Wu, S. LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer. Cell Death Dis. 12, 282 (2021).33731702 10.1038/s41419-021-03556-4
583. Qin Y Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade Oncogene 2019 38 390 405 10.1038/s41388-018-0451-5 30111819
Qin, Y. et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene 38, 390–405 (2019).30111819 10.1038/s41388-018-0451-5
584. Park JW Han JW Targeting epigenetics for cancer therapy Arch. Pharm. Res. 2019 42 159 170 10.1007/s12272-019-01126-z 30806885
Park, J. W. & Han, J. W. Targeting epigenetics for cancer therapy. Arch. Pharm. Res. 42, 159–170 (2019).30806885 10.1007/s12272-019-01126-z
585. Mann BS Johnson JR Cohen MH Justice R Pazdur R FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 2007 12 1247 1252 10.1634/theoncologist.12-10-1247 17962618
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R. & Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12, 1247–1252 (2007).17962618 10.1634/theoncologist.12-10-1247
586. Terranova-Barberio M HDAC inhibition potentiates immunotherapy in triple-negative breast cancer Oncotarget 2017 8 114156 114172 10.18632/oncotarget.23169 29371976
Terranova-Barberio, M. et al. HDAC inhibition potentiates immunotherapy in triple-negative breast cancer. Oncotarget 8, 114156–114172 (2017).29371976 10.18632/oncotarget.23169
587. Thomas S Thurn KT Biçaku E Marchion DC Münster PN Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy Breast Cancer Res. Treat. 2011 130 437 447 10.1007/s10549-011-1364-y 21298336
Thomas, S., Thurn, K. T., Biçaku, E., Marchion, D. C. & Münster, P. N. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res. Treat. 130, 437–447 (2011).21298336 10.1007/s10549-011-1364-y
588. O’Connor OA Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study J. Clin. Oncol. 2015 33 2492 2499 10.1200/JCO.2014.59.2782 26101246
O’Connor, O. A. et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J. Clin. Oncol. 33, 2492–2499 (2015).26101246 10.1200/JCO.2014.59.2782
589. Juergens RA Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer Cancer Discov. 2011 1 598 607 10.1158/2159-8290.CD-11-0214 22586682
Juergens, R. A. et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1, 598–607 (2011).22586682 10.1158/2159-8290.CD-11-0214
590. Connolly RM Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat: a phase II national cancer institute/stand Up to cancer study Clin. Cancer Res. 2017 23 2691 2701 10.1158/1078-0432.CCR-16-1729 27979916
Connolly, R. M. et al. Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat: a phase II national cancer institute/stand Up to cancer study. Clin. Cancer Res. 23, 2691–2701 (2017).27979916 10.1158/1078-0432.CCR-16-1729
591. Faivre EJ Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer Nature 2020 578 306 310 10.1038/s41586-020-1930-8 31969702
Faivre, E. J. et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature 578, 306–310 (2020).31969702 10.1038/s41586-020-1930-8
592. Feng M Xu H Zhou W Pan Y The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma J. Exp. Clin. Cancer Res. 2023 42 44 10.1186/s13046-023-02615-2 36755269
Feng, M., Xu, H., Zhou, W. & Pan, Y. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. J. Exp. Clin. Cancer Res. 42, 44 (2023).36755269 10.1186/s13046-023-02615-2
593. Pang Y The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer J. Transl. Med. 2022 20 336 10.1186/s12967-022-03545-x 35902869
Pang, Y. et al. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer. J. Transl. Med. 20, 336 (2022).35902869 10.1186/s12967-022-03545-x
594. Stuhlmiller TJ Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains Cell Rep. 2015 11 390 404 10.1016/j.celrep.2015.03.037 25865888
Stuhlmiller, T. J. et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 11, 390–404 (2015).25865888 10.1016/j.celrep.2015.03.037
595. Leonard B BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC Cancer Res. 2018 78 4331 4343 10.1158/0008-5472.CAN-18-0459 29792310
Leonard, B. et al. BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. Cancer Res. 78, 4331–4343 (2018).29792310 10.1158/0008-5472.CAN-18-0459
596. Sun C BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency Cancer Cell 2018 33 401 416.e408 10.1016/j.ccell.2018.01.019 29533782
Sun, C. et al. BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency. Cancer Cell 33, 401–416.e408 (2018).29533782 10.1016/j.ccell.2018.01.019
597. Fiorentino FP BET-inhibitor I-BET762 and PARP-inhibitor talazoparib synergy in small cell lung cancer cells Int. J. Mol. Sci. 2020 21 9595 10.3390/ijms21249595 33339368
Fiorentino, F. P. et al. BET-inhibitor I-BET762 and PARP-inhibitor talazoparib synergy in small cell lung cancer cells. Int. J. Mol. Sci. 21, 9595 (2020).33339368 10.3390/ijms21249595
598. Yang L Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition Sci. Transl. Med. 2017 9 eaal1645 10.1126/scitranslmed.aal1645 28747513
Yang, L. et al. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci. Transl. Med. 9, eaal1645 (2017).28747513 10.1126/scitranslmed.aal1645
599. Karakashev S BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer Cell Rep. 2017 21 3398 3405 10.1016/j.celrep.2017.11.095 29262321
Karakashev, S. et al. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer. Cell Rep. 21, 3398–3405 (2017).29262321 10.1016/j.celrep.2017.11.095
600. Powell AA Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines PLoS One 2012 7 e33788 10.1371/journal.pone.0033788 22586443
Powell, A. A. et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 7, e33788 (2012).22586443 10.1371/journal.pone.0033788
601. Steinert G Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer Cancer Res. 2014 74 1694 1704 10.1158/0008-5472.CAN-13-1885 24599131
Steinert, G. et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 74, 1694–1704 (2014).24599131 10.1158/0008-5472.CAN-13-1885
602. Adams DL Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy Clin. Cancer Res. 2017 23 5948 5958 10.1158/1078-0432.CCR-17-0802 28679765
Adams, D. L. et al. Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy. Clin. Cancer Res. 23, 5948–5958 (2017).28679765 10.1158/1078-0432.CCR-17-0802
603. Papadaki MA Clinical relevance of immune checkpoints on circulating tumor cells in breast cancer Cancers 2020 12 376 10.3390/cancers12020376 32041353
Papadaki, M. A. et al. Clinical relevance of immune checkpoints on circulating tumor cells in breast cancer. Cancers 12, 376 (2020).32041353 10.3390/cancers12020376
604. Morales M RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation EMBO Mol. Med. 2014 6 865 881 10.15252/emmm.201303675 24867881
Morales, M. et al. RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation. EMBO Mol. Med. 6, 865–881 (2014).24867881 10.15252/emmm.201303675
605. Hsu TH Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells Cell Death Differ. 2015 22 801 814 10.1038/cdd.2014.175 25361079
Hsu, T. H. et al. Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells. Cell Death Differ. 22, 801–814 (2015).25361079 10.1038/cdd.2014.175
